HIV-1 persistence during ART by Ruggiero, A
  
 
HIV-1 persistence during ART 
 
 
 
 
Thesis submitted in accordance with the requirements of  
The University of Liverpool for the degree of Doctor in Philosophy  
 
 
By 
 
 
Alessandra Ruggiero  
June 2016 
 
 
 
  
 
 
i 
 
 
Declaration of Authorship 
I declare that except where indicated by specific reference in the text, this work is my 
own work. Work done in collaboration with, or with the assistance of other, is indicated 
as such and acknowledged. 
 
 
 
 
 
……………………………………………………… 
 
 
Alessandra Ruggiero 
June 2016 
 
 
 
 
 
 
 
 
 
 
ii 
 
 
Acknowledgments 
I wish to express my gratitude to everyone that helped and supported me through my 
PhD experience. First, I would like to thank my primary supervisors Prof. Anna Maria 
Geretti for giving me the opportunity of joining her research group and for guiding me 
through the whole process. Thank you to my second supervisor Dr. Georgios Pollakis 
for his constant and useful feedback and support.  
 
I wish to thank all patients and the ERAS team for their contribution; the Immunology 
Diagnostic Service of the Royal Free Hospital for the immunology tests; Dr Mark 
Hopkins at the Royal Liverpool University Hospital for CMV and EFV testing; Dr. 
Matthew Strain, Mr Stephen Lada and Prof. Douglas Richman for performing the 2-
LTR circular HIV-1 DNA assays. I am grateful to Prof. Linos Vandekerckhove for 
allowing me to spend some time with his group at the University of Gent and achieve 
competence in the Alu-gag assay; thanks also to Dr. Ward De Spiegelaere for his 
guidance. Thank you to Dr. Alessandro Cozzi-Lepri for the help on data analysis. Thank 
you also to the SSAT team for patient’s recruitment.  
 
I am very grateful to Prof. Bill Paxton for the scientific discussions on my project and 
for the invaluable support during my PhD and during my writing up.  
 
I would like to thank all my “ex-colleagues” from the Geretti group for their untiring 
support over the years. I would like to thank Maria and “my” student Lydia for their 
contribution to produce data on total and integrated HIV-1 DNA; the research 
technicians for generating soluble markers and virology data for the ERAS study. 
 
Thank you to my friends: the “Cool Ronald Ross” group for the limitless support and a 
special thank you to Lindsay and Jordan for the language-related help. Thank you to 
my Italian friends in Liverpool and in Italy for their love and support. 
 
Last but not least I thank my family: my parents, my sister and her husband, my 
nephews, my mother and sister in law. Thank you to my husband Giovanni, this work 
is dedicated to you above everyone else for your limitless love, support and patience. 
iii 
 
 
Abstract 
HIV-1 persistence during ART 
Alessandra Ruggiero 
 
Antiretroviral therapy (ART) suppresses HIV viremia, but it does not eliminate the 
stable cellular reservoir of integrated viral DNA that is generated early during infection. 
As a consequence, low levels of HIV are detected in patients with consistent viral 
suppression (HIV-1 RNA<50 copies/ml) in CD4 cells in different body compartments 
including plasma, peripheral cells and CD4 T-cell subsets.  
 
We first explored the levels of HIV-1 RNA below the cut-off of clinical assay (HIV-1 
RNA load<50 copies/ml, herein referred to as ‘residual viremia’) in a group of patients 
who switched from Atripla to Eviplera due to toxicity. Furthermore, we studied HIV-1 
DNA and RNA loads in peripheral blood of patients with stable virological suppression 
(HIV-1 RNA<50 copies/ml) while being on first line-ART with 1 NNRTI and 2 NRTIs. 
The measured virological markers included the residual HIV-1 RNA load in plasma 
quantified by an ultrasensitive assay; total and integrated HIV-1 DNA in both peripheral 
blood mononuclear cells (PBMC) and the CD4 T-cell subsets using quantitative PCR 
methods; 2-LTR circular HIV-1 DNA in PBMC using droplet digital PCR assay. 
Furthermore, a panel of cellular and immunological markers of immune activation, as 
measured by flow cytometry and ELISA assay respectively, were available for the 
analysis. Additionally we explored alternative methods to quantify and to study HIV-1 
persistence. 
 
In patients that switched from Atripla to Eviplera we observed that overall the patients 
showed maintained virologic suppression until the end of the observation; however, 4 
patients experienced virologic rebound with HIV-1 RNA>50 copies/ml and this was 
predicted by a progressive increase in residual HIV-1 RNA levels over time.  
 
iv 
 
 
Patients on suppressive ART were studied with a cross sectional approach and we 
observed detection of residual HIV-1 RNA and 2-LTR circular DNA in a proportion of 
patients and total HIV-1 DNA in PBMC the whole study group. Additionally, we found 
that residual HIV-1 RNA levels and total HIV-1 DNA were associated with sCD27 and 
CD8+HLA-DR/DP/DQ+ T-cells, respectively. Following setting-up of the Alu-gag 
qPCR assay, we measured integrated HIV-1 DNA in PBMC and we confirmed the 
association with CD8+HLA-DR/DP/DQ+ T-cells. 
 
In the context of assay development, we proposed the Alu-5LTR assay as an alternative 
to the Alu-gag assay for integrated HIV-1 DNA quantification and preliminary results 
showed increased sensitivity. Furthermore, we identified and characterized the tools 
needed to set up an in vitro system to study direct and cell-to-cell HIV-1 infection. 
 
Results from my thesis showed the importance of residual HIV-1 RNA monitoring to 
detect virus rebound. Moreover, patients on suppressive ART for a long period showed 
HIV detection in plasma and in cells which was associated with high levels of immune 
activation, suggesting a role for the host immune environment in HIV persistence. In 
the context of assay developments for more sensitive quantification of integrated HIV 
DNA reservoir, our proposed Alu-5LTR assay as described in this thesis may be a 
potential alternative. 
 
 
 
 
 
 
 
 
 
v 
 
 
TABLE OF CONTENTS 
 
DECLARATION OF AUTHORSHIP ....................................................................... I 
ACKNOWLEDGMENTS .......................................................................................... II 
ABSTRACT ............................................................................................................... III 
TABLE OF CONTENTS ........................................................................................... V 
LIST OF FIGURE .................................................................................................... XI 
LIST OF TABLE ................................................................................................... XIII 
LIST OF ABBREVIATIONS ................................................................................XVI 
1 CHAPTER 1: GENERAL INTRODUCTION .................................................. 1 
1.1 HIV discovery, origin, and genetic diversity ..................................................... 1 
1.2 The viral life-cycle ................................................................................................ 3 
1.2.1 Virion structure .............................................................................................. 3 
1.2.2 Genome and proteins ..................................................................................... 4 
1.2.1 Virus replication cycle ................................................................................... 7 
1.2.1.1 Binding and fusion with host cells ......................................................... 7 
1.2.2 Uncoating, reverse transcription and nuclear import ................................... 10 
1.2.2.1 Virus integration .................................................................................. 11 
1.2.2.2 Gene expression ................................................................................... 12 
1.2.2.3 Viral particle assembly, budding and maturation ................................ 13 
1.2.3 Pathogenesis ................................................................................................. 13 
1.2.3.1 HIV transmission and primary infection .............................................. 15 
1.2.3.2 Plasma viremia and anti-HIV immune response dynamics ................. 16 
vi 
 
 
1.2.3.3 Virus dissemination into target tissues, immune activation and CD4 T-
cell loss dynamics ................................................................................................ 17 
1.3 Antiretroviral drugs ........................................................................................... 20 
1.3.1 Entry inhibitors: CCR5 antagonists and fusion inhibitors ........................... 22 
1.3.2 Reverse transcriptase inhibitors ................................................................... 22 
1.3.2.1 NRTIs ................................................................................................... 23 
1.3.2.2 NNRTIs ................................................................................................ 23 
1.3.3 Protease inhibitors (PI) ................................................................................ 24 
1.3.4 Integrase inhibitors ....................................................................................... 24 
1.4 HIV-1 persistence during ART ......................................................................... 26 
1.4.1 Latently infected cells: a long-lived viral reservoir ..................................... 26 
1.4.2 Mechanisms of persistence .......................................................................... 28 
1.4.2.1 Cell proliferation .................................................................................. 28 
1.4.2.2 Ongoing viral replication ..................................................................... 29 
1.4.2.3 Cell to cell virus transmission .............................................................. 30 
1.4.3 Tools to measure the HIV reservoir ............................................................. 31 
1.4.3.1 Intracellular HIV-1 nucleic acid quantification ................................... 32 
1.4.3.2 Detection of plasma HIV-1 RNA load and virological suppression 
threshold 36 
1.5 Aims of the thesis ............................................................................................... 38 
2 CHAPTER 2: MATERIALS AND METHODS ............................................. 40 
2.1 Study populations and sampling....................................................................... 40 
2.2 Cell separation .................................................................................................... 42 
2.2.1 PBMC .......................................................................................................... 42 
2.2.2 CD4 T-cell subsets ....................................................................................... 44 
2.3 Virological assays ............................................................................................... 47 
2.3.1 HIV-1 RNA quantification .......................................................................... 47 
2.3.1.1 Validation of the ultrasensitive assay .................................................. 48 
2.3.2 HIV-1 DNA quantification .......................................................................... 50 
2.3.2.1 DNA isolation from PBMC and CD4 T-cell subsets ........................... 50 
vii 
 
 
2.3.2.2 Total HIV-1 DNA quantification ......................................................... 50 
2.3.2.3 Integrated HIV-1 DNA quantification ................................................. 51 
2.3.2.4 2-LTR circular HIV-1 DNA quantification ......................................... 54 
2.3.3 HIV-1 p24 ELISA ........................................................................................ 56 
2.4 Immunology ........................................................................................................ 57 
2.4.1 Flow cytometry ............................................................................................ 57 
2.4.2 ELISA assays ............................................................................................... 59 
2.5 Statistical Method .............................................................................................. 61 
2.6 Mammalian cell lines maintenance .................................................................. 63 
3 CHAPTER 3: RESIDUAL PLASMA HIV-1 RNA DETECTION IN 
PATIENTS SWITCHING FROM A SINGLE-TABLET REGIMEN OF CO-
FORMULATED TENOFOVIR/EMTRICITABINE/EFAVIRENZ TO ONE 
CONTAINING CO-FORMULATED 
TENOFOVIR/EMTRICITABINE/RILPIVIRINE ................................................ 65 
3.1 INTRODUCTION .............................................................................................. 65 
3.2 METHODS ......................................................................................................... 67 
3.2.1 Study population .......................................................................................... 67 
3.2.2 Assay optimisation ....................................................................................... 67 
3.2.3 Sample processing ....................................................................................... 68 
3.2.4 Statistical analysis ........................................................................................ 69 
3.3 RESULTS ........................................................................................................... 69 
3.3.1 Validation of the ultrasensitive viral load assay .......................................... 69 
3.3.1.1 Manual extraction ................................................................................ 70 
3.3.1.2 Automated extraction ........................................................................... 73 
3.3.2 Study population at baseline ........................................................................ 74 
3.3.3 Plasma HIV-1 RNA levels after the switch ................................................. 74 
3.4 DISCUSSION ..................................................................................................... 79 
4 CHAPTER 4: FACTORS ASSOCIATED WITH HIV-1 PERSISTENCE IN 
A POPULATION OF STABLE SUPPRESSED INDIVIDUALS ......................... 83 
viii 
 
 
4.1 INTRODUCTION .............................................................................................. 83 
4.2 METHODS ......................................................................................................... 84 
4.2.1 Study population .......................................................................................... 84 
4.2.2 Quantification of residual HIV-1 RNA in plasma ....................................... 84 
4.2.3 Drug concentration ....................................................................................... 85 
4.2.4 Quantification of total and 2-LTR circular HIV-1 DNA in peripheral blood 
mononuclear cells (PBMC) ...................................................................................... 85 
4.2.5 Markers of immune activation ..................................................................... 85 
4.2.6 Statistical analysis ........................................................................................ 85 
4.3 RESULTS ........................................................................................................... 86 
4.3.1 Study population .......................................................................................... 86 
4.3.2 Virological and immunological parameters ................................................. 87 
5 CHAPTER 5: ESTABLISHING AN ASSAY FOR MEASURING 
INTEGRATED HIV-1 DNA LOAD IN PERIPHERAL BLOOD 
MONONUCLEAR CELLS AND PURIFIED CD4 T-CELL SUBSETS............ 111 
5.1 INTRODUCTION ............................................................................................ 111 
5.2 METHODS ....................................................................................................... 113 
5.2.1 Study population ........................................................................................ 113 
5.2.2 Isolation of CD4 T subsets ......................................................................... 113 
5.2.3 Integrated HIV-1 DNA assay ..................................................................... 114 
5.2.4 Quantification of total HIV-1 DNA ........................................................... 115 
5.3 RESULTS ......................................................................................................... 115 
5.3.1 Study population ........................................................................................ 115 
5.3.2 Isolation of CD4 T subsets ......................................................................... 116 
5.3.3 Establishment of the integrated HIV-1 DNA assay ................................... 119 
5.3.4 Integrated HIV-1 DNA load in resting and non-resting CD4 T-cells ........ 122 
5.4 DISCUSSION ................................................................................................... 123 
6 CHAPTER 6: INTEGRATED HIV-1 DNA LOAD IN PERIPHERAL 
BLOOD IS ASSOCIATED WITH THE FREQUENCY OF CD8 CELLS 
ix 
 
 
EXPRESSING HLA-DR/DP/DQ IN PATIENTS RECEIVING LONG-TERM 
SUPPRESSIVE ANTIRETROVIRAL THERAPY .............................................. 127 
6.1 INTRODUCTION ............................................................................................ 127 
6.2 METHODS ....................................................................................................... 129 
6.2.1 Study population ........................................................................................ 129 
6.2.2 Quantification of residual HIV-1 RNA in plasma ..................................... 129 
6.2.3 HIV-1 subtyping ........................................................................................ 129 
6.2.4 Quantification of total, integrated and 2-LTR circular HIV-1 DNA in 
peripheral blood mononuclear cells ....................................................................... 129 
6.2.5 Markers of immune activation ................................................................... 130 
6.2.6 Detection of cytomegalovirus and Epstein-Barr virus DNA ..................... 130 
6.2.7 Statistical analysis ...................................................................................... 131 
6.3 RESULTS ......................................................................................................... 133 
6.3.1 Study population ........................................................................................ 133 
6.3.2 Factors associated with integrated HIV-1 DNA load ................................ 140 
6.4 DISCUSSION ................................................................................................... 147 
7 CHAPTER 7: METHODOLOGICAL DEVELOPMENT OF 
EXPERIMENTAL APPROACHES TO STUDY HIV-1 PERSISTENCE ........ 151 
7.1 Section A: Development of a new integrated HIV-1 DNA load assay ......... 151 
7.1.1 INTRODUCTION ..................................................................................... 151 
7.1.2 METHODS AND RESULTS .................................................................... 153 
7.1.3 DISCUSSION ............................................................................................ 156 
7.2 Section B: In vitro system to study cell-to-cell transmission ........................ 159 
7.2.1 INTRODUCTION ..................................................................................... 159 
7.2.2 METHODS AND RESULTS .................................................................... 160 
7.2.2.1 Lentiviral vectors production ............................................................. 160 
7.2.2.2 Co-culture system I: MT4-mCherry cell line as donor cells and Rev-
CEM as target cells. ........................................................................................... 164 
7.2.2.3 Co-culture system II: HLA-A2 negative PBMC as donor cells and 
HLA-A2 positive PBMC as target cells. ............................................................ 167 
x 
 
 
7.2.3 DISCUSSION ............................................................................................ 170 
8 CHAPTER 8: GENERAL DISCUSSION AND FUTURE DIRECTIONS 172 
9 APPENDIX 1: PUBLISHED PAPER ............................................................ 176 
10 BIBLIOGRAPHY ............................................................................................ 204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
 
LIST OF FIGURE 
Figure 1.1 Virion structure ......................................................................................... 4 
Figure 1.2 HIV-1 Genome ........................................................................................... 5 
Figure 1.3 HIV-1 cell cycle .......................................................................................... 9 
Figure 1.4 Natural course of HIV-1 infection .......................................................... 14 
Figure 1.5 GALT damage during HIV-1 infection ................................................. 18 
Figure 1.6 Sites of action of available classes of antiretroviral drugs ................... 21 
Figure 1.7 Illustration of qPCR principles .............................................................. 33 
Figure 1.8 Illustration of ddPCR principle .............................................................. 35 
Figure 2.1 CD4 T-cell subsets isolation protocol ..................................................... 46 
Figure 2.2 Alu-gag assay ............................................................................................ 53 
Figure 2.3 Sandwich ELISA ...................................................................................... 56 
Figure 2.4 Example of Mallow statistic approach for variable selection .............. 63 
Figure 3.1 Kinetics of plasma HIV-1 RNA from baseline (B/L) to week24 after the 
switch from Atripla to Eviplera ................................................................................ 77 
Figure 3.2 Plasma HIV-1 RNA levels measured in the whole cohort over time .. 78 
Figure 4.1 Markers of HIV-1 persistence in patients with 1-15 years of duration of 
suppressive ART ........................................................................................................ 91 
Figure 4.2 Markers of cellular immune activation in patients with 1-15 years of 
duration of suppressive ART .................................................................................... 92 
Figure 4.3 Soluble markers of cellular immune activation in patients with 1-15 
years of duration of suppressive ART ...................................................................... 93 
Figure 5.1 Representative example of resting CD4 T-cell purity ........................ 117 
Figure 6.1 Association between integrated HIV-1 DNA and virological and 
immunological factors ............................................................................................. 141 
Figure 6.2 Association between residual plasma HIV-1 RNA levels and 2-LTR 
circular HIV-1 DNA levels and %CD8+HLA-DR/DP/DQ+.................................. 143 
Figure 7.1 Primer combinations for Alu-gag and Alu-5LTR assays ................... 152 
Figure 7.2 Results from the qPCR2 on the Alu-gag and Alu-5LTR PCR assays
 .................................................................................................................................... 155 
xii 
 
 
Figure 7.3 Example of validation of plasmid via restriction enzyme mapping .. 162 
Figure 7.4 Validation of MT4-mCherry and Rev-CEM cell lines ....................... 166 
Figure 7.5 Characterization of Rev-CEM by immunofluorescence .................... 167 
Figure 7.6 Co-culture assay in PBMC .................................................................... 169 
 
 
 
 
 
 
 
 
xiii 
 
 
LIST OF TABLE 
Table 1.1 Regimens recommended for starting ART in HIV-positive adults. ..... 25 
Table 2.1 Breakdown of patient’s recruitment and samples available for testing 
for the study on switching Atripla to Eviplera ........................................................ 41 
Table 2.2 Breakdown of recruitment for the ERAS study. .................................... 42 
Table 2.3 List of all primers used in this thesis ....................................................... 55 
Table 2.4 List of all antibodies used in flow cytometry assays in this thesis ........ 59 
Table 2.5 List of all ELISA assay kits used to measure soluble markers of immune 
activation in this thesis ............................................................................................... 61 
Table 3.1  Validation of manual RNA extraction.................................................... 71 
Table 3.2 Individual runs performed to validate the manual RNA extraction assay
 ...................................................................................................................................... 72 
Table 3.3 Validation of automated RNA extraction ............................................... 73 
Table 3.4 Baseline characteristics of the study population .................................... 74 
Table 3.5 Plasma HIV-1 RNA levels before and over 24 weeks after switching from 
Atripla to Eviplera ..................................................................................................... 76 
Table 4.1 General characteristics of the study population at the time of 
recruitment ................................................................................................................. 88 
Table 4.2 Virological and immunological profile of the study population at the time 
of recruitment ............................................................................................................. 89 
Table 4.3 Univariate linear regression analysis of mean difference in log-
transformed virological and immunological parameters per 10 years of 
suppressive antiretroviral therapy ........................................................................... 90 
Table 4.4 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in residual plasma HIV-1 RNA load ........... 96 
Table 4.5 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in residual plasma HIV-1 RNA load in 
patients with residual plasma load ≤11 copies/ml (N=102) .................................... 97 
xiv 
 
 
Table 4.6 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in 2-LTR circular HIV-1 DNA load in PBMC.
 ...................................................................................................................................... 98 
Table 4.7 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in total HIV-1 DNA load in PBMC ............. 99 
Table 4.8 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in total HIV-1 DNA load in CD4 T-cells .. 100 
Table 4.9 Influence of Black and White ethnicity on markers of HIV-1 persistence 
(N=100) ...................................................................................................................... 101 
Table 4.10 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in 2-LTR circular HIV-1 DNA load in PBMC 
in 100 patients with white or black ethnicity ......................................................... 102 
Table 4.11 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in total HIV-1 DNA load in CD4 T-cells in 100 
patients with white or black ethnicity .................................................................... 103 
Table 4.12 Influence of EFV levels on markers of HIV-1 persistence (N=86).... 104 
Table 4.13 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in residual plasma HIV-1 RNA load in 84 
patients on EFV ........................................................................................................ 105 
Table 5.1 Characteristic of the ERAS study population ...................................... 116 
Table 5.2 Recovery and purity of resting and non-resting CD4 T-cells ............. 118 
Table 5.3 Setting up of the integrated HIV-1 DNA method in Liverpool ........... 120 
Table 5.4 HIV-1 DNA loads in PBMC from ERAS1 and ERAS2 populations .. 121 
Table 5.5 Integrated HIV-1 DNA loads in resting and non-resting CD4 T-cells122 
Table 6.1 Characteristics of the study population overall, and stratified by 
duration of suppressive therapy as below (Group I) or above (Group II) the 
median of 6.4 years .................................................................................................. 135 
Table 6.2 Univariate linear regression analysis of mean difference in log-
transformed virological and immunological variables per 10 years of suppressive 
antiretroviral therapy .............................................................................................. 137 
Table 6.3 Comparative analysis of subjects whose integrated HIV-1 DNA load fell 
within the lowest or the highest quartile ................................................................ 138 
xv 
 
 
Table 6.4 Univariate and multivariable linear regression analysis of factors 
associated with the mean difference in integrated HIV-1 DNA load .................. 142 
Table 6.5 Multivariable linear regression analysis of factors associated with the 
mean difference in integrated HIV -1 DNA load over 10 years of suppressive 
antiretroviral therapy in a model including nadir CD4 cell count. ..................... 145 
Table 6.6 Sensitivity analysis replacing integrated with total HIV-1 DNA in the 
two multivariable modelsa. ...................................................................................... 146 
Table 7.1 qPCR2 efficiency with Alu-gag and Alu-3LTR PCR assay settings ... 156 
Table 7.2 Plasmids characteristics .......................................................................... 161 
Table 7.3 Transfection mixes .................................................................................. 163 
Table 7.4 Virus titre estimation by p24 Elisa assay .............................................. 164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xvi 
 
 
LIST OF ABBREVIATIONS 
ABC Abacavir  
AIDS   Acquired immune deficiency syndrome  
APC Allophycocyanin 
ART   Antiretroviral therapy  
AZT Zidovudine  
BL Baseline  
bp Base pair 
ART   Active antiretroviral therapy  
CD4 Cluster of Differentiation 4 
CD8 Cluster of Differentiation 8 
CDC Centre for Disease Control and Prevention 
CI Confidence interval 
CMV Cytomegalovirus 
CNS Central nervous system 
CSF Cerebrospinal fluid 
Ct Cycle threshold 
CTL Cytotoxic CD8 T-cells 
d4T Stavudine 
DDI Didanosine  
ddPCR Droplet digital PCR 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethyl sulfoxide 
EDTA Ethylenediaminetetraacetic acid 
EFV   Efavirenz  
ELISA Enzyme-linked immune-enzymatic assay 
ENV Envelope 
FBS Fetal bovine serum 
FITC Fluorescein isothiocyanate 
FTC  Emtricitabine  
Gag Group specific antigen protein 
GFP Green fluorescent protein 
HEK-293 Human Embryonic Kidney 293 cells 
HIC HIV-1 controllers 
HIV   Human immunodeficiency virus  
HLA Human leukocyte antigen 
hrs Hours 
hs-CRP High-sensitivity C-reactive protein 
IL Interleukin 
xvii 
 
 
INSTI Integrase strand transfer inhibitor 
IQR Interquartile range 
IS Internation standandard 
IUMP Infectious unit per milliliter 
kb Kilobase 
L Litre 
ln Natural logarithm 
LPS Lipopolysaccharide 
LTR Long terminal repeats 
MGB Minor groove binding 
MHC Major histocompatibility complex 
nm Nanometer 
NNRTI   Non-nucleoside reverse transcriptase inhibitor  
NRTI Reverse transcriptase inhibitor 
NVP Nevirapine 
OD Optical density 
OFR Open reading frame 
PBMC Peripheral Blood Mononuclear cells 
PBS Phosphate-buffer saline 
PCR  Polymerase chain reaction 
PE R-phycoerythrin  
PFA Paraformaldehyde 
PI Proteinase inhibitor 
qPCR Quantitative PCR 
RNAseH Ribonuclease H 
RPMI Roswell Park Memorial Institute medium 
RPV   Rilpivirine  
RRE Rev responsive element 
RT Room temperature 
sCD14 Soluble CD14 
SIV Simian Immunodeficiency virus 
TAR Tat responsive elements 
TDF   Tenofovir disoproxil  
TE buffer Tris-EDTA buffer 
VLS Viral load suppression 
VOA Viral outgrowth assay 
VS Virological synapses 
VSV Vesicula stomatitis virus 
WHO World health organisation 
X2 Chi-square test 
xg Centrifugal force 
 
 
1 
 
 
1 CHAPTER 1: General introduction 
The human immunodeficiency virus (HIV) is a member of the family Retroviridae, 
genus of Lentivirus (International Committee on Taxonomy of Viruses, 2002). HIV is 
transmitted through body fluids (blood, sexual fluids, and breast milk) and causes the 
acquired immunodeficiency syndrome (AIDS). At the end of 2014, 36.7 million  people 
globally were living with HIV-1 and 1.1 million people died from AIDS-related 
illnesses (UNAIDS, 2016). Although the discovery of HIV dates back to the early 
1980s, a vaccine is still not available. Antiretroviral therapy (ART) however effectively 
suppresses virus replication preventing disease progression and mortality.  
1.1  HIV discovery, origin, and genetic diversity 
In1981-1982, the Morbidity and Mortality Weekly Report (MMWR) from the Centre 
of Disease Control and Prevention (CDC) in the U.S. described cases of Pneumocystis 
carinii pneumonia and Kaposi sarcomas (Hymes et al., 1981) occurring among healthy 
young men, predominantly sexually active homosexuals. In line with the fact that such 
opportunistic infections were known to be limited to severely immunosuppressed 
(Walzer et al., 1974) individuals, clinical examination of the patients confirmed that all 
of them had immune deficiency. Similar clinical conditions were soon reported in 
Western Europe (Vilaseca et al., 1982, Rozenbaum et al., 1982, Francioli et al., 1982), 
and not only in men having sex with men, but also in heterosexuals, subjects who had 
received blood or blood products, and intravenous drugs users. The common 
denominator was a “cellular-immune dysfunction related to a common exposure” 
(Centers for Disease, 1981), and in 1982 CDC officially defined the condition as the 
Acquired immune deficiency syndrome (AIDS). 
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In 1983, Luc Montagnier and Françoise Barré-Sinoussi from the Pasteur Institute in 
Paris first isolated a retrovirus from cultures of T lymphocytes derived from a patient 
with cervical lymphadenopathy, which they named Lymphadenopathy-Associated 
Virus (LAV) (Barre-Sinoussi et al., 1983). A few months later in 1984, Robert Gallo 
and colleagues at the National Cancer Institute of Bethesda in the U.S. announced the 
discovery of a new T lymphotropic virus in patients with AIDS that they named Human 
T-Lymphotropic Virus type III (HLTV-III). Sero-epidemiological analyses supported 
the hypothesis that HLTV-III was the etiological agent of AIDS (Popovic et al., 1984). 
In the same year, Jay Levy’s group isolated an AIDS-associated virus (ARV) from 22 
patients with AIDS.  In 1985, the full genomes from LAV, HTLV-III, and ARV were 
obtained demonstrating that they were variants of the same virus (Ratner et al., 1985). 
In May 1986, the International Committee on the Taxonomy of Viruses named the virus 
the Human Immunodeficiency Virus (HIV).  
 
Later in the same year a second retrovirus was isolated from two West African patients, 
which were hospitalized in Portugal and France, and presented with AIDS-like clinical 
features (Clavel et al., 1986). The new virus was called HIV type 2 (HIV-2), while the 
former was renamed HIV type 1 (HIV-1). In 2008, Luc Montagnier and Françoise 
Barré-Sinoussi were awarded the Nobel Prize in Physiology or Medicine for the 
discovery of HIV-1. 
 
HIV-1 is more transmissible and virulent than HIV-2 and as such it is more widely 
spread globally, whereas HIV-2 has a more limited geographical distribution in West 
Africa and countries with links to this region. Phylogenetic analysis of viral sequences 
shows homology between HIV and the simian immunodeficiency virus (SIV) which 
infects non-human primates including chimpanzees (Hahn et al., 2000) (SIVcpz) and 
gorillas (SIVgor). Three genetically distinct HIV-1 groups originated by independent 
zoonotic transmission events of SIVcpz into humans: group M (“major”), group O 
(“outlier”), and group N (“non-M, non-O”) (Ward et al., 2013, Gao et al., 1999). One 
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additional group named P was identified recently which appears to be more directly 
related to SIVgor. Group M strains are responsible for the HIV-1 pandemic and nearly 
95% of AIDS cases. Group O, N, and P strains are mainly found in Central and West 
Africa.  
 
HIV-1 group M is further divided into nine subtypes: A, B, C, D, E, F, G, H, J, K that 
show inter-subtype genetic variability in the gag and env genes (Geretti, 2006). HIV-1 
diversity is mainly caused by fast replication cycle of the virus coupled with the high 
error prone rate of the reverse transcriptase (RT) enzyme (Preston et al., 1988, Jacobs 
et al., 2014). Within these subtypes, recombinant forms have been identified by full-
length genome sequence and they can be classified either as unique recombinant forms 
(URFs) or circulating recombinant forms (CRFs). URFs are defined as recombinant 
viruses that have been found in only one individual or an epidemiologically linked 
cluster and they do not show evidence of spread; CRFs are recombinant viruses that 
have been identified in at least three epidemiologically unlinked individuals (Geretti, 
2006). Currently, 75 different CRFs have been described (HIV sequence database, 
2016). 
1.2 The viral life-cycle 
1.2.1 Virion structure  
Similar to other retroviruses, HIV-1 consists of an enveloped particle approximately 
100 nm in diameter (Figure 1.1). The virion envelope (ENV) consists of a lipid bilayer 
membrane, derived from the host cell, and a viral trimeric envelope protein complex. 
Each trimeric structure comprises three surface glycoproteins named gp120 and three 
trans-membrane protein named gp41. Underneath the viral envelope, the matrix protein 
(Matrix, MA, p17) surrounds the viral capsid, which consists of the major capsid protein 
(CA, p24) and the nucleocapsid protein (NC, p7p9). The capsid contains two identical 
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molecules of single stranded RNA and three viral enzymes: protease, integrase, and 
reverse transcriptase (RT) (Barre-Sinoussi, 1996). 
 
 
 
 
Figure 1.1 Virion structure 
(adapted from Barré-Sinoussi, the Lancet 1996). Schematic picture (a) and electron 
micrograph (b) of a HIV-1 particle. Env= envelope; PROT = protease; INT= integrase; RT= 
retro-transcriptase; MA= matrix; CA= capsid; NC= nucleocapsid protein.  
 
 
1.2.2 Genome and proteins 
The HIV-1 genome is approximately 9.2 kb in size and contains nine open reading 
frames (ORFs) which encode 15 distinct proteins (Watts et al., 2009). At the two edges 
of the genome there are two long terminal repeats (LTRs): the 5’ LTR contains 
transcription regulatory factors, while the 3’LTR contains the polyadenylation site. A 
schematic representation of the viral genome organization is given in Figure 1.2. 
 
a) b) 
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Figure 1.2 HIV-1 Genome 
(adapted from JM Watts et al., Nature 2009). The full genome contains 9 open reading frames 
(ORF): gag, pol, vif, tat, vpu, vpr, rev, env, nef. Grey boxes= ORF; white boxes= LTR as they 
appear in the virion. MA= Matrix; Ca= capsid; NC= nuscleocapside; PR= protease; RT= 
retro-transcriptase; IN=integrase; SP= signal peptide.  
 
 
 
 
Three of the nine ORFs encodes for polyprotein precursors that undergo further 
processing: Gag (p55), Gag-Pol (p160) and Env (glycoprotein, gp160). P55 is cleaved 
by the viral protease enzyme to produce the matrix, capsid, nucleocapsid, and p6 
proteins. These viral proteins are fundamental for virus assembly, as discussed further 
below in the text.  
 
Gag-Pol precursors encode for the viral enzymes which will be contained into mature 
viral particles. Some poly-protein undergoes autocatalysis and the first enzyme to be 
produced is protease, which is responsible for processing the other gag-pol proteins 
(Pearl and Taylor, 1987, Yang et al., 2012) to yield the RT and integrase enzyme. RT 
is involved in three enzymatic processes: reverse transcription of the viral RNA into 
DNA, RNAseH activity to mediate the degradation of the RNA strand in the RNA-
DNA duplex (Sarafianos et al., 2009) obtained from the reverse transcription, and DNA 
polymerase activity to produce a second strand of DNA. RT lacks proof-reading 
activity, creating a highly favourable condition for HIV genetic evolution during 
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replication. The integrase enzyme regulates the integration of the linear viral DNA 
produced by RT into a host chromosome (Li et al., 2011).  
 
The Env precursor gp160 is digested by host furin-like protease (Stein and Engleman, 
1990) to produce a typical spike conformation comprising the gp120 sub-unit on the 
viral surface, which mediates binding of the viral particle to the CD4 receptor and one 
of several co-receptors on host target cells. Three gp120 glycoproteins are attached non-
covalently (Pancera et al., 2010) to three gp41 proteins, which are trans-membrane 
proteins responsible for the fusion between the virus and the cellular membrane.  
 
The other six ORFs encode for 6 accessory proteins that do not require further 
processing: tat, rev, vif, vpr, nef, vpu. Tat and Rev are two trans-activating proteins. 
Tat regulates viral genome expression, including transcription of the three polyproteins 
and synthesis of the full viral genome, by binding the Tat responsive element (TAR) 
situated within the viral genome. Rev is involved in the export of messenger RNA from 
the nucleus to cytoplasm. Vif is the viral infectivity factor and it is required for 
production of infectious virions by inducing degradation of the intracellular APOBEC 
protein, which exerts antiviral activity by inducing an inactivating hyper-mutation in 
the HIV-1 genome. Vpr or viral protein R is involved in viral transcription, cell cycle 
control, infectivity and nuclear import of the HIV-1 DNA pre-integration complex. Nef 
or negative regulator factor sustains infection by interaction with human cellular 
functions, including down regulation of the expression of the human leukocyte antigen 
(HLA) genes that encodes the class I major histocompatibility complex (MHC), thus 
facilitating viral escape from immune recognition. Vpu protein is known to assist the 
budding of the newly formed virions from the infected cells membrane. 
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1.2.1 Virus replication cycle 
The HIV-1 replication cycle requires approximately 24 hours to be completed (Perelson 
et al., 1996) and it includes a series of sequential steps (Figure 1.3). 
1.2.1.1 Binding and fusion with host cells  
The HIV-1 envelope spikes mediate the initial phases of infection. Gp120 has a high 
affinity for the CD4 receptor that is expressed on the surface of different cell types 
including T-cells (Kwong et al., 1998), macrophages, dendritic cells (DC), 
hematopoetic stem cells, and astrocytes (Iordanskiy et al., 2013). After the binding of 
gp120 to the CD4 receptor, the envelope spikes regions V1-V2 and V3 region are re-
arranged to from a bridging sheet structure that enables the exposure of the co-receptor 
binding site (Kwong et al., 1998, Liu et al., 2008). Two molecules have been identified 
as the major co-receptor in vivo: the α-chemokine receptor (CXCR4) and the β-
chemochine receptor CCR5. Depending on which co-receptor is used to enter the cells, 
HIV-1 strains can be classified as: CCR5 tropic (R5) if using only the CCR5 co-
receptor, CXCR4 tropic (X4) if using only the CXCR4 co-receptor, or dual tropic if 
using either CCR5 or CXCR4. An HIV-infected individual may show different a 
mixture of R5, X4 or dual tropic virus and in this case is defined as being mixed tropic 
(M). Regardless the routes of transmission, R5 tropic viruses are preferentially 
transmitted and drive the initial phase of HIV infection. Individuals with homozygous 
genetic defects in the CCR5 receptors (Δ32 deletion) are naturally resistant to HIV 
infection (Hutter et al., 2009). Co-receptors expression varies depending on cell types; 
in particular CCR5 is predominantly expressed on the surface of macrophages and a 
subset of memory CD4 T-cells, whereas CXCR4 is constitutively expressed on many 
cell type, including CD4 T-cells and macrophages (Este and Telenti, 2007).  
 
Binding of the co-receptor induces a disruption of the interaction between the gp120 
and gp41 and results in an extended gp41 conformation (Roche et al., 2015, Roux and 
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Taylor, 2007). In this extended state, gp41 C-terminal domain is anchored to the viral 
membrane and the highly hydrophobic N-terminal fusion peptide of gp41 is free to 
insert into the host cell membrane. This early exposed gp41 conformation is termed 
pre-hairpin intermediate (PHI) (Sackett et al., 2009). Following insertion into the host 
cell membrane, the extended gp41 folds back into a stable trimer-of-hairpins in a six-
helix bundle (6HB) structure where the C-terminal and the N-terminal domain are in 
close interaction. This conformational change, called final state hairpin conformation, 
is needed for the contact between the viral and host membrane (Jiao et al., 2015) 
resulting in the formation of a fusion pore (Melikyan et al., 2000) through which the 
viral content is delivered into the cellular cytoplasm.  
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Adapted from Pasternak AO et al. 2013 (Pasternak et al., 2013) 
 
 
 
 
 
 
 
Figure 1.3 HIV-1 cell cycle 
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1.2.2 Uncoating, reverse transcription and nuclear import 
After entering the cells, HIV undergoes uncoating (Ambrose and Aiken, 2014) and the 
RNA genome and associated enzymes are injected into the cytoplasm. This is followed 
by reverse transcription of the viral RNA into double stranded DNA prior to import into 
the nucleus for integration into the host genome. The capsid dissociation occurs in 
proximity of the nuclear membrane, thus allowing passage of the viral genome through 
the cytoplasm without intracellular DNA sensors (Rasaiyaah et al., 2013).  
 
As described before, the RT enzyme is responsible for the reverse transcription that 
initiates with the binding of a host transfer RNA (tRNALys3) primer to a primer binding 
site (PBS) situated at the 5’ end of the positive single strand viral RNA.  Primer binding 
allows the viral polymerase to copy the 5’into minus DNA viral strand: this step 
generates DNA/RNA hybrid that acts as substrate for RNase H activity of the RT which 
degrades the RNA strand, leaving the nascent viral DNA. This DNA sequence includes 
the repeated sequence of the viral genome (called R, repeat) that are identical at the 5’ 
and 3’ end. Therefore, the free nascent viral DNA can bind its complementary sequence 
at the 3’ end of the viral RNA. This step is known as minus strand transfer and it allows 
the polymerase to continue the elongation of the minus strand viral DNA from the 3’ 
end towards the 5’ end. As the DNA synthesis proceeds, RNase H degrades the RNA 
from RNA/DNA hybrids excluding a specific region called polypurin tracts (PPT). 
These regions, in particular one situated towards the 3’ end of the viral RNA, serve as 
primers for the synthesis of the positive DNA strand that copies the 5’ end including 
the U3, R and U5 sequence but also the first 18 nucleotides of the tRNALys3. RNase H 
partially degrades the tRNA facilitating the exposure of a region at the 3’ end of the 
plus viral DNA that is complementary to the PBS sequence at the 5’end of the minus 
viral DNA. Following the pairing of the two regions (plus-strand transfer), both the 
minus and plus DNA strands are extended until the entire DNA is double stranded and 
with same end sequences containing U3-R-U5 regions (long terminal repeats, LTR).  
 
11 
 
 
Migration of the viral DNA towards the nucleus is regulated by the pre-integration 
complex (PIC) that includes viral (e.g., p17, p24, RT, integrase and vpr) and cellular 
proteins (Jayappa et al., 2012), which engages nuclear pore proteins (NUP) such as 
NUP358 and NUP153 to promote the translocation of the viral genome into the nucleus.  
1.2.2.1 Virus integration  
This reaction happens in three steps which are catalysed by the integrase enzyme, which 
exhibits two distinct catalytic activities: the 3’ processing and the strand transfer 
(Kvaratskhelia et al., 2014). During the first step, the 3’ end of the linear viral DNA is 
modified to end with a CAOH-3’ sequence. The 3-idroxyl group is used by the integrase 
in the second step during which the integrase generates a cut in the complementary host 
DNA and covalently binds the 3’ ends of the viral DNA to the 5’ ends of the target 
DNA. Following this strand transfer process, the viral and host DNA have unpaired 
regions of DNA (gaps) that recruits host cellular DNA damage response proteins, 
including polymerase, nuclease and ligase, which repair these gaps.  HIV integration 
sites are random within the human genome, even though it has been shown that the 
virus preferentially integrates into actively transcribed genes to ensure efficient gene 
expression (Marshall et al., 2007). The cellular transcription activator factor 
LEDGF/p75 has a role in the efficiency of integration by binding both the integrase and 
the active transcription DNA loci to direct the viral integration in these regions. 
 
A fraction of the linear viral DNA is not integrated and can either become circularised 
to contain one or two LTR (1- and 2-LTR circular DNA) or can remain linear which 
then undergoes degradation mediated by the host cell (Butler et al., 2002, Sharkey, 
2013). The half-life of these non-integrated forms is still debated, however it is 
generally accepted that circularised viral DNA is more stable when compared with the 
linear form and therefore they could be used to track viral persistence. 
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Integrated HIV DNA, also called provirus, has a long half-life and it provides the 
genetic information for the production of new viral particles, including genomic and 
messenger RNA.  
1.2.2.2 Gene expression 
A single strong promoter in the viral 5’LTR region drives viral expression, subjected to 
regulation by cellular transcription factors that are expressed only when cells are 
activated (Nabel and Baltimore, 1987). The most important of these transcription 
factors are the NF-ĸB factors that bind to the viral genome in two adjacent regions 
within the 5’LTR. Transcription of viral genes leads to the production of three 
categories of messenger DNA (mRNA molecules): fully spliced mRNAs that encodes 
the viral proteins Tat, Rev and Nef, the partially spliced mRNAs that encode for Env 
and the accessory proteins Vif, Vpr and Vpu and unspliced mRNA that act both as the 
virion genomic RNA and the mRNA for the Gag/Gag-pro-pol polyproteins. Initial 
expression produces short fully spliced mRNA that are exported to the cytoplasm by 
constitutive cellular pathways to generate the viral proteins. Among those, Tat and Rev 
play key roles in the regulation of HIV-1 genome expression. Tat interacts with a TAR 
in the 5’ end of the nascent HIV-1 transcript and with the positive transcription 
elongation factor (pTEFb) acts to promote transcript elongation (Cullen, 1991); Rev 
mediates the transport of the unspliced and partially spliced mRNA from the nucleus to 
the cytoplasm by interaction with the cellular nuclear export factor CRM1. In the 
cytoplasm, incompletely spliced mRNA produces Env and the accessory proteins, 
whereas unspliced mRNA generates the Gag/Gag-pro-pol polyproteins or functions as 
genomic RNA (Karn and Stoltzfus, 2012). 
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1.2.2.3 Viral particle assembly, budding and maturation  
After the translocation of the viral mRNA into the cytoplasm, viral proteins are 
synthesized and assembled together to compose the immature viral particle (Freed, 
2015). In the rough endoplasmic reticulum (RER), the incompletely spiced mRNA 
generates the Env spikes composed by gp120 and gp141 which are transported to the 
secretory pathway to the plasma membrane. In the cytoplasm, the unspliced mRNA is 
synthesized to produce the Gag-Pol and Gag polyproteins to generate the viral enzymes 
and the viral proteins that are needed for virus particles assembly. The matrix protein 
target Gag to the plasma membrane and it is responsible for the incorporation of Env 
glycoproteins in the virions (Fiorentini et al., 2006). The capsid protein regulates Gag 
multimerization that will form the conical core of the virion. The NC protein is an RNA 
binding protein and it recruits the double strand genomic HIV-1 RNA via its interaction 
with specific sequences at the 5’UTR (Ψ region) in order to coordinate the packaging 
of the genomic RNA into the virion (Dawson and Yu, 1998). The P6 protein is 
responsible for the incorporation of Vrp, Vif and Nef. Furthermore, interaction of the 
p6 domain and the endosomal sorting complex required for transport (ESCRT) 
mediates the in the release of the virus from the cells, a dynamic process called budding 
(Muller et al., 2002). During budding, the viral protease enzyme promotes the 
maturation of the viral particle to become an infectious virion. In particular, the Gag 
precursor is cleaved into the mature matrix, capsid, and nucleocapsid and p6 proteins 
and this step induces morphological transformation in the virion including the re-
organization of CA to form the conical capsid core.   
1.2.3 Pathogenesis 
In absence of treatment, the course of HIV-1 infection proceeds through three main 
phases: primary/acute infection, asymptomatic/clinical latency, and the symptomatic 
phase leading to the development of AIDS as illustrated in Figure 1.4. The symptomatic 
acute phase is characterized by high viremia, a sharp drop in CD4 T-cell counts, 
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establishment of reservoirs of latently infected cells, and the development of the anti 
HIV-1 specific immune response (Douek et al., 2003). This is followed by a drop in 
viral load and a partial and temporary increase in CD4 T-cell numbers that marks the 
beginning of a long asymptomatic phase during which the virus production and the CD4 
T-cell number decline is slow. When CD4 T-cell count is less than 200 cells/L, the 
opportunistic tumours and infections that characterize AIDS are established in the 
patient. The typical rate of progression is such that AIDS and death occur within 10-12 
years from initial infection. However, the course of the infection is different from 
patient to patient and it is driven by a complex interplay between virus replication and 
host immune responses as described in the following sections. 
 
 
 
 
 
 
Figure 1.4 Natural course of HIV-1 infection 
(adapted from Viviana Simon and David D.Ho 2003, Nature reviews). This figure depicted the 
reciprocal relationship between plasma HIV load increase and CD4 T-cell loss over the course 
of infection. 
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1.2.3.1 HIV transmission and primary infection 
HIV can be transmitted via body fluids such as semen, vaginal secretion, blood, and 
breast-milk. The infection occurs when the virus enters the body via the bloodstream 
through: shared needles, blood transfusion, damaged skin, mother-to-child transmission 
during childbirth and via the placenta when transmitted from mother to child during 
pregnancy. Transmission can also occur through the mucous membranes that cover a 
variety of body cavities such as conjunctiva, rectum and genital mucosa. Transmission 
via mucosa can also occur through tissue damage through which HIV can enter. 
Additionally, these body compartments are highly populated by dendritic cells (DC), 
macrophages and CD4+T cells, all of which express high levels of the CD4 receptor and 
CCR5 co-receptor and are highly permissive for HIV-1 infection (Keele et al., 2008). 
As discussed previously R5 virus represents the majority of the transmitted virus. This 
tropism represents a crucial adaptation of the virus that promotes infection of a subset 
of effector CD4 T-cells differentiated in lymphoid tissue, which represent a large initial 
target population (Okoye and Picker, 2013, Brenchley et al., 2004, Picker and Watkins, 
2005). Furthermore, the dissemination of HIV throughout the body is also supported by 
DCs that bind and present HIV to CD4 T-cells. This is a natural immune mechanism 
that serves to elicit specific immune responses against any pathogens; however in the 
case of HIV this protective mechanism gives the virus direct access to the CD4 T-cells 
cells which are its preferred target of infection. HIV-infected T-cells remain sequestered 
in lymph nodes until a threshold of replication is reached (typically within 2-4 weeks 
post infection) and subsequently a burst of plasma viremia occurs and the virus is 
disseminated within days around the body (Weber, 2001). This period is termed primary 
HIV infection (PHI) and it covers the period between the virus transmission and the 
completion of the induction of the primary immune response. 
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1.2.3.2  Plasma viremia and anti-HIV immune response dynamics  
Virus transcription in infected cells is positively regulated by cellular factors that bind 
the HIV-1 LTR and is associated with a high plasma HIV RNA burden that can reach 
levels that exceed 5x106 copies/ml (Weber, 2001) during the acute phase/primary 
infection and becomes detectable at around 11 days post-exposure. The viremic peak 
has been associated with a transient reduction of CD4 T-cells. However, both the 
plasma viremia burden and the CD4 T-cell loss resolve spontaneously after 2-4 weeks, 
in association with the presence of a vigorous HIV-1-specific cell-mediated immune 
response which includes cytotoxic CD8 T-cells (CTL) and CD4 T-helper cells. It is 
generally accepted that CD4 T-helper cell responses are generally weak during the 
course of infection, whereas the CTL response seems to be the major effector cells of 
anti-HIV immune responses (Weber, 2001) and this has been proved by several studies 
that have reported the presence of HIV genetic variants that can escape from CTL 
function (Borrow et al., 1994, Phillips et al., 1991). Nonetheless, other mechanisms are 
believed to be involved in the control of viremia in the initial period following infection. 
First non-neutralizing antibodies may bind core, matrix and envelope viral proteins and 
direct virus clearance via Fc receptor mediated mechanism (Weber, 2001). 
Furthermore, exhaustion of infected CD4 T-cells may reduce virus production without 
the presence of immune responses (Weber, 2001).  
 
During the following 10-24 weeks the HIV viral load drops to its lowest point known 
as “set-point”. This is different for each patient and is also a predictor of prognosis 
(Mellors et al., 1996). At this stage, anti-HIV antibody responses are strong and can be 
detected (seroconversion) and the so-called chronic HIV infection phase/clinical 
latency phase starts. Over the clinical latency phase, HIV genetic diversity increases to 
escape from CTL action and its replication is persistent with approximately 108 virions 
produced/day. Interestingly, disease progression is associated with the emergence of 
X4 tropic virus, normally dual or mixed population, in 50% of untreated patients. It still 
is not clearly defined if the emergence of X4 variants is a consequence rather than the 
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cause of disease progression. It has been proposed that the increase in CD4 T-cells 
expressing CXCR4 in individuals with CD4 counts<400 cells/L may favour the rise of 
X4 tropic virus (Lin et al., 2005). Of note, this CXCR4 over-expression seems to be 
mediated by IL-7 produced to induce cell proliferation to compensate for lymphopenia 
(Brieu et al., 2011, Fiser et al., 2010, Llano et al., 2001). On the other hand clinical 
studies on patients treated with CCR5 antagonist drugs showed that the appearance of 
R4 viruses was rapidly outgrown by R5 viruses upon drug discontinuation, indicating 
a lack of overall advance for X4 viruses when a drug selective pressure is removed (van 
der Ryst and Westby, 2007). 
 
 
1.2.3.3  Virus dissemination into target tissues, immune activation and 
CD4 T-cell loss dynamics 
R5-tropic virus dominates acute and chronic infection as described above. Cell targets 
of primary infection are mainly macrophages, dendritic cells and CD4 T-cells. Studies 
that tracked HIV-1 viral genotypes in local microenvironment showed that initial 
propagation of infection is mainly clonal and it is localized in mucosal tissues where 
cell density is particularly high (Douek et al., 2003). Efficient HIV-1 production and 
propagation from infected cells to adjacent CD4+CCR5+ cells is supported by T cell 
activation that can be mediated by different mechanisms. First, HIV-1 gene products 
themselves including Nef, Tat, Vpr and Enf can induce T cell-activation independently 
from T cell receptor pathways; furthermore, the mucosal environment is rich in 
inflammatory cytokines that can contribute to cell activation (Douek et al., 2003). As 
result of HIV infection, lymphoid architecture is disrupted as well as the functionality 
of gut-resident immune cells, e.g. IL-17 and IL-22 producing cells that normally block 
translocation of opportunistic pathogens that populate the gut lumen (Figure 1.5). 
Therefore, translocation of microbial products in peripheral blood can in turn induce 
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monocyte activation that leads to soluble CD14 (sCD14) production. It can also lead to 
the activation of CD4 and CD8 lymphocytes which results in the expression of 
activation markers including CD69 (Sousa et al., 2002), CD26, CD38 and the human 
leukocyte antigen complex HLA-DR/DP/DQ (French et al., 2009) on the surface of 
these T cells. Similarly there is an increased level of soluble plasma protein expression 
including neopterin, CD30, CD27 and tumour necrosis factor receptors (sTNFR) 
(French et al., 2009, Lawn et al., 2001). This generalized status of immune activation 
increases the damage to the gut barrier which can become independent of virus 
replication, however immune activation still sustains disease progression and viral 
production in the absence or presence of treatment (Tincati et al., 2016, Marchetti et al., 
2008). In this context, several studies have tried to identify specific markers of immune 
activation as predictors of disease progression. .  
 
 
 
Adapted from Tincati C et al 2016. Figure representing the induction of GALT damage during 
untreated and ART treated HIV-1 infection.  
 
Figure 1.5 GALT damage during HIV-1 infection 
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Sandler and colleagues demonstrated that levels of sCD14 and markers of gut epithelial 
dysfunction, coagulation (D-Dimer) and inflammation (hsCRP and IL-6) correlate with 
disease progression and mortality in both untreated and treated patients (Sandler et al., 
2011). Furthermore, studies have been performed to investigate the clinical significance 
of the T-cell activation during HIV-1 infection. Among the soluble markers, the soluble 
CD30 and CD27, two members of the sTNFR family, have been associated with disease 
progression (Rizzardi et al., 1996, Pizzolo et al., 1994). In the context of cellular 
markers of immune activation, expression of CD38 and HLA-DR/DP/DQ on CD4 and 
CD8 T-cells has been described as a strong predictor of disease progression in several 
studies (reviewed by (Lichtfuss et al., 2011) (Klatt et al., 2013)). Of note, individuals 
that are naturally capable of controlling HIV-1 progression (long term non-progressors, 
LNTP) have been found to have lower expression of CD38, HLA-DR/DP/DQ and 
CD26 (Carbone et al., 2003, Brostrom et al., 1998). The findings of studies on LTNP 
confirm that higher levels of immune activation might support HIV-1 progression. 
 
Gut damage and microbial translocation are not the only driving forces that support this 
chronic immune activation: coinfections with other microbes have been implicated as 
possible responsible factors (Younas et al., 2016). Latent viruses such as 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivated more frequently 
during HIV infection due to the depletion of CD4+T cells and it has been shown that 
such viruses can drive cell activation during untreated and potentially, treated HIV 
infection (Klatt et al., 2013, Naeger et al., 2010). In the context of HIV progression, 
CMV and EBV directly drive CD8 T cell activation and this mechanism contributes to 
the general immune activation status (Doisne et al., 2004, Paiardini and Muller-
Trutwin, 2013). Furthermore, levels of asymptomatic CMV replication in the male 
genital tract of ART treated HIV-1 infected individuals has been associated with plasma 
immune inflammation and higher proviral HIV-1 DNA load in peripheral blood 
mononuclear cells (PBMCs), despite virological suppression. 
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Chronic immune activation supports disease progression that is associated with rapid 
and massive CD4 T-cell depletion (mainly of the CCR5+CD4+ memory T-cell subset) 
during acute infection followed by slow and constant T-cell depletion during the 
chronic phase (Douek et al., 2003). Different mechanisms (Doitsh and Greene, 2016) 
have been proposed to explain declines in such population. Initially, this depletion was 
thought to reflect a viral cytopathic effect occurring in productive CD4 T-cell infection 
(Alimonti et al., 2003). However, while viral production is extensive throughout the 
course of infection, loss of CD4 T-cell is much slower. This enigma suggests that CD4 
T-cell-driven viral cytopathicity alone cannot explain the cell loss and course of disease 
(Douek et al., 2003). Other studies showed that most of the dying cells in lymph nodes 
of infected patients were bystander CD4 T-cells that themselves were not actively 
infected (Finkel et al., 1995). Bystander cell death can be driven by both cellular factors 
(Herbeuval et al., 2005) (e.g. tumour necrosis factors) and viral factors including HIV-
1 Tat, Vpr and Nef which are released by infected cells (Schindler et al., 2006). 
Moreover, recent studies (Monroe et al., 2014) showed that abortive infection events 
particularly in resting cells can activate cell suicide as the consequence of the presence 
of viral DNA within the cells (Munoz-Arias et al., 2015).  
 
Cell depletion towards the end of the chronic phase and the beginning of the AIDS 
phase has been associated with the emergence of CXCR4 viruses that in vitro showed 
high cytotoxicity for peripheral immature T-cells produced by the thymus to 
compensate for T-cell loss. 
1.3 Antiretroviral drugs  
Antiretroviral drugs are classified according to the targeted step in the viral cycle 
(Figure 1.6). The main targets of antiretroviral therapy are: viral entry by targeting the 
interaction between HIV and host cell (CCR5 antagonists) and the fusion step (fusion 
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inhibitors); reverse transcription (nucleoside/nucleotide analogues and non-nucleoside 
reverse transcription inhibitors, NRTIs and NNRTIs); integration (integrase strand 
transfer inhibitors, INSTIs) and protease (protease inhibitors, PIs). 
 
 
 
Figure 1.6 Sites of action of available classes of antiretroviral drugs 
(adapted from Maartens G. et al.  2014, The Lancet). 
 
 
The first antiretroviral drug to be licensed in 1987 was the NRTI zidovudine, which 
was soon followed by other compounds with similar mechanism of action (e.g., 
lamivudine, stavudine and didanosine). Following the disappointing result of 
monotherapy and dual therapy with NRTIs, a milestone was achieved in the second half 
of the 90s with the introduction of the PIs saquinavir and indinavir, and then the NNRTI 
nevirapine. In 1995-1996 it was demonstrated that it was possible to fully suppress virus 
replication using a combination of three drugs with two different mechanisms of action, 
which for many years consisted of two NRTIs plus either a PI or an NNRTI. In more 
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recent years, INSTIs have emerged as the preferred third agent in triple ART 
combinations. In addition, studies have explored the use of PI monotherapy and dual 
therapy with a PI as second agent as shown in 2015 guidelines by European AIDS 
Clinical Society (EACS Guidelines, 2015). In 2015, 25 antiretroviral drugs were 
available and they are described in following sections. 
1.3.1 Entry inhibitors: CCR5 antagonists and fusion inhibitors 
As discussed above, HIV-1 enters the cells via a multistep process that includes: 
engagement of the CD4 receptor and CCR5 or CXCR4 co-receptors by gp120 and 
conformational changes of the gp41 envelope protein that leads to fusion between the 
viral and host membrane.  
 
Maraviroc is the only co-receptor antagonist available. It binds to the transmembrane 
region of CCR5 (Dorr et al., 2005) on the host cell, and induces a conformational 
change that inhibits the interaction between the co-receptor and gp120. Given its 
specific action, patients are tested for viral tropism before starting such treatment.  
 
Enfuvirtide (T-20) is the only fusion inhibitor available. It is a peptide that mimics 
components of the HIV-1 fusion machinery and displaces them. Specifically, it binds 
the heptad repeat region 1 (HR1) in the N-terminal domain and prevents the formation 
of the six helical bundle that is needed to allow fusion.  
1.3.2 Reverse transcriptase inhibitors 
The RT enzyme is essential for the HIV-1 replication because it allows the transcription 
of the viral RNA into double stranded DNA prior to integration into the host genome. 
Blocking this step of the virus cycle is a key aspect of successful treatment. At present, 
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the RT enzyme can be targeted by either by competitive (NRTIs) or allosteric (NNRTIs) 
inhibition. 
1.3.2.1 NRTIs 
Nucleoside and nucleotide RT inhibitors are analogues of the natural deoxy-nucleotides 
that normally compose DNA molecules. These agents bind the active site of RT 
competing with the natural substrate and are incorporated by RT into the growing DNA 
chain. However, NRTIs lack the 3’-hydroxyl group on the deoxyribose, and once 
incorporated do not allow formation of the phosphodiester bound that is needed for the 
next nucleotide to be incorporated, resulting in premature chain termination (Parker et 
al., 1991, Zdanowicz, 2006). There are currently 7 available NRTIs: Abacavir (ABC), 
Emtricitabine (FTC), Lamivudine (3TC), Zidovudine (AZT), Tenofovir disoproxil 
(TDF), Didanosine (DDI), Stavudine (d4T). Some of them can be administrated in 
combined fixed doses such as: Kivexa (ABC plus 3TC), Trizivir (ABC, 3TC, AZT), 
Truvada (FTC, TDF), Descovy (FTC, Tenofovir alafenamide TAF), Combivir (3TC, 
AZT).  
1.3.2.2 NNRTIs 
The NNRTIs do not bind directly to the active site of RT to block its functionality. They 
bind to a pocket in the p66 subdomain of RT that is near the enzyme active site, causing 
a conformational change that inhibits the enzyme polymerization activity. Currently 
licensed NNRTIs comprise Efavirenz (EFV), Etravirine, Nevirapine (NVP), and 
Rilpivirine (RPV).  
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1.3.3 Protease inhibitors (PI) 
PIs are competitive inhibitors that bind to the active site of the viral protease enzyme 
preventing binding of Gag and Gag-pol precursor, the natural substrate of the enzyme. 
Of note, Rabi et al. 2013 showed that PIs do not only affect virion maturation, but also 
block entry, reverse transcription, and post-reverse transcription step: the independent 
inhibition of multiple distinct steps in the virus replication cycle makes this drug 
uniquely effective. Currently licensed PIs comprise: Atazanavir (ATV), Darunavir 
(DRV), Indinavir, Fosamprenavir, Lopinavir (LPV), Nelfinavir (NFV), Ritonavir 
(RTV), Saquinavir (SQV), and Tipranavir (TPV). PIs have low and variable 
bioavailability and relatively short plasma elimination half-life; these limits can be 
compensated by multiple daily administrations, even though this practice may reduce 
the patient’s adherence to the regimen (Cooper et al., 2003). An alternative procedure 
is to use a small dose of RTV, not for its direct antiviral activity but to inhibit the 
metabolism of co-administered PIs, thus boosting their concentration and improving 
their pharmacokinetics, with greatly enhanced activity and more patient-friendly dosing 
schedules. Recently cobicistat has been introduced as an alternative booster. Co-
formulations include ATV and DRV with cobicistat and LPV with RTV.  
1.3.4 Integrase inhibitors 
The integrase strand transfer inhibitors (INSTIs) block the action of the integrase by 
binding to its active site and preventing divalent cationic ions from binding to the 
enzyme catalytic site. To date, 3 INSTIs have been approved: Dolutegravir (DTG), 
Elvitegravir (EVG), and Raltegravir (RAL). EVG is boosted by co-formulated  
cobicistat (EVG/c).  
 
In Table 1.1 a list of regimens that are recommended for starting ART in HIV-positive 
adults is given. 
 
25 
 
 
Table 1.1 Regimens recommended for starting ART in HIV-positive adults. 
EACS 2016a DHSS 2016  
ABC 3TC DTG HLA-B*5701 negative 
TDF FTC DTG  
TDF FTC RAL  
TDF FTC EVG/c Pre-treatment estimated CrCl ≥70 mL/min 
TAF FTC EVG/c Pre-treatment estimated CrCl ≥30 mL/min 
TDF FTC DRV/r  
TDF FTC 
RPV 
 CD4 count >200 cells and VL <100,000 cps 
a to be released in autumn 2016. EACS= European AIDS clinical society; DHSS= 
Department of Health and Human Service (USA). CrCl= creatinine clearance.  
The introduction of the multidrug combination therapy for HIV-1 has notably increased 
life expectancy of HIV-infected individuals. HIV-1 replication is controlled 
significantly by continuous and uninterrupted therapy. However, if ART is stopped 
virus replication resumptions quickly. Virological rebound is driven by a pool of 
infectious HIV-1 provirus within CD4+ T cells and monocytes that populate sanctuary 
sites located in various body compartments including gut associated lymphoid tissue, 
peripheral lymphoid tissue, peripheral blood and brain (Chun et al., 2015). This virus 
reservoir represents a substantial obstacle to an HIV cure, it is established early after 
initial infection and its levels remain stable during treatment from when patients start 
therapy and during the chronic phase (Ruggiero et al., 2015, Josefsson et al., 2013). 
Nonetheless, it has been shown that initiation of ART during the acute phase 
considerably reduces the size of the viral reservoir (Zhang et al., 1999, Chun et al., 
2007). The establishment of the HIV-1 reservoir and the mechanisms that have been 
proposed to support the viral persistence will be discussed in the following sections. 
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1.4 HIV-1 persistence during ART 
In 1997, Perelson and colleagues demonstrated that HIV-1 RNA concentration in 
plasma dropped by 99% in the first two weeks of antiretroviral therapy (Perelson et al., 
1997). This first decay reflects the combined effect of inhibition of active virus 
replication with immune-mediated clearance of free plasma virus, which is known to 
have a short half-life (less than 6 hours). A second, slower phase of viral decay follows 
as a reflection of the turnover of chronically infected cells. Initial estimates calculated 
that based on the typical life-span of HIV-infected cells, 3.1 years of suppressive ART 
would eliminate HIV-1. In the same year, Chun TW (Chun et al., 1997b) demonstrated 
the presence of a latent HIV reservoir in resting memory CD4 T cells. Two years later, 
Finzi and colleagues (Finzi et al., 1999) described a model by which a stable reservoir 
could be established when infected activated CD4 T-cells rather than die as a result of 
HIV infection return to a resting state, maintaining integrated HIV-1 DNA. They 
estimated that the mean life of such latent viral reservoir was around 44 months and 
that viral eradication could have been achieved in 60 years of ART. To date, it is widely 
demonstrated that plasma HIV-1 RNA and cellular HIV-1 DNA can still be detected 
even after long period of effective and suppressive ART (Palmer et al., 2008). The 
source of this persistence has been identified in a pool of latently long-lived infected 
cells that present integrated HIV-1 DNA at stable levels and with little genetic evolution 
during treatment (Josefsson et al., 2013). 
1.4.1 Latently infected cells: a long-lived viral reservoir 
The term ‘viral latency’ indicates a type of persistent viral infection defined as ‘a state 
of reversibly non-productive infection of individual cell’ (Siliciano and Greene, 2011). 
In the case of HIV, the ‘individual cells’ are represented primarily by resting memory 
CD4 T-cells (Finzi et al., 1997). Memory cells include memory stem cells (TSCM) 
(Gattinoni et al., 2011), defined as CD45RA+CCR7+CD28+CD95+CD62L+), central 
memory cells (TCM, defined as CD45RA
-CD95+CCR7+CD62L+), transitional memory 
cells (TTM, defined as CD45RA
-CD95+CCR7+CD62L-), and effector memory cells 
(TEF, defined as CD95
+CCR7-CD62L-) (Sallusto et al., 2004). TSCM and TCM are long-
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lived and in a resting state (Buzon et al., 2014b); upon activation after T cell receptor 
(TRC) triggering (Sallusto et al., 1999), transitional memory cells start proliferating 
prior to differentiating into TEF (Geginat et al., 2003). In vitro studies have shown that 
activated CD4 T-cells are highly susceptible to HIV infection, whereas resting cell need 
are significantly less susceptible (Buzon et al., 2014b) in the absence of direct 
stimulation (Buzon et al., 2014b, Swiggard et al., 2005). Two pathways are proposed 
to explain the establishment of the viral reservoir. In the dominant pathways, a fraction 
of infected activated T-cells survive the infection and revert to a resting G0 state 
(Siliciano and Greene, 2011) (TCM) while carrying integrated HIV-1 provirus. In the 
second pathway HIV can directly infect cells in a resting state (Chavez et al., 2015). 
The two models are not mutually exclusive. In both cases, resting cells create a 
favourable environment for viral persistence, including a pattern of gene expression 
that enables long-term survival, and the ability to respond to antigenic stimulation 
(Siliciano and Greene, 2011). Under these conditions, HIV can persist for a long period 
in a transcriptionally silent state that protects it from both immune responses and 
antiretroviral therapy. Of note, in vitro studies have demonstrated that these cells can 
express at least some viral protein in absence of (Pace et al., 2012) virus production. 
This suggest potential for ongoing stimulation of HIV-specific immune responses 
during suppressive ART; however, this hypothesis has not been consistently 
demonstrated and is in conflict with the decrease of anti-HIV CD8 T-cell responses 
observed over time in treated patients.  
 
The latent reservoir is established early after primary infection (Finzi et al., 1997) and 
it is refractory to treatment. Interestingly, emerging evidence showed that treatment 
initiation during primary HIV infection may reduce viral reservoir formation (Ngo-
Giang-Huong et al., 2001) and accelerate immune restoration by preserving T and B 
cell function (Oxenius et al., 2000). In particular, one study identified 14 individuals 
that were able to control plasma viremia after the interruption of prolonged ART 
initiated during acute infection (Saez-Cirion et al., 2013). 
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1.4.2 Mechanisms of persistence 
1.4.2.1 Cell proliferation  
Memory T-cells can proliferate upon antigenic (antigen-driven proliferation) or 
cytokine-mediated (homeostatic proliferation) stimulation (Bosque et al., 2011). 
Antigen-driven proliferation induces cell activation and the cells differentiate into TEF. 
Activated T-cells can both produce new virus if infected, and become susceptible to 
infection if uninfected. Both immune recognition and effective ART can block both 
outcomes, providing a rational for HIV eradication strategies that aim to induce T-cell 
activation and viral gene expression as a way of reducing the size of the viral reservoir. 
Several observations support the hypothesis that newly produced virus originating from 
latently infected cells is unable to produce ongoing rounds of replication. These include 
the key observation that in stably suppressed patients, any detectable plasma HIV-1 
RNA is generally detected at very low copies (1-3 copies/ml) and is typically 
represented by a few clones (reflecting origin from a relatively small source) that are 
genetically stable (Josefsson et al., 2013).     
 
Homeostatic proliferation is a natural process aimed at keeping the T-cell count at 
physiological levels. It is independent of antigenic stimulation and mediated by IL-7 
(Boyman et al., 2007, Kondrack et al., 2003) and the proliferating cells can be identified 
by the expression of the surface marker Ki67 (Coiras et al., 2016). The cells undergoing 
homeostatic proliferation do not actively produce virus due to low NF-ĸB induction. 
However, by multiplying the integrated provirus they provide effective expansion of 
the viral reservoir (Bosque et al., 2011). 
 
Two independent studies (Maldarelli et al., 2014, Wagner et al., 2014) recently 
investigated the influence of HIV integration sites on cell proliferation during long-term 
suppressive ART (>10 years). Integration preferentially occurs within oncogenic genes, 
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such as MKL2 and BACH2, and can be found to recur within clonally expanded cells. 
These observations suggest that HIV can promote cell proliferation independently of 
antigenic or homeostatic proliferation. 
1.4.2.2 Ongoing viral replication  
Several putative markers of recent virus replication can be measured in subjects 
receiving seemingly effective ART, including low levels of plasma RNA, intracellular 
RNA forms, and 2-LTR circular HIV-1 DNA. Whether detection equals ongoing virus 
replication is debated. However, it is possible to propose that at least a subset of treated 
patients has low grade virus production ongoing in compartments where drug 
penetration or activity are suboptimal.  Work from Fletcher et al. 2014 demonstrated 
variable drug concentrations in lymphoid tissue relative to peripheral blood, with 
evidence of viral persistence in tissues with low drug exposure. Deposition of collagen 
can cause fibrosis (Schacker et al., 2006) and disruption of the lymphoid architecture 
which may favour the formation of pockets of viral persistence. Intensification with the 
INSTI raltegravir has also been shown to cause an increase in intracellular episomal 
HIV-1 DNA (Buzon et al., 2010), which indirectly reflects ongoing virus replication. 
 
HIV-1 also invades the central nervous system (CNS) and HIV-1 RNA levels remain 
detectable in the cerebrospinal fluid (CSF) despite ART. Some studies have found that 
HIV-1 RNA levels in the CSF can be higher than those in plasma, a phenomenon called 
CSF/plasma discordance (Eden et al., 2010, Nightingale et al., 2016) and that it is 
present in 12% of HIV-1 infected patients that are periodically examined by lumbar 
puncture. Such evidences have proposed that the CNS can act as a site for viral 
reservoir, ongoing viral replication and evolution of drug resistance (Garvey et al., 
2009, Canestri et al., 2010).  
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1.4.2.3 Cell to cell virus transmission  
HIV can also be disseminated by direct cell-to-cell contact. This process occurs via the 
assembly of supra-molecular complexes called virological synapses (VS) that ensure 
contact between the virus-donor cell and the target cell (Jolly and Sattentau, 2005). The 
VS formation starts with the actin-dependent polarization of the viral proteins Env and 
Gag to the plasma membrane at the site of the cell-to-cell contact where the CD4 
receptor from the uninfected cells has been recruited (Alvarez et al., 2014). Cell-to-cell 
adhesion is promoted by Env-CD4 interactions and stabilized by cellular adhesion 
molecules (eg. LFA-1 and ICAM-1,3). Once the interaction between virus donor and 
target cell is stable, virus is assembled and released into the synaptic cleft before fusing 
with the target cell (Agosto et al., 2015). This mechanism has been described in the 
context of virus spread promoted by interaction between dendritic cells and T cells, or 
between infected and uninfected T cells (Sattentau, 2008) and generally is associated 
with virus burden in lymphoid tissue where cells density is very high. Of note, 
macrophages are also able to transmit virus to CD4 T-cells via VS (Kumar et al., 2014); 
interestingly it has been shown that HIV infected macrophages can attract lymphocytes 
in their vicinity by secretion of specific cytokines/chemokines (e.g. MIP-1β, MCP-1 
and CCL-5) and further promote viral transfer (Herbein et al., 2010). Moreover, other 
studies have suggested that HIV-1 Nef may alter the physiologic characteristic of the 
infected macrophages in a way that enhances viral dissemination (Swingler et al., 2003) 
to CD4 T-cells. 
 
By experimental-mathematical investigation, Iwami S. et al. 2015 demonstrated that 
more than half or virus infections are produced by cell-to-cell infection and this is also 
reflected in higher viral fitness. Of note, Sigal et al. 2013 demonstrated in vitro that 
cell-to-cell virus spread is considerably less sensitive to the action of the RT inhibitors. 
Similar results were found also by Titanji B.K. et al. 2013, who progressed previous 
work by demonstrating that PIs appeared particularly effective in blocking cell-to-cell 
transmission. Taken together these findings indicated that different drug classes impact 
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on the cell-to-cell virus dissemination and potentially on the maintenance of the viral 
reservoir. 
1.4.3 Tools to measure the HIV reservoir 
Measuring the viral reservoir, including HIV-1 RNA in plasma and HIV-1 DNA in 
cells, is paramount to understand viral persistence and to test innovative therapy 
strategies. Patients with persistent virological suppression, defined as plasma HIV-1 
RNA levels below the cut-off of the clinical assay (50 HIV-1 RNA copies/ml), have 
traces of plasma viral RNA copies (herein referred to as ‘residual HIV-1 RNA’) that 
can be measured by ultrasensitive quantitative PCR assay. However, whether detection 
of so few HIV-1 RNA copies in plasma reflects ongoing viral replication as supported 
by the integrated HIV-1 reservoir despite suppressive ART, it is still debate. Of note, 
quantitative PCR assays quantify HIV-nucleic acids without necessarily addressing 
their integrity and functionality. Not all integrated HIV-1 DNA is replication-
competent. Different outgrowth assays have been developed, sharing the common 
feature that resting CD4 T-cells are isolated from peripheral blood, stimulated to induce 
global T cell activation, and virus expression, with subsequent infection of CD4 T-cells. 
Virus production in culture is then measured as p24 concentration or RT activity. 
Resting CD4 T-cells are broadly defined as cells that do not express the HLA-DR 
activation marker. They are typically purified from whole CD4 T-cell populations and 
can generally be defined by the following expression profiles: CD4+HLA-DR-CD25-
CD69-  (Laird et al., 2013) or CD4+HLA-DR-CD38- T cells (Buzon et al., 2014b).  
 
In recent work from an international collaboration (Eriksson et al., 2013), integrated 
HIV-1 DNA load measured in peripheral blood mononuclear cells showed good 
correlation with the viral outgrowth assay.  
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1.4.3.1 Intracellular HIV-1 nucleic acid quantification 
Intracellular HIV-1 nucleic acids comprise unintegrated (Sloan and Wainberg, 2011) 
and integrated (Graf and O'Doherty, 2013, Liszewski et al., 2009) forms of HIV-1 DNA 
that together constitute the total HIV-1 DNA, and cell-associated RNA (Pasternak et 
al., 2013). Two quantitative PCR technologies are currently used for quantification: 
real-time quantitative PCR (qPCR) (Bustin et al., 2009) and digital droplet PCR 
(ddPCR). The two methodologies show important differences.  
 
In qPCR, the amplification of the target DNA is monitored in real-time: each sample is 
amplified when the forward and reverse primers alongside a specific probe bind to the 
target DNA molecule. The probe is a single stranded DNA sequence complementary to 
the target sequence, flanked by one fluorescent reporter and one quencher molecule. In 
absence of amplification, the quencher prevents fluorescent emission by the reporter; 
when target DNA is amplified, the polymerase moves along the template and the 
quencher is cleaved from the reporter and emits a signal (Figure 1.7a, Taqman 
chemistry). Fluorescent signal increases by each cycle and reflects the abundance of the 
target DNA. The number of cycles at which the fluorescence from the amplified 
samples is higher than the background signals is called threshold cycle (Ct) (Bustin et 
al., 2009). Higher sample concentration will allow the signal to exceed the threshold 
sooner, resulting in smaller Ct values (Figure 1.7b). Sample to sample variation 
resulting from pipetting errors is controlled by adding a passive reference dye that is 
not amplified during the qPCR: if a well does not present the required amount of passive 
reference, the reaction is not valid. Quantification of samples is calculated by 
interpolation of Ct values obtained from known concentration of a validated standard. 
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a) 
 
 
 
 
 
b) 
 
a) Adapted from Taqman comics, Real-Time PCR Handbook. Each PCR cycle includes an 
annealing phase during which the probe binds a specific sequence on the DNA target; an 
extension phase while the polymerase proceeds with the amplification of the DNA target 
meanwhile cuts the reporter molecule from the TaqMan hydrolysis probe allowing fluorescent 
signal to be emitted. b) Adapted from Life Technologies, Real-Time PCR Handbook. 
Amplification plots depicting fluorescent signal from known quantity of samples. Higher 
concentrations are reflected by greater amplification that corresponds to lower Ct values. 
 
 
Figure 1.7 Illustration of qPCR principles 
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In ddPCR, a single sample is partitioned into thousands of nano-sized droplets that 
independently undergo PCR reaction by using a TaqMan hydrolysis probe technology 
as seen for qPCR; the end-point PCR product is then analysed with a fluorescent reader 
that scores each single individual droplet as positive or negative for fluorescent signal 
(Figure 1.8a and b). The fraction of positive droplets (p) is inputted into the formula 
[1.1] that applies Poisson statistics to allow absolute quantification of the target and its 
Poisson-based 95% confidence interval (CI). 
 
[1.1] copies/droplet= -ln (1-p) 
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a) 
 
 
 
b) 
 
a) Adapted from Thermofisher scientific, Digital PCR system introduction. Cartoon depicting 
the different steps of the protocol: sample is portioned into single droplets; then qPCR is run 
and fluorescent signals are red with a fluorescent reader to identify positive (red dots) and 
negative (grey dots). b) Adapted from Biorad ddPCR Bullettin 6407. Graph showing each 
droplet (x axis, event number) from one sample that is plotted vs fluorescent intensity (y axis, 
channel 1 amplitude). Positive droplets are those above the threshold line (pink line here). 
 
 
Figure 1.8 Illustration of ddPCR principle 
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The main difference between the two methods is that the ddPCR provides an absolute 
quantification without requiring an external standard. Both qPCR and ddPCR are 
currently used to quantify intracellular HIV-1 DNA and RNA, whereas only qPCR 
assays have been developed for integrated HIV-1 DNA quantification so far.  
 
Una O’Doherty and colleagues developed the Alu-gag PCR assay which can quantify 
0.6 proviruses for each 100,000 cells (Liszewski et al., 2009). Integrated HIV-1 DNA 
is amplified using primers that bind to the human genome and the HIV-1 gag sequence. 
Following PCR amplification (PCR1), qPCR (qPCR2) is run to produce sample 
quantification. A standard that contains a known quantity of integrated HIV-1 DNA is 
run in parallel to determine integrated HIV-1 DNA load in the samples. De Spiegelaere 
W. and colleagues recently described a variation of the method that uses Ct values 
obtained by qPCR to calculate absolute number of HIV-1 integration based upon 
Poisson statistics (De Spiegelaere et al., 2014).  
1.4.3.2 Detection of plasma HIV-1 RNA load and virological 
suppression threshold 
With the introduction of highly active triple antiretroviral therapy in the 90s, the HIV-
1 RNA levels in plasma (“viral load”) became established as the key surrogate marker 
of treatment efficacy. As described above, viral load spontaneously decline within 6 
months of the initial infection to a certain set-point that is a powerful predictor of the 
rate of CD4 count decline and the risk of disease progression and mortality among 
untreated patients. Upon ART initiation, viral load is suppressed and the risk of disease 
progression is reduced. Based on this close relationship with clinical outcomes, 
continuous viral load suppression below the detection limit of commercially available 
assays is the key goal of ART. The threshold indicating optimal virological suppression 
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has changed over time, reflecting the technical evolution of viral load assays (Doyle et 
al., 2012). First generation assays had a lower limit of detection of 400 HIV-1 RNA 
copies/ml. Second generation assays had a lower limit of detection at 50 HIV-1 RNA 
copies/ml. One example of such an assay is the Amplicor v1.5 assay which was used 
extensively in clinical trials of triple ART and introduced the concept of <50 copies/ml 
as the desirable level of suppression. With the advent of real-time PCR, third generation 
assays were developed with lower limits of quantification below 50 HIV-1 RNA 
copies/ml, which can also qualitatively report HIV-1 RNA detection below the 
quantification limit (Doyle and Geretti, 2012). Within this group the most widely used 
are the Roche COBAS TaqMan HIV-1 Test Version 2.0 and the Abbott RealTime HIV-
1 VL assay with lower limits of detection of 20 and 40 HIV-1 copies/ml, respectively.  
 
In the research setting, various techniques have been employed to increase the 
sensitivity of detection down to a few HIV-1 RNA copies/ml in order to measure the 
‘residual’ HIV-1 RNA. These assays have helped elucidate the kinetics of HIV-1 RNA 
decline in plasma after starting ART. The prototype “single copy” HIV-1 RNA assay 
was developed by Palmer et. al in 2003. In this method, 7 ml plasma volume was 
ultracentrifuged at 170,000xg for 30’ in a Sorvall T-1270 rotor prior to manual RNA 
extraction. Purified RNA was then reverse transcribed into cDNA and this was 
amplified by quantitative real time PCR (qPCR), by binding the HIV-1 gag region. To 
control for the whole process, an internal virion standard consisting of the replication-
competent avian sarcoma-leukosis retroviral vector RCAS BP(A) (RCAS) was added 
to the plasma sample prior to ultracentrifugation and quantified by qPCR in parallel to 
the HIV-1 RNA. In parallel, known quantity of an HIV-1 and RCAS RNA were run to 
allow quantification. Results showed viral RNA detection as low as 1 copy/ml in 
patients on antiretroviral therapy and in that period represented a confirmation of 
previous predictions (Dornadula et al., 1999) that viremia can persist at low levels that 
cannot be detected by routine screening. 
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1.5 Aims of the thesis 
 
Current therapies are effective to drastically reduce HIV-1 replication and to decrease 
levels of immune activation. However, HIV-1 persists in sanctuary sites and the host 
immune system functionality appears altered when compared to healthy individuals. A 
relationship between levels of viral persistence and the host immune system has been 
proposed, however it warrants further investigation. 
 
In relation to this question, I believed there was scope to quantify levels of the HIV-1 
reservoir, measured as residual HIV-1 RNA in plasma and the different HIV-1 DNA 
forms in cells, in a population of patients that maintained continuous virological 
suppression while being on 1NNRTI and 2NRTIs for up to 15 years. Furthermore, I 
explored associations between the different forms of the HIV-1 reservoir and various 
markers of cellular and immune activation that were previously described as markers 
of disease progression in the absence of treatment.  
 
I also had the occasion to participate in a clinical trial of patients switching from an 
EFV based regimen (Atripla) to a non-EFV based regimen (Eviplera) due to 
cytotoxicity. In this context, I explored the impact of the switch on the virological 
suppression measured as levels of residual HIV-1 RNA in plasma by an ultrasensitive 
assay that I first optimized.  
 
Finally, I also worked to optimise the assays used to study the HIV-1 persistence. In 
particular, I developed a more sensitive technique used to measure the integrated HIV-
1 DNA that represents the cellular HIV-1 reservoir. Furthermore, I set up a novel in 
vitro assay that could be used for testing novel drug formulations. 
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2 Chapter 2: Materials and Methods 
2.1 Study populations and sampling 
1) Population of subjects switching from Atripla (coformulated tenofovir, 
emtricitabine, efavirenz) to Eviplera (coformulated tenofovir, emtricitabine, 
rilpivirine). The trial was based at the Chelsea and Westminster Hospital in London, 
but recruitment involved different hospitals as listed in Table 2.1. All subjects had 
received Atripla for ≥12 weeks, and showed plasma HIV-1 RNA suppression <50 
copies/ml, a CD4 count > 50 cells/mm3, and persistent central nervous system (CNS) 
toxicity attributed to efavirenz. The treatment regimen was switched to Eviplera and 
improved CNS tolerability was the primary end-point. Plasma samples were collected 
immediately before switching (baseline) and at week 4, 12, and 24 after switching and 
stored on site at -80C until ready for shipment frozen to the University of Liverpool on 
dry ice (Table 2.1 an overview of available samples is given). Ethics was approved by 
local authorities; EudraCT registration number was 2012-002205-22 and the study was 
registered at clinicaltrial.gov (identifier number NCT017701882). All patients provided 
written informed consent. 
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Table 2.1 Breakdown of patient’s recruitment and samples available for testing 
for the study on switching Atripla to Eviplera 
Hospital, responsible N patients Samples available for 
testing 
  BL W4 W12 W24 
Chelsea and Westminster Hospital 9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
Brighton Hospital 15 15 14 15 15 
St Mary’s Hospital 5 5 5 5 5 
Mortimer Market Centre 8 8 8 8 5 
Total 37 37 36 37 34 
BL= baseline 
2) The ERAS population included subjects on first-line ART with two NRTIs plus 
efavirenz or nevirapine (NNRTI), and showed continuous viral load suppression (<50 
copies/ml) from the first six months of therapy up to sampling date, while undergoing 
2 viral load measurements per year, without transient elevations above 50 copies/ml 
or treatment interruptions. No patients underwent a change in NNRTI, whereas changes 
in NRTI were permitted. Recruitment was stratified by duration of ART to range from 
1 to over 10 years and it was carried out at different centres across the United Kingdom 
as listed in Table 2.2. Blood samples (40-50 ml) of venous were collected in EDTA 
tubes and plasma and peripheral blood mononuclear cells (PBMC) were isolated as 
described below. Until use, plasma samples were stored at -80oC and PBMC in liquid 
nitrogen. The study was approved by National Research Ethics Service (London-
Dulwich) and was included in the National Institute for Health Research Clinical 
Research Network (NIHR CRN) Portfolio. All patients provided written informed 
consent. 
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Table 2.2 Breakdown of recruitment for the ERAS study. 
Hospital ERAS 
Royal free Hospital 46 
N. Middlesex Hospital 14 
St Mary’s Hospital 20 
Mortimer Market Centre 4 
St Thomas’ Hospital 3 
King College Hospital 4 
Royal Liverpool University Hospital 57 
Total 148 
3) Healthy volunteers with HLA-A2 positive or negative pseudo-type were recruited at 
the Institute of Infection and Global health (IGH). These cells were used to set up in 
vitro assay (chapter 7) were the HLA-A2 negative PBMCs were directly infected with 
free HIV-1 particles (donor cells) and used to infect HLA-A2 positive cells (target 
cells). The HLA-A2 expression was used to discriminate between donor and target 
cells. Up to 50 ml of venous blood samples were collected in Heparin tubes and PBMC 
were isolated as described below and stored in Liquid Nitrogen until use. The 
University of Liverpool Interventional Ethics Committee approved the study (no. 
RETH000685). All subjects gave written informed consent.  
2.2 Cell separation 
2.2.1 PBMC 
Venous blood samples collected in EDTA or heparin tubes were processed within 2 
hours of collection by density gradient centrifugation with Histopaque®-1077 (Sigma 
Aldrich, Poole Dorset UK) to allow PBMC isolation. Blood was first centrifuged at 
1000xg for 10’ at 180C (acceleration 4, break 0) to isolate plasma. Remaining blood 
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was further diluted 1:1 in PBS and layered over Ficoll in pre-labelled 50 ml tubes (20 
ml of diluted blood onto 15 ml of Histopaque®-1077). Tubes were placed into centrifuge 
buckets with extreme care to avoid disruption of the layer to be spun at 500xg for 30’ 
at 18-20°C (acceleration 4, brake 0).  After centrifugation, the following layers will be 
visible from top to bottom of the tube: plasma and PBS, PBMC, Ficoll and blood. The 
PBMC layer was collected with sterile plastic Pasteur pipettes and transferred into pre-
labelled 50 ml tubes. PBS (Thermofisher, Leicestershire UK) was added up to 50 ml 
and cells were washed by 8’ centrifugation at 500xg, 18-20°C (acceleration and brake 
= 4). After the first wash, supernatant was discarded and the cell pellet was re-
suspended in 10 ml of PBS; 5 µl of cell suspension was taken for the cell count and the 
remaining cells were washed as described above. For cell count, 45 µl of trypan blue 
0.4% (Thermofisher, UK) were added to cell suspension to allow visualization of dead 
cells. Ten microliters of cell-trypan blue suspension was applied to a hemocytometer 
slide chamber. By using a microscope with a 10X objective, alive and dead cells could 
be discriminated and live cells (unstained by trypan blue) on one set of 4 corner squares 
were counted. The total number of cells was then calculated with the following formula 
[2.1] multiplied by the dilution factor, in this case equal to 10:    
                        
[2.1] cells/ml= (number of counted cells/4) * 104  
 
Dead cells (stained by trypan blue therefore of blue color) were also counted to calculate 
cell viability. Only samples with >90% viable cells were used. Up to 25x106 cells were 
used fresh for CD4 T-cell isolation, whereas remaining cells were frozen as follows. 
Up to 107 cells were re-suspended in freezing medium containing 90% of heat-
inactivated FBS (Sigma, Poole Dorset UK) and 10% DMSO (Sigma, UK) and 
transferred to pre-labelled cryogenic vials. Tubes were transferred into a cooling box 
containing pure iso-propanol (Mr Frosty Nalgene, Thermofisher), and placed into the -
80oC freezer to allow a cooling rate of 1oC/min. When cells were frozen (after at least 
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one night), cryovials were moved to Liquid Nitrogen tank (-135oC to -190oC) for long 
storage period.  
2.2.2 CD4 T-cell subsets  
Freshly isolated PBMC were used to obtain highly purified resting and non-resting CD4 
T-cells by using a two-step protocol as described in Laird GM et al. and summarised in 
Figure 2.1. PBMC (20-25x106 cells) were washed twice by re-suspending cell pellet in 
5 ml of wash/staining buffer (WS buffer) containing PBS with 5% bovine serum 
albumin (BSA, Sigma Aldrich UK) and 2 mM EDTA 0.5 M pH 8.0 (ThermoFisher 
scientific UK) prior to centrifugation at 300xg for 5’ at RT. After the second wash, cell 
pellet was resuspended in WS buffer (40 µl each 107 cells) and the CD4+ T Cell Biotin-
Antibody Cocktail (CD4+T cell isolation kit Miltenyi Biotec Ltd., Bisley UK) (20 µl 
each 107 cells) was added to the cells. The cocktail contained biotin-conjugated 
antibodies binding non CD4 T-cells and specifically: CD8 T-cells, monocytes, 
neutrophils, eosinophils, B cells, NK cells, granulocytes, γ/δ T cells, and erythroid cells. 
After 5’ incubation at 4°C, CD4+ T Cell MicroBead cocktail (CD4+T cell isolation kit 
Miltenyi Biotec Ltd, UK) (20 µl each 107 cells) was added in order to magnetically 
label the non-target cells and incubated for 10’ at 40C (Figure 2.1a). During the 
incubation, LS columns (Miltenyibiotec, Bisley UK) were activated by rising with 2 ml 
of WS buffer while they were placed in the magnetic separator. Once the incubation 
with the CD4+T cell isolation kit was finished, the cell suspension volume was adjusted 
to 500 µl and loaded onto the activated LS column in the magnetic separator (Figure 
2.1b). Unbound cells (CD4+T cells) passed through the column and were collected in a 
pre-labelled 15 ml tube; the LS columns were washed twice with 1 ml of WS buffer 
and the total effluent was gathered to maximise yield of obtained CD4+T cells. The 
obtained CD4 T-cells were then resuspended in WS buffer (40 µl per 107 cells) and 
anti-CD69 biotin-conjugated antibody (CD69 MicroBead Kit II Miltenyi Biotec Ltd, 
UK) was added (10 µl per 107 cells). After 15’ incubation at 40C, anti-Biotin beads (20 
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µl per 107 cells, CD69 MicroBead Kit II Miltenyi Biotec Ltd, UK), anti-CD25 
conjugated beads (20 µl per 107 cells, CD25 MicroBead II Miltenyi Biotec Ltd, UK) 
and anti-HLA-DR conjugated beads (20 µl per 107 cells, CD25 MicroBeads Miltenyi 
Biotec Ltd, UK) were added and incubated for an additional 15’ at 4°C (Figure 2.1c). 
After the incubation, cells were washed by adding 1 ml of WS buffer prior to 
centrifugation at 300xg for 7’. After centrifugation, cell pellet was resuspended in 500 
µl and loaded onto the pre-activated column (prepared as described above) for magnetic 
separation. Resting CD4 T-cells were collected in the flow-through together with the 
total effluent raised to wash the column, as described previously (Figure 2.1d), whereas 
the complementary population containing the CD4+CD26+/CD69+/HLA-DR+ T-cells 
remained linked to the LS columns. Differently from Siliciano lab, these cells were 
isolated from the columns as follow. LS columns were removed from the magnetic rack 
and placed on a suitable collection tube; 3 ml of WS buffer were pipette onto the LS 
columns and the volume containing the cells was collected after pulling it out with a 
syringe.  Resting and non-resting CD4 T-cells were count and one aliquot (5-10 x105 
upon cell availability) was used for flow cytometry analysis performed as described 
below in this chapter. For each population, a minimum 5x106 cells were frozen as 
described above. 
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Figure 2.1 CD4 T-cell subsets isolation protocol 
Figure depicting the two-step protocol that was used for CD4 T-cell subsets isolation. First step:  CD4 T-cells isolation (a,b); second step: resting and 
non-resting CD4 T-cells isolation. Coloured circles represent: non-CD4 T-cells (white); CD4+CD69+T-cells (purple); CD4+CD25+T-cells (magenta); 
CD4+HLA-DR+T-cells (green); CD4+ CD69- CD25- HLA-DR- T-cells (blue). Black square: magnetic rack. NK= natural killer cells. 
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2.3 Virological assays 
2.3.1 HIV-1 RNA quantification 
An alternative version (herein referred to as “ultrasensitive assay”) of the Abbott Real 
Time HIV-1 assay (Doyle et al., 2012) (Abbott, Maidenhead UK) was used to quantify 
residual plasma HIV-1 RNA. The original assay showed quantification at 40 HIV-1 
RNA copies/ml and 20 HIV-1 RNA copies/ml with 100% and 95% probability, 
respectively; with the ultrasensitive assay we were able to achieve quantification of 3 
HIV-1 copies/ml and 1 HIV-1 copy/ml with 95% and 50% probability, respectively. In 
the ultrasensitive assay 8 ml of plasma sample containing HIV-1 RNA were used for 
the assay instead of 1ml as for the standard assay. Plasma was concentrated by 
ultracentrifugation of plasma samples at 215,000xg for 45’ at 4°C in polycarbonate 
tubes (Beckman Coulter, High Wycombe UK) by using Beckman SW41 swinging 
bucket rotor (Beckman Coulter, UK) prior to RNA extraction. Pellet was resuspended 
in 1 ml of basematrix (Seracare, Milford USA) and it was used as input for automated 
RNA extraction onto the m2000sp™ instrument (Abbott) according to manufacturer 
instruction as for the standard assay. Abbott m™ Sample Preparation System solutions 
(Abbott) were loaded onto the m2000sp™: this technology uses magnetic particle beads 
to allow selective RNA isolation. Out of the 1 ml concentrated plasma RNA, 600 µl 
was used for extraction and RNA was eluted in 88 µl of which 50 µl were dispensed 
into an Abbott 96-well optical plate for the real-time PCR reaction. Following this step, 
Abbott real-time amplification reagents kit (Abbott) containing primers, probe and 
polymerase enzyme was loaded into the m2000sp™ which generated the mastermix 
and dispensed it into the Abbott 96-well optical plate containing the eluted RNA. The 
plate was then ready, after manual application of the optical seal, for transfer to the 
Abbott m2000rt (Abbott) for the real time reaction. Results were automatically 
analysed by the Abbott ROW Software (Abbott) and three types of results could be 
obtained: target quantified, target detected but not quantified, target not detected.  
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In the first case, the concentration of the sample HIV-1 RNA was automatically 
calculated by the software by using the following formula: 
 
[2.2] log10 copies/ml of target = (Ct-intercept)/slope  
 
The Ct indicated the threshold cycle obtained by the qPCR of the sample; whereas the 
intercept and the slope were obtained by running two calibrators that produced a 
standard curve. Given that the two calibrators were run under the same extraction and 
qPCR conditions described above for the samples, this formula expressed the log10 
HIV-1 copies/ml when the extraction input volume was 1 ml, the elution volume was 
88 µl, and the real-time PCR input volume was 50 µl. For results that were target 
detected but not quantified, the calculation was carried out manually by using the same 
formula [2.2]. Further, target not detected were not quantifiable. 
 
According to Abbott recommendation, each run was validated as follows. An HIV-1 
unrelated sequence was introduced at the beginning of the process and simultaneously 
quantified; further, three controls were added in each run: one high positive 
(CONTROL H), one low positive (CONROL L) and one negative (CONTROL NEG). 
Moreover, the two calibrators were run in triplicate each time reagents lots were 
changed to ensure consistency between runs. Primers used for this automated assay are 
specific for Group M, subtypes A-D, CRF01_AE, CRF02_AG, subtypes FH, group N 
and O as indicated in the manufacturer’s instructions (Abbott).   
 
2.3.1.1 Validation of the ultrasensitive assay 
Ultrasensitive assay for detection of low levels of HIV-1 RNA in plasma was validated 
in the context of another study by spiking 8 ml of HIV-negative plasma with four 
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dilutions of the 3rd World Health Organisation (WHO) HIV-1 international standard 
(NIBSC code: 10/152, Hertfordshire UK). The International Standard (IS) has been 
assigned an International Unit (IU) value of 185,000 IU/ml by NIBSC. When tested 
with Abbott real time PCR assay, 1 ml contained 117,489 copies (NIBSC). The standard 
was prepared as recommended from the manufacturer. One ampule was resuspended in 
1 ml of ddH20 and vortexed for 15’. Upon reconstitution, 13.7 µl of standard suspension 
was mixed with 986.3 µl of basematrix (Seracare, Massachusetts USA) and vortexed 
for 15’ to produce a 2534 IU/ml stock solution. Stock was diluted 1:31.7 to make up 80 
IU/ml concentration aliquots which were stored at -80oC for future use. Alternatively, 
stock solution was further diluted in 8 ml of basematrix to achieve following 
concentrations: 15.8 IU/ml (10 copies/ml), 7.9 IU/ml (5 copies/ml), 4.7 I/ml (3 
copies/ml) and 1.6 IU/ml (1 copy/ml). Dilutions were run with Abbott assay following 
ultracentrifugation as described above and results showed 95% detection rate of 3 
copies HIV-1 RNA/ml and a 50% detection rate of 1 copy HIV-1 RNA/ml. 
 
In the context of this thesis, sensitivity of an alternative ultrasensitive assay which 
started with reduced plasma input (2 ml) was explored. Manual and automated HIV-1 
RNA extraction methods were tested and results from validation runs are shown in 
Chapter 3. All runs were performed by using frozen 80 IU/ml aliquots of IS for 
consistency. After thawing, 80 IU/ml stock was diluted in basematrix to make 40 IU/ml, 
20 IU/ml, 10 IU/ml and 5 IU/ml concentration. 
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2.3.2 HIV-1 DNA quantification 
2.3.2.1 DNA isolation from PBMC and CD4 T-cell subsets 
Frozen cells were quickly thawed in water bath at 37°C and washed twice by adding 
PBS prior to centrifugation at 400xg to eliminate the DMSO. Cell pellet was then 
resuspended in 400 µl of PBS and used as input for DNA isolation. The QIAamp DNA 
mini kit (Qiagen, Manchester UK) was used as follow. Lysis buffer (400 µl) and 
proteinase K (40 µl) were mixed to cell suspension and first incubated at 56°C for 30’, 
therefore at 100°C for 40’ as described in Geretti et al. Purified DNA was eluted in 100 
µl of elution buffer containing 10 mM Tris-Cl plus 0.5 mM EDTA at a pH of 9.0 (TE 
buffer). Extracted DNA was quantified by spectrophotometry (Nanodrop, Labtech, 
Uckfield, UK). 
2.3.2.2 Total HIV-1 DNA quantification 
Total HIV-1 DNA in PBMC was quantified via qPCR using the Applied Biosystems 
7500 Real-Time PCR system, as described in Geretti et al. (2013). A total of 1 µg of 
cellular DNA (equivalent to 150,000 cells) was input in each reaction, along with a 1:10 
sample dilution to detect inhibition. The standard curve incorporated four quantities of 
input HIV-1 DNA at 6,000, 600, 60 and 6 copies per reaction. Although a commercial 
kit was available (the Generic HIV DNA cell kit Biocentric, Bandol France) having an 
in-house quantification method was desirable for cost savings. Therefore, a standard 
curve was produced using cloned HIV-1 LTR DNA plasmid and it was measured in 
every run to allow quantification. All runs were performed in a 50 µl volume containing 
DNA extract (1 µg of eluted DNA), 200 nM of primers and 400 nM of probe (listed in 
Table 2.4), 1X qPCR SuperMix with 50 nM of ROX passive reference dye 
(Thermofisher). Thermocycling conditions were 2’ at 50°C and 10 min at 95°C, 
followed by 50 cycles at 95°C for 15 sec, and 60°C for 1’. HIV-1 DNA copies/µg 
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quantification was calculated by the software and then converted into HIV-1 DNA 
copies/106 PBMC using the formula [2.3]:  
 
[2.3] HIV-1 DNA copies/106 PBMC = HIV-1 DNA copies/µg x 106/150,000 
 
The sensitivity for this assay was 40 and 20 HIV-1 DNA copies/106 PBMC at 95% and 
50% detection rate, respectively as previously described (Avettand-Fenoel et al., 2009). 
The validation for this assay was determined in the context of another study by 
comparing the consistency of the standard curve produced with the HIV-1 LTR plasmid 
versus the one produced using the commercial Generic HIV DNA cell kit (Biocentric, 
Bandol France). Results from five independent experiments showed a strong linear 
relation between input HIV-1 DNA and Ct values with R2>0.9, where the R2 was a 
statistical measure of how close the data were to the regression line that fitted the Ct 
values per each input concentrations. Coefficients of variations were <1% per each 
replicate.  
2.3.2.3 Integrated HIV-1 DNA quantification 
Integrated HIV DNA was quantified by a repetitive-sampling Alu-gag method 
published by Spiegelaere et al. 2014. This protocol included two steps: a first 
amplification PCR step (PCR1) is followed by a second quantification real-time PCR 
step (qPCR2) that measures the HIV-1 DNA load. During the first step, PCR was 
performed using one reverse primer targeting the HIV gag sequence and a forward 
primer targeting the human Alu sequence on 40 replicates (primers are listed in Table 
2.3). This step allowed the exponential amplification of integrated HIV-1 DNA when 
both primers bind the target, the linear amplification of the unintegrated HIV-1 DNA 
when only gag primers binds the target sequence along, and of the human genome when 
only Alu is capable of binding ( 
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Figure 2.2a).  While amplification of human genome could not be quantified by 
qPCR2, linear amplification of unintegrated HIV-1 DNA can be measured and this 
generates difficulties for discrimination of the unintegrated vs integrated HIV-1 DNA. 
To correct for this linear amplification, 30 replicates with only HIV-1 gag primers were 
run to allow linear amplification of unintegrated HIV-1 DNA (“gag” control). All the 
reaction contained 200 nM of primers, 1X Promega GoTaq mix and 0.5 U/µl GoTaq 
polymerase (Promega, Southampton UK), 10nM dNTPs (Promega), DNA extract 
ranging from 50-250 ng/reaction depending on total HIV-1 copies, water to reach 50 µl 
of final volume reaction. Thermocycling conditions were 2’ at 95°C; 40 cycles of the 
following steps: 95°C for 15’’- 50°C for 15’’- 70°C for 3.30’; followed by 15’ at 70°C.  
Following amplification, 2 µl of PCR product was employed for the qPCR containing 
400 nM of primers, 200 nM of probe, 1X qPCR SuperMix with ROX (Invitrogen UK, 
cat # 11743500), water to a final volume of 10 µl. qPCR was performed on 2 machines 
following validation of the systems: Roche qPCR System (supported by LightCycler 
480 SW 1.5 software) and AB 7900HT System. Thermocycling conditions were 2’ at 
50°C and 5’ at 95°C, followed by 45 cycles at 95°C for 15’’, and 60°C for 1’. The 
integrated HIV-1 DNA copy number was obtained by input of the Ct value into pre-
designed computational template (Microsoft Excel), which applies Poisson’s principles 
for quantification (http://www.integratedhivpcr.ugent.be). Within the Alu-gag 
replicates, each reaction well was scored as positive for integrated HIV-1 DNA if the 
Ct value was lower than the average Ct values produced by the “gag” control 
(threshold). Number of positive wells was divided by number of Alu-gag replicates to 
calculate the percent positive (p) reaction per well. This value was input into the 
formula [1.1] to allow quantification of the integrated HIV-1 DNA per each replicate. 
Results were divided by “0.1” to take into account the limit of quantification for this 
assay that is 10% of the total integration events. The assay was valid only when at least 
4 reaction wells were scored as positive. Figure 2.2 provides an illustration of the 
method. 
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Figure 2.2 Alu-gag assay 
F= forward primer; R=reverse primer; qPCR=quantitative PCR; CI= confidence interval. 
 
 
PCR 1 
qPCR 2 
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In the context of this thesis, we explored alternative primer combination to optimize the 
detection limit of this method. The primers that we used are listed in Table 2.43 and the 
results we obtained are shown in chapter 7.  
 
2.3.2.4 2-LTR circular HIV-1 DNA quantification 
2-LTR circular HIV-1 DNA was quantified in collaboration with prof. Douglas 
Richman research group by digital droplet PCR (ddPCR) as described in M.C. Strain et 
al. 2013 Primers and probe were listed in Table 2.4. 
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Table 2.3 List of all primers used in this thesis 
 
Assay Target  Primer sequence (5’ – 3’) 
Total HIV-1 DNA 
assay 
 
 
 
HIV-1 NEC005  
(sense) 
GCCTCAATAAAGCTTGCC 
 HIV-1 NEC131  
(anti-sense) 
GGCGCCACTGCTAGAGATTTT 
 HIV-1 probe FAM/AAGTRGTGTGTGCCC/MGB -NFQ 
Alu-gag assay for 
integrated HIV-1 
DNA 
 
 
 
PCR1 Alu sense GCCTCCCAAAGTGCTGGGATTACAG 
Gag anti-sense GTTCCTGCTATGTCACTTCC 
qPCR2 RU5 sense TTAAGCCTCAATAAAGCTTGCC 
RU5 anti-sense GTTCGGGCGCCACTGCTAGA 
RU5 probe FAM/CCAGAGTCA/ZEN/CACAACAGAC
GGCACA/3IABKFQ/ 
Alu-5LTR assay  
for integrated   
HIV-1 DNA 
 
 
 
 
 
PCR1 Alu sense  GCCTCCCAAAGTGCTGGGATTACAG 
RU5 sense GTTCGGGCGCCACTGCTAGA 
qPCR2 HIV-1 NEC005  
(sense) 
GCC TCA ATA AAG CTT GCC 
 HIV-1 NEC131  
(anti-sense) 
GGC GCC ACT GCT AGA GAT TTT 
 HIV-1 probe FAM/CCAGAGTCA/ZEN/CACAACAGAC
GGCACA/3IABKFQ/ 
2-LTR circular  
HIV-1 DNA assay 
HIV-1 MH535  
(sense) 
AAC TAG GGA ACC CAC TGC TTA AG 
HIV-1 MH536 
(antisense) 
TCC ACA GAT CAA GGA TAT CTT GTC 
HIV-1 probe  FAM/ACACTACTTGAAGCACTCAAGGC
AAGCTTT/MGB 
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2.3.3 HIV-1 p24 ELISA 
In the setting up of an in vitro system to study HIV-1 persistence, HIV-1 p24 protein 
was quantified in the supernatant of infected cells to estimate viral titre, by using 
sandwich Lenti-X™ p24 Rapid Titer Kit (Clontech/Takara Bio Europe, Saint-Germain-
en-Laye France) as recommended by the manufacturer. The rational of the sandwich 
ELISA is depicted in Figure 2.3.  
 
 
 
 
 
Figure 2.3 Sandwich ELISA 
Adapted by Clonotech Lenti-X™ p24 Rapid Titer Kit User Manual. Anti-p24 coated=capture 
antibody that is bound to a well of the microtiter plate; p24= HIV-1 p24 protein; anti p24-
Biotin= antibody binding the protein of interest that was biotin conjugated; streptavidin-HRP= 
anti biotin antibody that carried HRP. 
 
The sandwich ELISA method measured a protein of interest between two layers of 
antibody (capture and detection). Capture antibody was coated to the wells in the 
microtiter well plate and quantitatively binds the target protein (in this case HIV-1 p24) 
in the sample. Specifically-bound target is detected using a biotinylated anti-p24 
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secondary antibody which is further bound by streptavidin conjugate to the horseradish 
peroxidise (HRP). When the HRP-substrate is added, it develops colour intensity in 
proportion to the quantity of the target protein concentration 
 
After equilibration of all reagents at RT, lysis buffer (20 µl/well of a 96 well plate) was 
disposed into the selected wells that were pre-coated with anti-p24 capture antibody. 
Sample and standard dilutions were added in duplicates (200 µl/well) and plate was 
incubated at 37°C for 1 hr. After incubation plates were washed 5 times by aspirating 
the content of each well and by filling it with wash buffer (300 µl/well); plates were 
tapped dried before adding the anti-p24 biotin conjugate detector antibody (100 
µl/well). After 30’ incubation at RT, plate were washed 5 times as described before and 
substrate solution was added (100 µl/well) and incubated for 20’ at RT. Stop solution 
(100 µl/well) was added prior to acquisition by microtiter plate reader at 450 nm to 
obtain the optical density values (OD450). Average of OD450 obtained from the standard 
dilutions were plotted in y-axis and concentrations in x-axis to obtain a regression line 
equation for quantification. Only equations with R2 value>0.9 were accepted. To 
calculate p24 concentration (x) in each sample, average OD450 values (y) were inserted 
into the obtained equation. This sandwich ELISA approach allowed quantification 
down to 6 pg/ml p24. 
2.4 Immunology 
2.4.1 Flow cytometry  
In the context of the ERAS study (Chapter 4 and 6 of this thesis), cellular markers of 
immune activation were measured by flow cytometry on fresh blood at the Department 
of Clinical Immunology, Royal Free Hospital London under the supervision of Mrs 
Tahami Fariba. The Multitest IMK Kit (Becton Dickinson BD, Oxford UK) was used 
for lymphocyte counts according to manufacturer instructions; events were acquired by 
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using BD FACSCalibur and the analysis was performed by using CellQuest program. 
Markers of immune activation were measured as follows. Blood pellet was resuspended 
in 1X Hoffman’s lysis buffer (100 ml of solution contained 8.3 g NH4Cl, 1.0 g KHCO3, 
37 mg disodium EDTA dissolved in water, stock solution 10X) and incubated for 10’ 
at RT to allow cell lysis. Cells were then added into the 96 well plate (round bottom) 
and incubated with the relevant antibody as listed in Table 2.4 for 15’  at RT; following 
incubation, cells were washed 4 times where 1 wash was perfomed as follows: 
centrifuge the plate, flick out supernatant, add 150 l PBSA buffer (PBS containing 
0.2% albumin and 0.2% Sodium Azide), dry plate, cover with sealer, centrifuge the 
plate. Cells were resuspended in 1% paraformaldehyde (PFA) and incubated for 30’ 
prior to acquisition with BD FACSCalibur; analysis was performed by using CellQuest 
program. 
 
For the integrated HIV-1 DNA load in CD4 T-cell sub-populations study (Chapter 5 of 
this thesis), flow cytometry was used for the detection of markers of cellular immune 
activation including HLA-DR, CD25 and CD69 expression on CD4 T-cells. Cell 
suspension (5x105 cells in 40 µl of WS buffer previously described) was stained with 
the relevant antibody; all antibodies used were diluted 1:5 as recommended from 
manufacturer (Biolegend, London UK). After 30’ incubation at RT, cells were washed 
twice in 1ml of PBS and centrifugation at 300xg for 5’ at RT. After the last wash cells 
were resuspended in 100 µl of 2% PFA solution and acquired within 24 hrs. BD Accurri 
C6 Facs Machine (BD) was used to record 10,000 events for each sample and data 
analysis was performed by using C Flow Plus (BD) software.  
 
For the development of in vitro assays to study HIV-1 persistence during ART, flow 
cytometry was used to measure HLA-A2 expression on CD4+ T-cells and to quantify 
intracellular HIV-1 p24 protein as measure of infection, as described in Chapter 7.  
 
All antibodies used in this thesis were listed in Table 2.4. 
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Table 2.4 List of all antibodies used in flow cytometry assays in this thesis 
Study Target (fluorocrome) Company (Cat #) 
Chapters 4 and 6 
 
 
 
 
 
 
 
 
 
CD3 (Cy5) BD (555341) 
CD8 (FITC) BD (345772) 
CD4 (FITC) BD (555346) 
CD4 (Cy5) BD (555348) 
CD38 (PE BD (555460) 
CD26 (PE) BD (555437) 
CD69 (PE) BD (555531) 
HLA-DR, P, Q (PE) Serotec (MCA477PE) 
Chapter 5 CD4 (PE) 
 
Biolegend (317410) 
HLA-DR (APC) Biolegend (307610) 
CD25 (APC) Biolegend (302609) 
CD69 (FITCH) Biolegend (310904) 
Chapter 7 HLA-A2 (PE) 
 
Biolegend (551285) 
HIV p24 (FITCH) 
 
Beckman (6604665) 
2.4.2 ELISA assays  
Different commercially available ELISA kits were employed to measure plasma levels 
of the following soluble markers of immune activation: CD14, CD27, CD30, hsCRP, 
IL6, D-Dimer. An overview with the different kit and correspondent sensitivity is 
provided in Table 2.5. All kits used a sandwich ELISA approach as described in Figure 
2.3. All kits provided plates that were pre-coated with relevant antibody and instructions 
from the manufacturer were followed. Samples were diluted as indicated in Table 2.5 
and added to the wells. For CD27, CD30, IL6, soluble standard curve dilutions were 
already present in dedicated wells in the plate and they only need to be reconstituted by 
addition of water (100 µl); furthermore the detection antibody was already contained in 
all the wells. For these kits, 3 hrs incubation guaranteed the binding of the relevant 
markers contained in the plasma to both the capture and the detector antibody. 
Conversely, for the CD14, D-Dimer, and hsCRP kits the standard was provided in 
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powder form that needed to be re-constituted in water and diluted. Sample and standard 
dilutions were first incubated with capture antibody for 1-3 hrs (depending on the kit) 
at RT; following this incubation the plate was washed as described for the p24 ELISA 
kit and the relevant conjugate detection antibody was added and incubated for 1 hr. 
Following incubation with the detector antibody, all kits were washed as described 
above and the substrate solution was added and incubated for 10’-30’ depending on the 
kit. Stop solution was added before acquisition by microtiter plate reader at 450 nm. 
Raw data were produced by research technicians and analysed in the context of this 
thesis according to manufacturer instructions. For CD27, CD30, IL-6, hsCRP pre-
designed calculation sheet was available. For CD14, OD450 and p24 pg/ml standard 
concentration were log transformed and plotted with OD450 in y-axis and p24 pg/ml in 
x-axis prior to generate the linear regression curve equation that was used for 
quantification as done for the p24 ELISA. For D-Dimer, OD450 values were plotted in 
x-axis and log10p24 pg/ml in x-axis prior to analysing the data to fit a polynomial curve 
with order 2. 
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Table 2.5 List of all ELISA assay kits used to measure soluble markers of 
immune activation in this thesis 
 
Soluble marker Sample dilutions Sensitivity Company  
(city, country) 
CD14 1:200-1:400 125 pg/ml R&D system, UK 
D-Dimer 1:2 23.7 ng/ml USCN, China 
hsCRP 1:100 0.02 µg/ml Demeditec, Germany 
CD27 1:50 0.2 U/ml EBiosciences, UK 
CD30 1:4 0.33 ng/ml EBiosciences, UK 
IL6 None 0.92 pg/ml EBiosciences, UK 
2.5 Statistical Method 
Different statistical approaches were used throughout the thesis as specified in the 
single chapters. Generally, non-parametric Wilcoxon-Mann-Witney test was used to 
compare continuous variables and chi-squared (X2) test was used to compare un-paired 
categorical variables. When variables were paired, Wilcoxon matched-pairs signed rank 
test or McNemar X2 test were used for continuous variables or categorical variables, 
respectively. Where the analyses required variables to be expressed as medians, 
undetectable results were generally assigned an arbitrary midpoint value between zero 
and the median lower limit of detection of the assay used for quantification, as specified 
in each chapter.  
 
For the ERAS studies, characteristics of the study population were stratified into groups 
based upon duration of suppressive antiretroviral therapy. The mean differences (with 
95% confidence interval, CI) over 10 years of suppressive ART of virologic and 
immunologic factors were analysed by univariate linear regression analysis after log 
transformation of the variables. Spearman’s test was used to explore association 
between integrated HIV-1 DNA and immunological and virological factors. The 
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association between markers of HIV-1 persistence and the other immunological and 
virological variables was characterised further by univariate and multivariable linear 
regression modelling. For the ERAS study (Chapter 4), variables to be included in the 
multivariable linear regression models were selected based upon univariate analysis 
results and only factors with p<0.1 were included. For the integrated HIV-1 DNA study 
(Chapter 6), a ‘best subset’ approach and the Mallow Cp test were used for the selection 
of variables to be included in the multivariable model. This method is applied to find 
the best model involving a subset of input predictors. An example of a Mallow Cp 
output is given in Figure 2.4. The analyses were performed with SAS 9.4 in 
collaboration with Dr. Alessandro Cozzi-Lepri at University College London. 
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Figure 2.4 Example of Mallow statistic approach for variable selection 
Cp= Cp value, with lower values being the most powerful; p= parameters included into the 
selection. 
2.6 Mammalian cell lines maintenance 
MT-4 and Human Embryonic Kidney 293 (HEK-293) cells were provided by Prof. 
Andew Owen, University of Liverpool. MT-4 cells are human T-cells transformed by 
co-cultivation with leukaemia lymphocytes harbouring HTLV-1. MT-4 cells are 
persistently infected with HTLV-1 and may shed HTLV-1 in culture (Pauwels et al., 
1987). HEK-293 cells are a widely used cell line generated by transformation of human 
embryonic kidney cells with defective adenovirus 5 (HadV-5) (Graham et al., 1977). 
Rev-CEM cells were purchased from the National Institute of Health (NIH) AIDS 
Research & Reference Reagent Program (cat. # 11467). This is a reporter human T-cell 
lymphoma cell line engineered to contain the green fluorescent protein (GFP) gene. As 
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GFP is coupled to a Rev Responsive Element (RRE), the cells only express GFP upon 
expression of the Rev gene during HIV infection (Wu et al., 2007). 
 
Upon arrival from external sources, MT-4 and Rev-CEM cell were quickly thawed at 
37°C and resuspended in 10 ml of cool Roswell Park Memorial Institute medium 
(RPMI-1640), containing L-glutamine (Thermo Fisher scientific) complemented with 
10% FBS (Thermo Fisher scientific). Cell pellet was harvested by centrifugation at 
200xg for 5’ and resuspended in 10 ml of pre-warmed complemented RPMI-1640, 
transferred to a culture flask, and placed in the incubator to allow cell growth. Cells 
were generally split 1:4 twice a week depending on growth rate. HEK-293 cells were 
thawed as described above, but Dulbecco’s Modified Eagle Medium (DMEM, Thermo 
Fisher scientific, UK) complemented with 10% FBS (Thermo Fisher scientific, UK), 
5% penicillin/streptomycin (Thermo Fisher scientific, UK) and 5 nM of L-Glutamine 
(Thermo Fisher scientific, UK) was used instead of complemented RPMI-1640. Once 
thawed, cell suspension was added to 10 ml of pre-warmed supplemented DMEM. Cell 
pellet was harvested by centrifugation at 400xg for 5’, resuspended in 10 ml of pre-
warmed supplemented DMEM, transferred to a culture flask, and place in the incubator 
to allow cell growth. Being adherent cells, flasks were placed horizontally in the 
incubator. 
 
MT-4 and Rev-CEM cells are grown in suspension and each passage was performed by 
diluting cell suspension 1:5 in supplemented RPMI-1640 every 4-5 days depending on 
cell density and growth rate.  HEK-293 cells were split 1:4 to 1:6 every 4-5 days 
depending on cell density as follow. When confluent, cells were washed with PBS 
(Fisher thermoscientific) and cells were incubated with trypsin-EDTA solution (Fisher 
thermoscientific) for 2-5’ at 37°C to allow cell detachment from the flask. Following 
incubation, cells were resupended in complemented DMEM and split as needed. All 
cells types were frozen at a concentration of 107 cells/ml as described for PBMC above 
in this chapter.  
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3 Chapter 3: Residual plasma HIV-1 RNA detection in 
patients switching from a single-tablet regimen of co-
formulated tenofovir/emtricitabine/efavirenz to one 
containing co-formulated 
tenofovir/emtricitabine/rilpivirine 
3.1 INTRODUCTION  
Co-formulated tenofovir/emtricitabine/efavirenz (Atripla) and 
tenofovir/emtricitabine/rilpivirine (Eviplera) are triple single tablet regimens (STRs) 
approved for once daily HIV-1 treatment. Both consist of one non-nucleoside reverse 
transcriptase inhibitor (NNRTI, efavirenz or rilpivirine) plus the nucleosides/nucleotide 
reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF) and 
emtricitabine (FTC). Until recently, efavirenz (EFV)-based triple ART was the 
preferred combination for starting therapy in the United Kingdom (UK) (Asboe et al., 
2012, Geretti and Tsakiroglou, 2014), and the majority of treated individuals achieved 
plasma HIV-1 RNA (“viral load”) suppression (Gulick et al., 2006, Cassetti et al., 
2007). However, EFV can induce central nervous system (CNS) toxicity (Sanchez 
Martin et al., 2013), which results in people discontinuing therapy both in the context 
of clinical trials and in routine clinical practice (reviewed in Geretti and Tsakiroglou, 
2014)    . The STR formulation of rilpivirine (RPV) with TDF and FTC has been 
compared with Atripla in the context of a randomised clinical trial (STAR), where it 
showed superior overall efficacy in patients with pre-ART plasma HIV-1 RNA 
<100,000 copies/ml. The better performance relative to EFV reflected improved 
tolerability and fewer discontinuations due to side effects. RPV however showed 
reduced potency in subjects with viral loads >100,000 copies/ml, which resulted in an 
increased number of virological failures compared with EFV (Cohen et al. AIDS 2014). 
As a result, Eviplera is only recommended for the initial treatment of subjects with pre-
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ART viral load <100,000 copies/ml. The improved CNS safety profile, small tablet size, 
and good virological activity at low viral load make Eviplera an attractive option for 
patients who are already established on suppressive EFV-based ART but experience 
poor tolerability and therefore require a switch of therapy. 
 
Third generation viral load assays reliably quantify HIV-1 RNA below the previously 
established cut-off of 50 copies/ml (e.g., 40 copies/ml with the Abbott RealTime assay 
and 20 copies/ml with the Roche TaqMan v.2 assay) and also report qualitative HIV-1 
RNA detection below these thresholds. For example, with the Abbott RealTime assay, 
the manufacturer indicates that with 30, 20, and 10 HIV-1 RNA copies/ml detection 
rates were 96%, 88%, and 68%, respectively. Investigators have interrogated cohort 
data to determine whether a lower cut-off than 50 copies/ml should be introduced to 
define optimal viral suppression. Data produced using the Abbott Real-Time assay 
demonstrated that treated patients with detectable HIV-1 RNA between 40 and 49 
copies/ml and those with qualitative detection below 40 copies/ml were more likely to 
experience viral rebound above 50 and 400 copies/ml over 12 months of follow-up 
relative to subjects with undetectable HIV-1 RNA (Doyle et al., 2012). Importantly, the 
effect of HIV-1 RNA detection below 50 copies/ml was independent of other known 
predictors of viral rebound including adherence levels (Doyle and Geretti, 2012, Doyle 
et al., 2012). Similar findings have been reported with the TaqMan assay v1 and v2 
(Alvarez Estevez et al., 2013, Henrich et al., 2012). Moreover, in patients with HIV-1 
RNA levels <50 copies/ml while receiving triple ART, a switch to a simplified 
atazanavir/ritonavir monotherapy regimen was associated with a progressive increase 
in HIV-1 RNA levels prior to virologic rebound >50 copies/ml (Wilkin et al., 2009).  
 
The above findings indicate that monitoring plasma HIV-1 RNA loads with increased 
sensitivity can help predict viral load rebound (Wilkin et al., 2009) during ART. In 
order to explore this concept further, we investigated subjects receiving suppressive 
(HIV-1 RNA <50 copies/ml) first-line ART with Atripla who switched to Eviplera in 
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the context of a clinical trial. Following assay optimisation, ultrasensitive HIV-1 RNA 
measurements were made using stored plasma samples collected at the time of the 
switch (baseline) and at regular time points over the subsequent 24 weeks of follow-up. 
3.2  METHODS 
3.2.1 Study population  
The trial was a phase III, open-label, multi-centre, pilot study. Eligible subjects had 
received Atripla for at least 12 weeks, showed a viral load <50 copies/ml and a CD4 
count >50 cells/mm3, had never previously received RPV or experienced virological 
failure, and were experiencing grade 2-4 CNS toxicity considered to be related to EFV. 
A total of 37 patients switched from Atripla to Eviplera and underwent follow-up for 
24 weeks. The study-related standard viral load was measured at the centre of care using 
either the Versant HIV RNA v3.0 bDNA assay or the Roche TaqMan v2 assay. Plasma 
samples collected at baseline and at week 4, 12, and 24 after switching were stored at -
80°C prior to shipping to the University of Liverpool on dry ice. Ethics was approved 
by local authorities and the study was registered at clinicaltrial.gov (identifier number 
NCT017701882) and the EudraCT registration number was 2012-002205-22.  
3.2.2 Assay optimisation 
As described in Chapter 2, our group developed an ultrasensitive HIV-1 RNA 
quantification assay that detected 1-3 copies/ml with an input of 8 ml of plasma. 
However, in this study the volume of plasma available for testing at each sampling point 
was ≤2 ml. Therefore, an alternative assay needed to be tested with a reduced plasma 
input in order to assess which was the higher sensitivity that could be achieved. The 
first step was virus concentration by ultracentrifugation of the sample at 215,000xg for 
45’ at 4°C as described in Chapter 2. We then compared two different RNA extraction 
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methods: the Abbott manual extraction kit and the automated m2000sp extractor, as 
detailed in the methods chapter. For manual extraction, following ultracentrifugation 
the pellet was resuspended in 600 µl of basematrix and used as input for the RNA 
extraction. After 20’ incubation at 50°C with 100 µl of magnetic micro particle beads 
and 2.4 ml of lysis buffer, RNA was eluted in 66 µl volume. For automated extraction, 
pellets were resuspended in 1ml of basematrix and loaded onto the Abbott m2000sp 
instrument which eluted the RNA in 88 µl volume. With both methods, 50 µl of eluate 
was used as input in the Abbott m2000rt instrument. As described in Chapter 2, 
quantification results obtained from the Abbott software were based on an input volume 
for RNA extraction of 1 ml and an elution volume of 88 µl. For the manual extraction 
assay those volumes were modified and we therefore had to calculate the results 
manually. In particular, raw data produced by the software were divided by 1.7 and by 
1.3 to correct for 600 µl plasma input and 66 µl elution volumes, respectively. Assay 
sensitivity was tested using dilutions of the World Health Organisation (WHO) 3rd 
International Standard for HIV-1 RNA in HIV-1 negative plasma. The dilutions were: 
40 IU/ml (26 copies/ml), 20 IU/ml (13 copies/ml), 10 IU/ml (7 copies/ml), 5 IU/ml (3.5 
copies/ml), and 1 IU/ml (1 copy/ml). The WHO recommended conversion factor for 
the Abbott RealTime assay was used to convert IU/ml into copies/ml, whereby 1 
copy/ml = 1.4 IU/ml. 
3.2.3 Sample processing   
Plasma samples were ultracentrifuged as described above; pellet was resuspended in 1 
ml of basematrix and loaded onto Abbott m2000sp instrument for the automated Abbot 
Real-Time assay (Maidenhead, UK). When plasma input volumes were smaller than 2 
ml, the lower limit of detection was calculated based on specific plasma input using the 
Abbott detection rates for 1.0 ml. Median plasma input volume was 1.5 with a median 
lower limit of detection of 17 copies/ml. Levels of viral load suppression after switching 
were categorized as follows: improved suppression was defined as HIV-1 RNA >10 
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copies/ml at baseline followed by consistent suppression ≤10 cps/ml; reduced 
suppression was defined as HIV-1 RNA measurements ≤10 copies/ml at baseline 
followed by ≥2 consecutive HIV-1 RNA measurements >10 copies/ml or ≥1 HIV-1 
RNA measurement >50 copies/ml during follow-up; loss of suppression was defined as 
HIV-1 RNA >50 copies/ml at week 12 and/or week 24.  
3.2.4 Statistical analysis 
For the validation tests, the coefficient of variation (CV) was calculated to describe the 
amount of variability relative to the mean of each standard dilution point within the 
same experiment; furthermore CV of each run was averaged to produce the overall CV 
per each standard dilution. CV>20% were considered unacceptable. Input plasma 
volumes were compared by non-parametric unpaired Mann Whitney test. HIV-1 RNA 
levels between baseline and other time points were compared by non-parametric paired-
sample Wilcoxon signed rank test for continuous variables and by McNemar Chi-2 test 
for categorical variables. All values were log-transformed prior to analysis. Where the 
analyses required variables to be expressed as medians, undetectable HIV-1 RNA 
results were assigned an arbitrary midpoint value between zero and the median lower 
limit of detection (= 9 cps/ml).  
3.3 RESULTS  
3.3.1 Validation of the ultrasensitive viral load assay  
Our initial aim was to validate an HIV-1 RNA quantification assay capable of utilising 
2 ml of plasma as assay input. To do so, we compared assay sensitivities following 
either manual or automated RNA extraction of serial dilutions of WHO 3rd International 
Standard for HIV-1 RNA.  
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3.3.1.1 Manual extraction 
A total of five independent experiments were performed (Table 3.1 and Table 3.2). The 
WHO Standard was tested at 40 IU/ml (26 copies/ml) in two experiments (4 replicates); 
at 20 IU/ml (13 copies/ml) in three experiments (6 replicates); at 10 IU/ml (7 copies/ml) 
in five independent experiments (19 replicates); at 5 IU/ml (3.5 copies/ml) in three 
experiments (7 replicates). HIV-1 RNA detection rates were 4/4 replicates (100%) at 
40 IU/ml, 6/6 (100%) at 20 IU/ml, 14/19 (74%) at 10 IU/ml, and 4/7 (57%) at 5 IU/ml. 
Median HIV-1 RNA levels were 34 copies/ml (IQR 27-38, range 10-42) for 40 IU/ml 
input; 34 copies/ml (IQR 25-42, range: 7-63) for 20 IU/ml input; 24 copies/ml (IQR 
14-29, range: 6-282) for 10 IU/ml input; and 10 copies/ml (IQR 5-18, range 5-29) for 
5 IU/ml input. Abbott controls were run in each of the five independent experiments 
and median values were 5 log10 copies/ml (range: 2-5) and 3 log10 copies/ml (range: 3-
3) for control H and L respectively, as expected. In one run, control H showed lower 
quantifications at 2 log10 copies/ml. In two independent runs, input values at 13 
copies/ml and 7 copies/ml were read at 63 and 282 copies/ml, respectively (Table 3.2). 
Averages of coefficients of variation calculated for each run were all above acceptable 
threshold of 20% and are shown in Table 3.2.
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Table 3.1  Validation of manual RNA extraction 
Standard IU/ml 
(copies/ml) 
Total replicates  
tested (runs) 
HIV-1 RNA 
  
Detected  
n (%) 
Median         
copies/ml (IQR) 
Range 
copies/ml 
40 (26) 4 (2) 4/4 (100) 34 (27-38) 10-42 
20 (13) 6 (3) 6/6 (100) 34 (25-42) 7-63 
10  (7) 19 (5) 14/19 (74) 24 (14-29) 6-282 
5 (3.5) 7 (3) 4/7 (57) 10 (5-18) 5-29 
Abbott Control H, log10 cps/ml
a 6 (5) 6/6 (100) 5.0 (4.9-5.0) 2.0-5.0 
Abbott Control L, log10 cps/ml
b 6 (5) 6/6 (100) 3.0 (3.0-3.0) 3.0-3.0 
a5.0 log10 cps/ml;
 b3.0 log10 cps/ml. 
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Table 3.2 Individual runs performed to validate the manual RNA extraction 
assay 
  HIV-1 input IU/ml (copies/ml) 
  40 (26) 20 (13) 10 (7) 5 (3.5) 
RUN 1 
 
Individual results (copies/ml) 40 22 24 4 
10 63 6 15 
CV between replicates, % 85 69 88 75 
  
 
    
RUN 2 Individual results (copies/ml) 37 33 12 UD 
32 7 282 5 
CV between replicates, % 9.3 94 130 NA 
      
RUN 3 Individual results (copies/ml)  34 39 UD 
 45 26 UD 
  UD 29 
CV between replicates, %  19 29 NA 
     
 
 
 
RUN 4 Individual results (copies/ml)   22  
  21  
  UD  
  24  
  6  
  30  
  11  
CV between replicates, %   47  
      
RUN 5 Individual results (copies/ml)   37  
  UD  
  UD  
  23  
  UD  
CV between replicates, %   32  
      
Avarage of CV between replicates, % 47 81 65 NA 
CV= coefficient of variation= (SD/average); UD= under limit of detection; NA= not 
available 
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3.3.1.2 Automated extraction 
One experiment was run (Table 3.3) using the WHO International Standard in 3 
replicates of 20 IU/ml (13 copies/ml), 8 replicates of 10 IU/ml (7 copies/ml), and 4 
replicates of 1 IU/ml (<1 copy/ml). HIV-1 RNA detection rates were 3/3 (100%) at 20 
IU/ml, 7/8 (88%) at 10 IU/ml, and 0/4 (0%) at 1 IU/ml. Median levels of detection were 
15 copies/ml (IQR 13-16, range 11-16) for 20 IU/ml input and 14 copies/ml (IQR 8-16, 
range: 5-24) for 10 IU/ml input. The coefficient of variation between replicates was 
below 20% for the 13 copies/ml input and above 20% for the 7 copies/ml input.  
 
 
 
Table 3.3 Validation of automated RNA extraction 
Standard IU/ml 
(copies/ml) 
Total 
replicates            
(runs) 
HIV-1 RNA 
CV between 
replicates 
(%) 
 Detected                 
n (%) 
Median          
cps/ml (IQR) 
Range 
cps/ml 
 
20 (13) 3 (1) 3/3 (100) 15 (13-16) 11 – 16 19 
10 (7) 8 (1) 7/8 (88) 14 (8-16) 5 - 24 75 
1 (0.7) 4 (1) 0/4 (0) - - NA 
Abbott Ctrl Ha, 
log10 cps/ml 
1 (1) 1 (100) - - 
 
Abbott Ctrl Lb , 
log10 cps/ml      
1 (1) 1 (100) - - 
 
 a=5.0 log10 cps/ml;
 b= 3.0 log10 cps/ml. CV= coefficient of variation= (SD/average). 
 
 
 
 
 
 
Taken together the results indicated that the automated extraction method provided 
better results demonstrated by lower coefficient of variation between replicates 
compared with the manual RNA extraction method for the 13 copies/ml dilution. Based 
upon these results we proceeded with sample testing by using the automated extraction.  
74 
 
 
3.3.2 Study population at baseline  
The cohort included 37 patients (33 male, 89%) with median duration of ART of 4 years 
(IQR 2-8) (Table 3.4). Overall 21/37 patients (57%) received only Atripla as treatment, 
whereas 16/37 (43%) patients had experienced median 3 drug changes (IQR 1-3) before 
receiving Atripla. For the whole population the median duration of receiving Atripla 
was 3 years (2-4). 
 
 
 
Table 3.4 Baseline characteristics of the study population 
 
 
 
 
 
3.3.3 Plasma HIV-1 RNA levels after the switch  
Overall plasma samples from 37 subjects were tested (n=144) using the automated 
extraction protocol as described above and the results are shown in Table 3.5. The input 
volume was smaller than 2.0 ml in the majority of the patients with a median volume 
of 1.5 ml. This lower volume affected the lower limit of detection, which was median 
17 copies/ml and ranged between 36 and 13 for the four time points. In particular, 
volumes was significantly smaller at week 4 (median 1.3, IQR 1.2-1.6) when compared 
with baseline (median 1.5, IQR 1.3-1.8) (p=0.03), but with no difference in volumes 
Total, n (%) 37 (100) 
Male gender, n (%) 33 (89) 
Duration of ART, median years (IQR) 4 (2-8) 
Atripla as the only regimen, n (%) 21 (57%) 
Treatment changes prior to Atripla, median (IQR) 3 (1-3) 
Duration of Atripla, median years (IQR) 3 (2-4) 
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tested at other time points (Table 3.5). The lower volume at week 4 compared to 
baseline was associated with a reduced rate of HIV-1 detection (p=0.001 Table 3.5). 
Among the samples tested, 134/144 (93%) yielded a valid result and overall 48/134 
(36%) of them showed detectable HIV-1 RNA. An increase in HIV-1 RNA detections 
rates was observed from baseline to week 24 and detection rates were 11/37 (30%) at 
baseline, 7/31 (23%) at week 4, 15/36 (42%) at week 12, and 15/30 (50%) at week 24 
(Table 3.5). The majority of test had HIV-1 RNA load<50 copies/ml (129, 96%) and 
within those, no-one had detectable HIVA-RNA between 40-49 copies, whereas 26 
(54%) tests yielded levels between 10 and 40 copies (Table 3.5). Nevertheless, 2/36 
(6%) and 3/30 (10%) of tests had HIV-1 RNA load > 50 at week 12 and 24 respectively.  
 
The kinetics of plasma HIV-1 RNA load over 24 weeks indicate that overall 33 patients 
maintained HIV-1 RNA levels <50 copies/ml for the whole period (Figure 1.1 a) and 
within this group, four subjects showed improved virus suppression after switching 
(Figure 3.1 b). Overall seven subjects showed reduced suppression (Figure 3.1 c), 
including 4/37 (10%) subjects that showed viral load rebound >50 copies/ml at week 
12 and/or week 24 (Figure 3.1 c points A, B, C, D).  In 2 patients with viral load rebound 
>50 copies/ml, we were able to observe a progressive increase in HIV-1 RNA levels 
prior to the rebound at week 12 or 24 (Table 3.1c points: C and D). Median HIV-1 RNA 
load was 9 copies/ml at each time point (Table 3.5), but a trend for significant increase 
of HIV-RNA load was observed starting at week 12 after baseline (Table 3.2, p=0.06).    
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Table 3.5 Plasma HIV-1 RNA levels before and over 24 weeks after switching from Atripla to Eviplera 
   HIV-1 RNA 
Time point N 
Median plasma 
volume, ml 
(IQR) 
Detected        
n (%) 
Detected between 
10-40 copies/ml    
n (%) 
Median cps/ml 
(IQR)a 
<50 copies/ml n 
(%) 
>50 copies/ml, n 
(%) 
Baseline 37 1.5 (1.3-1.8) 11 (30) 4/11 (36) 9 (9-9) 37 (100) 0 (0) 
Week 4 31 1.3 (1.2-1.6)c* 7 (23)d** 4/7 (57) 9 (9-9) 31 (100) 0 (0) 
Week 12 36 1.4 (1.2-1.7) 15 (42) 9/15 (60)  9 (9-15) 34 (94) 2 (6) 
Week 24 30 1.6 (1.3-1.7) 15 (50) 9/15 (60)  9 (9-14) 27 (90) 3 (10)c 
Total 134 1.5 (1.2-1.7) 48 (36) 26/48 (54)        9 (9-12) 129 (96) 5 (4) 
 asamples with undetectable HIV-1 RNA were assigned an arbitrary value of 9 copies/ml; c* p=0.04 vs. Baseline (Mann-Withney test);d** 
p=0.001 vs Baseline (McNemar Chi-2 test). cone patients experienced virologic rebound at weeks 12 and week 24.  
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Figure 3.1 Kinetics of plasma HIV-1 RNA from baseline (B/L) to week24 after the switch from Atripla to Eviplera 
 a) 33 patients showed HIV-1 RNA copies/ml stably below 50 copies/ml during the whole study period with levels ranging from <9  to 39 copies/ml. b) 
4 patients showed improved viral suppression after switching. c) 7 patients showed reduced suppression after switching; within this group, 4 patients 
showed HIV-1 RNA >50 copies/ml at week 12 and/or week 24. A= 185 HIV-1 RNA cps/ml; B1= 124 HIV-1 RNA cps/ml; B2= 78 HIV RNA cps/ml; C= 
113 HIV-1 RNA cps/ml; D= 69 HIV-1 RNA cps/m. X Axis represented the 4 time points: B/L= baseline; W4= week 4 after the switch; W12= week 12 
after the switch; W24= week 24 after the switch; y axis represented residual plasma HIV-1 RNA copies/ml.  
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Figure 3.2 Plasma HIV-1 RNA levels measured in the whole cohort over time 
For each time point, horizontal lines indicated median values of HIV-1 RNA and the vertical lines 
defined the interquartile range (IQR).  Non-parametric paired-sample Wilcoxon signed rank p value is 
shown. Number of total test for each time point was: baseline=37, week 4=31, week 12=36; week 
24=30.  
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3.4 DISCUSSION  
In this study, residual plasma HIV-1 RNA below 50 copies/ml was measured over 24 weeks in 
37 patients that switched suppressive ART with Atripla to Eviplera. Following optimisation of 
the ultrasensitive viral load assay, we showed that whilst the majority of patients maintained 
viral load suppression after the switch, seven subjects experienced reduced suppression and 
four had a viral load rebound >50 copies/ml. Importantly, in two subjects we were able to 
demonstrate a gradual increase in residual HIV-1 RNA levels prior to viral load rebound >50 
copies/ml, which indicates the importance of the ultrasensitive assay as a predictive tool for 
viral load rebound. 
 
Previous studies described ultrasensitive assays for quantifying residual HIV-1 RNA levels 
during suppressive ART that require input of large plasma volumes at 8 ml (Palmer et al., 
2003). In our lab, we validated an ultrasensitive assay that allowed us to detect down to 1-3 
copies/ml starting from 8 ml of plasma input (Chapter 2). In this study we had smaller quantities 
of plasma available for testing and the highest sensitivity we could expect with the automated 
procedure was around 13 HIV-1 RNA copies/ml. Although this threshold was acceptable based 
on previous observations that nearly HIV-1 RNA detection below 10 copies/ml is common in 
subjects that maintain long-term suppression <50 copies/ml (Maldarelli et al., 2007, Kiselinova 
et al., 2015), we decided to explore alternative procedures in order to optimise the assay to 
perform with improved sensitivity relative to the standard method. One previous study 
proposed a modified version of the Abbott RealTime assay with lower limit of quantification 
down to 5 copies/ml starting from 3 ml of plasma input (Amendola et al., 2011). The 
researchers used an open mode protocol which allowed the design of a standard curve with one 
point as low as 10 copies/ml ensuring robust quantification of very low concentrated samples. 
This option was not available for this study and we tested a manual RNA extraction protocol 
with reduced input volume from 1 ml to 600 µl and reduced elution volume from 88 µl to 66 
µl. Such modifications aimed to further concentrate the extracted RNA and to reflect this in the 
final calculation of the results, the raw data produced by the software were adjusted dividing 
by 1.7 and 1.3 to correct for input and elution volumes, respectively. Our results demonstrated 
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a high variability between replicates when testing either serial dilutions of the WHO 3rd 
International Standard for HIV-1 RNA or the Abbott assay positive controls. With the 
automated standard procedure, variability between replicates was reduced. Discordance 
between the two procedures could be explained by the modifications we introduced within the 
manual protocol, as well as by an intrinsic inter-operator variability that manual procedure 
carries, as described by others (Scott et al., 2011). Based on these results we established to use 
the automated procedure with a sensitivity of quantification at 13 HIV-1 RNA copies/ml for 
further testing. 
 
Previous reports have demonstrated that patients on suppressive ART show levels of HIV-1 
RNA between 1-10 copies/ml and which normally do not associate with viral rebound (Doyle 
and Geretti, 2012). In this study we did not have the assay sensitivity to explore viral kinetics 
at HIV-1 RNA levels below 10 copies/ml and we largely focused on HIV-1 loads ranging 
between 10 and 50 copies/ml. Previous work also showed that around 50% of patients on stable 
ART with the same NNRTI for median of 6 years had detectable HIV-1 load (Palmer et al., 
2008, Ruggiero et al., 2015, Kiselinova et al., 2015) whilst showing persistent viral load 
suppression confirmed by 2 HIV-1 VL test per year (Chapter 4 of this thesis). In the cohort 
presented here, before the switch to Eviplera all patients had HIV-1 RNA<50 copies/ml and 
50% of those were on stable ART with Atripla for median 4 years. After the switch, patients 
maintained stable viral load suppression during the whole study period, whereas 7 patients 
showed a reduced suppression with HIV-1 RNA levels between 10-40 and >50 HIV-1 RNA 
copies/ml at week 12 or 24 after starting Eviplera. One previous study by Doyle and colleagues 
demonstrated that patients on ART with detectable HIV-1 RNA <40 copies/ml had 11.3% and 
3.8% to experience virologic rebound at HIV-1 RNA levels above 50 and 400 copies/ml over 
12 months of follow up, respectively. In our study we found that 4/7 patients with reduced 
suppression experienced a lack of suppression with HIV-1 RNA>50 copies by the end of study. 
Moreover, within the 4 “rebounders”, overall 2/4 showed levels between 10-40 HIV-1 RNA 
copies/ml at the time point prior to lack of suppression. Our findings confirmed both the Doyle 
study and another work on therapy simplification (Doyle et al., 2012, Swindells et al., 2006) 
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demonstrating that viral rebound was predicted by a progressive increase in HIV-1 RNA levels. 
The virologic rebound observed in our study could be explained by different factors including 
pharmacological drug characteristics as well as psychological aspects associated with therapy 
switch. It has been demonstrated that EFV half-life averages around 40-55 hours (Boffito et 
al., 2009, Smith et al., 2001), which means that a missed dose will not necessarily reflect a viral 
rebound. RVP half-life is around 50 hrs as well, but it needs to be taken with an abundant meal 
in order to achieve maximal concentration when orally administrated (Hoetelmans et al., 2005, 
Crauwels et al., 2013, Lamorde et al., 2015). Switching therapy regimes already modify patient 
compliance due to psychological as well as logistical reasons; in this case new administration 
criteria are also present and this could have had a potential impact on the adherence resulting 
in lack of viral suppression.  
 
This study has a number of limitations, with the main being the lack of longer patient follow-
up, which could have strengthened the analysis, particularly for the 7 patients who showed 
reduced viral load suppression. Moreover, there was limited information available on the 
patient’s characteristics including factors such as the pre-ART viral load. Furthermore, the 
study was not powered to demonstrate virological non-inferiority between EFV and RPV and 
therefore it is difficult to achieve firm conclusions regarding the apparent risk of viral load 
rebound after switching away from EFV. In previous works RPV/FTC/TDF was considered a 
safe option to switch from EFV in case CNS toxicity, even though a small proportion of patients 
could experience virologic rebound at 48 weeks after switching (Mills et al., 2013). In line with 
these results, our data demonstrate that 33 out of 37 patients switching from Atripla to Eviplera 
were able to maintain viral load suppression with plasma HIV-1 RNA levels below 40 
copies/ml. Four patients showed virologic rebound and using our ultrasensitive testing we were 
able to predict the rebound for 2 of them. Our results confirmed the importance of routine 
monitoring HIV-1 RNA loads with an ultrasensitive assay with the aim of improving clinical 
management and preventing viral rebounds.   
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The results from this chapter have raised important questions around the debate as to what 
significance residual HIV-1 RNA levels have on HIV-1 persistence. In the following chapters 
we study a population of 104 patients treated with either EFV or NVP based ART for 1-15 
years and who demonstrate persistent viral load suppression (HIV-1 RNA <50 copies/ml) and 
characterize viral as well as immunologic factors that associate with HIV-1 persistence. 
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4 Chapter 4: Factors associated with HIV-1 persistence in a 
population of stable suppressed individuals 
4.1 INTRODUCTION 
Initiation of antiretroviral therapy (ART) causes a robust suppression of HIV replication, which 
results in a rapid decrease of plasma HIV-1 RNA below the limit of detection of commonly 
used diagnostic assays (20-50 copies/ml). Viral load undetectability defines the success of 
ART. However, research-based ultrasensitive assays can detect HIV-1 RNA at low levels in 
plasma of most treated patients, even after many years of seemingly suppressive ART. Other 
markers of HIV replication, including intracellular forms of HIV-1 RNA and unintegrated 
HIV-1 DNA (e.g., 2 long-terminal-repeat [LTR] circles), similarly decrease when ART is 
started (Mexas et al., 2012, Koelsch et al., 2008), but can remain detectable in the long-term 
despite undetectable levels of viral load in the plasma (Besson et al., 2014, Kiselinova et al., 
2015, Palmer et al., 2008). Long-lived resting CD4+T cells carry integrated HIV-1 DNA 
(Siliciano et al., 2003, Chomont et al., 2009)  as a viral reservoir which is established early 
after infection and is unresponsive to ART. This stable integrated reservoir fuels resumption 
of plasma viremia if ART  is stopped (Ruiz et al., 2000, Siliciano and Siliciano, 2015, Nicastri 
et al., 2008).  
 
Current research efforts aim to identify the source of plasma HIV-1 RNA and unintegrated 
HIV-1 DNA during seemingly suppressive ART, and to unravel the association between these 
markers and the integrated viral reservoir, as key to our understanding of how HIV infection 
may be eradicated (Chun, 2013, Chun et al., 2011). Such studies must take into account the 
complex interplay between the virus and the host immune system (Hatano, 2013, Klatt et al., 
2013). HIV-1 infection induces a state of chronic immune activation and inflammation that 
plays a key role in disease pathogenesis. Various soluble markers such as sCD14, D-dimers, 
highly sensitive C-reactive protein (hsCRP), IL-6, sCD30, and sCD27 have been found to be 
predictive of disease progression in untreated HIV-positive patients (Sandler et al., 2011, 
Pizzolo et al., 1994, Hazenberg et al., 2003). In addition, levels of sCD14, IL-6 and D-dimers 
have been associated with the risk of non-AIDS HIV-related morbidity, including 
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cardiovascular, renal and neurological disease and an increased risk of cancer (Sandler et al., 
2011) .  
 
Abnormal levels of cellular and soluble markers of immune activation and inflammation 
improve substantially with ART, although abnormalities may persist (Klatt et al., 2013, Hatano, 
2013). The aim of this study was to investigate the relationship between virological markers of 
HIV-1 persistence and markers of immune activation and inflammation during stably 
suppressive ART. In order to minimise confounding factors, a cohort of patients was selected 
with the exact characteristics overall indicative of highly stably suppressive first-line treatment 
with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus one non-
nucleoside reverse transcriptase inhibitor (NNRTI). 
4.2 METHODS 
4.2.1 Study population  
Study subjects were recruited within the ERAS cohort study described in details in Chapter 2. 
Briefly, eligible patients started first-line ART with two NRTIs plus either efavirenz (EFV) or 
nevirapine (NVP), achieved plasma HIV-1 RNA suppression <50 copies/ml within the first 6 
months of therapy, and during subsequent follow-up showed continuous viral load suppression 
(<50 copies/ml) without viral load elevations >50 copies/ml or treatment interruptions, while 
undergoing 2 viral load measurements per year and remaining on the initial NNRTI. Changes 
of the initial NRTIs (e.g., for toxicity) were allowed provided they were not associated with a 
treatment interruption or viral load rebound >50 copies/ml.   
4.2.2 Quantification of residual HIV-1 RNA in plasma 
Plasma HIV-1 RNA was quantified using a modified version of the Abbott RealTime HIV-1 
assay (Maidenhead, UK) starting from 8ml of plasma that was ultracentrifuged at 215,000xg 
for 45’ at 4oC. The assay 50% and 95% detection rates were 1 and 3 HIV-1 RNA copies/ml, 
respectively. 
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4.2.3 Drug concentration 
Plasma concentration of EFV or NVP was measured by pharmacology department of 
University of Liverpool using standard methodology. The concentrations were measured in 
untimed samples.  
4.2.4 Quantification of total and 2-LTR circular HIV-1 DNA in peripheral 
blood mononuclear cells (PBMC) 
Total HIV-1 DNA in PBMC was quantified by real-time PCR; the assay 50% and 95% 
detection rates were 20 and 40 HIV-1 DNA copies/106 PBMC, respectively (Geretti et al., 
2013) as previously reported. 2-LTR circular HIV-1 DNA was measured by digital PCR; the 
assay lower limit of detection was median 5 copies/106 PBMC (interquartile range, IQR 4-6).  
4.2.5 Markers of immune activation 
Cellular markers of immune activation were measured on fresh blood by flow cytometry at the 
Immunology Diagnostic Service of the Royal Free Hospital, in London as described in Chapter 
2. PBMC were stained with labelled antibodies against CD4 plus CD26, CD38, or CD69, and 
against CD8 plus either CD38 or HLA-DR/DP/DQ. Soluble markers of immune activation and 
inflammation were measured by plate enzyme-linked immune-enzymatic assay (ELISA) and 
analysed according to the manufacturers’ recommendations as described in Chapter 2.  
4.2.6 Statistical analysis 
The characteristics of the study population were summarised after stratification into three 
groups based upon duration of suppressive ART (0-4 years, 4-7 years, >7 years). Duration of 
suppressive ART was defined as the length of time following the first viral load measurement 
<50 copies/ml, which was recorded within six months of starting ART. Where the analyses 
required variables to be expressed as medians, undetectable results were given a midpoint value 
between zero and the lower limit of detection of each assay. Plasma drug concentrations for 
each patient were categorized as being above or below the recommended therapeutic dose for 
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wild-type virus (1000 ng/ml for EFV and 3400 ng/ml for NVP). For residual plasma HIV-1 
RNA, total and 2-LTR circular HIV-1 DNA, cellular and soluble markers of immune 
activation, the mean difference (with 95% confidence interval, CI) over 10 years of suppressive 
ART was analysed by univariate linear regression analysis after log transformation of the 
variables. Associations between variables were tested by univariate and multivariable linear 
regression analysis, using as outcomes residual plasma HIV-1 RNA, 2-LTR circular HIV-1 
DNA, and total HIV-1 DNA. Based upon results from the univariable models, all variables 
with p≤0.20 were included into the multivariable models. In the main multivariate analysis, 
only factors that had a number of observations >25 were considered, and as a result NNRTI 
used, gender, and ethnicity were excluded. Moreover, when age and duration of suppressive 
ART were eligible for inclusion into the same model, age was excluded due to the high co-
linearity between the two variables. Separate models explored a) the effects of including 
ethnicity, which excluded four subjects of Asian origin; and b) the effect of excluding two 
outliers with HIV-1 RNA levels >11 copies/ml; c) the effect of including continuous levels of 
EFV, which excluded eighteen patients on NVP. When modelling for total HIV-1 DNA, the 2-
LTR circular DNA level was not included due to strong co-linearity, and vice versa. Separate 
analyses described total HIV-1 DNA/106 CD4 T-cells (rather than PBMC); this was calculated 
after adjusting the load for the proportion of CD3+CD4+ cells in the sample as determined by 
flow cytometry; these analyses excluded the CD4 cell count and CD4/CD8 ratio. All statistical 
analyses were performed with IBM SPSS statistic v 22.0. 
4.3  RESULTS 
4.3.1 Study population  
A total of 104 patients who were receiving two NRTIs plus either EFV (n=86; 83%) or NVP 
(n=18; 17%) and had experienced plasma HIV-1 RNA suppression <50 copies/ml for median 
5 years were recruited and analysed cross-sectionally. Of these, 81/104 (78%) were men and 
59/104 (57%) were of white ethnicity (Table 4.1). Patients with longer duration of suppressive 
ART were predictably older (p=0.04), had a marginally higher current CD4 cell count (p=0.06) 
but a lower nadir CD4 cell count (p<0.001) and a higher pre-ART viral load (p=0.01), and were 
more likely to have experienced changes in the composition of the NRTI backbone after 
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starting therapy (p<0.001). Overall 48/104 patients (48%) changed one or more component of 
the NRTI backbone, with median 1 drug change per subject (IQR 1-2). At the time of sampling, 
NRTI backbones were tenofovir/emtricitabine (76/104, 73%), tenofovir/ lamivudine (2/104, 
2%) abacavir/emtricitabine (1/104, 1%), abacavir/lamivudine (21/104, 20%), 
zidovudine/lamivudine (4/104, 4%). Median levels of EFV and NVP were 1531 ng/ml (IQR 
846-2235) and 5889 ng/ml (3096-7416), respectively. Overall, 33/104 (32%) individuals had 
suboptimal plasma therapeutic drug concentration, defined as a level below the recommended 
cut-off for wild-type virus. 
4.3.2 Virological and immunological parameters 
Residual plasma HIV-1 RNA was detected in 52/104 (50%) patients; median levels were 2 
copies/ml and ranged between 1 and 35 copies/ml (Table 4.2). Among subjects with detectable 
HIV-1 RNA, 50/52 (96%) had levels ≤11 copies/ml. In PBMC, total HIV-1 DNA was detected 
in all subjects, with median levels of 2.5 log10 copies/10
6 PBMC and ranging between 1.3 and 
2.5 log10 copies/10
6 PBMC; 2-LTR circular HIV-1 DNA was detected in 24/104 (23%) patients 
at median levels of 3 copies/106 PBMC levels and ranging between 4 and 119 copies/106 
PBMC.  
 
The difference in virological and immunological parameters over 10 years of suppressive ART 
was initially analysed by univariate linear regression analysis (Table 4.3). Levels of residual 
HIV-1 RNA and 2-LTR circular HIV-1 DNA were lower with longer treatment duration, whilst 
HIV-1 DNA levels did not show a significant difference. Longer treatment duration was also 
characterised by a higher CD4 cell count and a lower percentage of CD4 and CD8 cells 
expressing the CD38 and the HLA-DR/DP/DQ activation markers, respectively. Soluble 
markers showed no significant trends, with the exception of a marginally significant decline in 
sCD27 levels. 
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Table 4.1 General characteristics of the study population at the time of recruitment 
Characteristic Total (n=104) Duration of suppressive ART stratum, years 
 <4 (n=34)  4-7 (n=35) >7 (n=35) 
Duration of suppressive ARTa, median years (IQR) 5 (3-8) 2 (2-3) 5 (5-6) 9 (8-10) 
Age, median years (IQR)  47 (40-53) 44 (36-49) 49 (39-53) 48 (43-55) 
Male, n (%)  81 (78) 29 (85) 29 (83) 23 (66) 
Ethnicity, n (%) White 59 (57) 20 (59) 22 (63) 17 (48.5) 
 Black 41 (39) 13 (38) 11 (31) 17 (48.5) 
 Asian 4 (4) 1 (3) 2 (6) 1 (3) 
Pre-ART HIV-1 RNA, median log10 copies/ml (IQR) 4.9 (4.6-5.3) 4.7 (4.1-5.1) 4.9 (4.6-5.3) 5.1 (4.8-5.6) 
Nadir CD4 count, median cells/mm3 (IQR) 201 (110-270) 279 (216-365) 166 (126-238) 118 (79-215) 
Efavirenz as NNRTI, n (%) 86 (83) 30 (88) 32 (89) 24 (69) 
NNRTI concentration, median ng/ml (IQR) EFV 1531 (846-2235) 1492 (735-2130) 1496 (866-2154) 1966 (855-2626) 
 NVP 5889 (3096-7419) 4545 (2798-6147) 2734 (2539-5743) 6311 (4390-7603) 
NNRTI concentration <target MECb, n (%) 33 (32) 12 (35) 11 (31) 10 (29) 
Changed the initial NRTI backbone n (%) 48 (46) 4 (12) 13 (37) 31 (89) 
a defined as the length of time after the first plasma HIV-1 RNA load <50 copies/ml; bMEC= minimum effective concentration recommended 
for wild-type virus; cuts off were 1000 ng/ml for EFV (Poeta et al., 2011) and 3400 ng/ml for NVP (Havlir et al., 1995). ART= antiretroviral 
therapy; NNRTI= non-nucleoside reverse transcriptase inhibitor; NRTI= nucleoside/nucleotide reverse transcriptase inhibitor.EFV= 
efavirenz, NVP= nevirapine. 
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Table 4.2 Virological and immunological profile of the study population at the time of recruitment 
Parameter Total (n=104) Duration of suppressive therapy, years 
 <4 (n=34)  4-7 (n=35) >7 (n=35) 
Detectable residual plasma HIV-1 RNA, n (%)  52 (50) 21 (62) 18 (51) 13 (37) 
Residual HIV-1 RNA, median cps/ml (IQR)a  2 (2-4) 2 (2-4) 2 (2-4) 2 (2-2) 
Detectable 2-LTRc HIV-1 DNA, n (%)  24 (23) 12 (35) 7 (20) 5 (14) 
2-LTRc HIV-1 DNA, median cps/106 PBMC (IQR)b 3 (3-3) 3 (3-7) 3 (3-3) 3 (3-3) 
Total HIV-1 DNA, median log10 cps/10
6 PBMC (IQR) 2.5 (2.1-2.8) 2.6 (2.3-3.0) 2.4 (1.7-2.8) 2.5 (2.1-2.8) 
Total HIV-1 DNA, median log10 cps/10
6 CD4 T-cells (IQR) 3.0 (2.6-3.4) 3.3 (2.8-3.5) 2.8 (2.4-3.3) 3.0 (2.6-3.4) 
CD4 count, median cells/mm3 (IQR) 581 (474-722) 548 (427-629) 580 (509-720) 632 (503-796) 
CD8 count, median cells/mm3 (IQR) 798 (656-1047) 808 (596-1060) 818 (685-1024) 679 (496-929) 
CD4+ CD38+, median percentage (IQR) 24 (16-34) 32 (23-36) 21 (15-31) 22 (15-28) 
CD4+CD26+, median percentage (IQR) 58 (46-64) 56 (47-67) 59 (49-63) 58 (44-64) 
CD4+CD69+, median percentage (IQR) 1 (1-2) 2 (1-3) 1 (1-2) 2 (1-2) 
CD8+CD38+, median percentage (IQR) 5 (3-7) 6 (4-8) 4 (3-6) 4 (3-6) 
CD8+HLA-DR/DP/DQ+, median percentage (IQR) 35 (24-42) 37 (27-47) 35 (26-40) 30 (20-39) 
sCD14, median μg/ml (IQR) 2.2 (1.8-2.5) 2.2 (1.8-2.4) 2 (1.8-2.5) 2.3 (1.9-2.5) 
D-Dimer, median μg/ml (IQR) 2.2 (0.8-3.2) 1.4 (0.7-3.2) 2.5 (0.9-3.2) 2.1 (0.8-3.1) 
hsCRP, median µg/ml (IQR) 1.4 (0.7-3.6) 1 (0.4-3.4) 1.9 (0.8-2.8) 2.1 (0.8-4) 
IL6 median pg /ml (IQR) 0.8 (0.5-2.1) 0.5 (0.5-1.2) 1.1 (0.5-2.3) 0.8 (0.5-2.1) 
sCD27, median U /ml (IQR) 61.8 (48.5-76.1) 64 (52.4-79.5) 61.1 (53.7-76.2) 59.6 (46.4-71.4) 
sCD30, median ng /ml (IQR) 11 (9-15.2) 10.7 (8.9-14.8) 11.9 (9.5-16.8) 10.9 (8.8-13.4) 
a Samples with undetectable HIV-1 RNA were assigned an arbitrary value of 1.5 copies/ml. bSamples with undetectable 2-LTRc HIV-
1 DNA were assigned an arbitrary value of 2.5 copies/106 PBMC. IQR= interquartile range; cps= copies; PBMC= peripheral blood 
mononuclear cells; 2-LTRc= 2-LTR circular HIV-1 DNA. 
90 
 
 
Table 4.3 Univariate linear regression analysis of mean difference in log-transformed virological and immunological parameters per 10 
years of suppressive antiretroviral therapy 
Parameter Mean difference 95% CI P 
Residual HIV-1 RNA, copies/ml -0.19 -0.38; -0.01 0.04 
2-LTRc HIV-1 DNA, copies/106 PBMC -0.19 -0.39; 0.02 0.08 
Total HIV-1 DNA, copies/106 PBMC 0.02 -0.35, 0.39 0.92 
CD4 count, cells/mm3 0.14 0.04, 0.25 0.01 
CD8 count, cells/mm3 -0.07 -0.19, 0.08 0.43 
CD4+CD38+ percentage -0.21 -0.34, -0.09 0.001 
CD4+CD26+ percentage -0.03 -0.11, 0.05 0.44 
CD4+CD69+ percentage -0.10 -0.28, 0.08 0.26 
CD8+CD38+ percentage -0.14 -0.31, 0.04 0.13 
CD8+HLA-DR/DP/DQ+ percentage -0.14 -0.27, -0.01 0.04 
sCD14 μg/ml  0.02 -0.04, 0.01 0.51 
D-Dimer ng/ml -0.03 -0.33, 0.14 0.49 
hsCRP μg/ml  0.01 -0.50, 0.52 0.79 
IL-6 pg/ml  0.10 -0.18, 0.39 0.46 
sCD27 U/ml -0.09 -0.18, 0.001 0.06 
sCD30 ng/ml -0.05 -0.19, 0.09 0.45 
aAll variables were log-transformed. CI= Confidence interval 
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Figure 4.1 Markers of HIV-1 persistence in patients with 1-15 years of duration of suppressive ART 
Dot plots representing a) HIV-1 RNA, b) 2-LTR circular HIV-1 DNA in PBMC, c) total HIV-1 DNA in PBMC in patients with 1-15 years of suppressive ART. 
Each dot represents patients with same x and y coordinates. Blue dotted lines indicate lower limit of detection: a) for HIV-1 RNA ultrasensitive assay=3 
copies/ml; b) for the 2-LTR HIV-1 DNA assay that is 5 copies/106 PBMC; c) for the total HIV-1 DNA assay that is 1.6 log10/10
6 PBMC. A=34 HIV-1 RNA 
copies/ml of one patient on EFV/ABC/3TC; B=24 HIV-1 RNA copies/ml of one patient on EFV/TDF/FTC. Y axis in a) and b) were split into two segments for 
a better visualization of the data. 
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Figure 4.2 Markers of cellular immune activation in patients with 1-15 years of duration of suppressive ART 
Dot plots representing a) % CD4 T-cells, b) % CD4+ CD38+T-cells, c) % CD4+ CD26+T-cells, d) % CD4+ CD69+T-cells, e) % CD8+ CD38+T-cells, f) % 
CD8+HLA-DR/DP/DQ+T-cell, in patients with 1-15 years of suppressive ART. Each dot represents patients with same x and y coordinates. Blue line in plot a) 
indicates 200 CD4 T-cells/mm3. Y axis in plots d and e were spitted into two segments for better visualization. d) lower segment=up to 10 % CD4+ CD69+T-
cells, higher segment from 50% to 100 % CD4+ CD69+T-cells; e) lower segment=up to 20 % CD8+ CD38+T-cells, higher segment from 30% to 100 % CD8+ 
CD38+T-cells.  
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Figure 4.3 Soluble markers of cellular immune activation in patients with 1-15 years of duration of suppressive ART 
Cross-sectional analysis of levels of sCD30, sCD27, IL-6, hs-CRP, D-dimers, and sCD14 in patients with 1-15 years of suppressive ART. Each dot represents 
one patient. Blue lines indicate the reference levels for healthy individuals that were : (a) sCD30 (Gao et al., 2015)= 25 ng/ml; (b) sCD27=164 U/ml (De Milito 
et al., 2002); c) IL6  (Tenorio et al., 2014)= 6pg/ml; d) hs-CRP= 3µg/ml (McBride and Cooper, 2008); e) D-Dimer= 0.5µg/ml (Lichtfuss et al., 2011); f) 
sCD14=2.5pg/ml (Sandler et al., 2011).  
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Factors associated with virological markers of HIV persistence 
 
By univariate analysis, residual HIV-1 RNA levels were lower with longer duration of 
suppressive ART, and were also positively associated with sCD27 levels; however the strength 
of the association was reduced after adjustment (Table 4.4). A sensitivity analysis that excluded 
the two outliers with HIV-1 RNA levels >11 copies/ml confirmed an independent positive 
association between residual HIV-1 RNA levels and sCD27 levels, but detected no evidence 
of a difference in HIV-1 RNA levels by duration of suppressive ART (Table 4.5). There was 
also no evidence of an association with total and 2-LTR circular HIV-1 DNA levels and with 
other markers of immune activation and inflammation.  
 
By univariate analysis, 2-LTR circular HIV-1 DNA levels were lower with longer duration of 
suppressive ART. After adjustment for duration of suppressive ART, CD4+CD26+ T-cells, pre-
ART HIV-1 RNA, hsCRP and sCD27, higher levels of 2-LTR circular HIV-1 DNA remained 
associated with duration of suppressive ART (Table 4.6). 
 
By univariate analysis, higher HIV-1 DNA levels in PBMC were associated with higher pre-
ART HIV-1 RNA. In the analysis adjusted for age, nadir CD4 T-cell, pre-ART HIV-1 RNA, 
CD8+CD38+ T-cells, CD8+HLA-DR/DP/DQ+ T-cells, sCD14, IL6, and CD30, higher levels of 
total HIV-1 DNA were strongly associated with higher pre-ART HIV-1 RNA and frequencies 
of CD8+HLA-DR/DP/DQ+ T-cells, and to younger age (Table 4.7). A sensitivity analysis was 
run on total HIV-1 DNA load in CD4 T-cells and this confirmed the positive association with 
pre-ART HIV-1 RNA load and CD8+HLA-DR/DP/DQ+ T-cells both in univariate and 
multivariable analysis (Table 4.8).  
 
The univariate analysis on patients with white or black ethnicity showed that levels of residual 
HIV-1 RNA and total HIV DNA load were similar in white compared with black, whereas a 
trend for association between ethnicity and 2-LTR circular HIV-1 DNA and total HIV-1 DNA 
in CD4 T-cells (Table 4.9). Based on these observations, we analysed factors associated with 
2-LTR circular HIV-1 DNA and total HIV-1 DNA in CD4 T-cells when ethnicity was included 
into the multivariable model. Results confirmed the association between 2-LTR circular HIV-
1 DNA and duration of suppressive ART (Table 4.10); further higher levels of total HIV-1 
DNA in CD4 T-cells were found in patients with higher levels of pre-ART HIV-1 RNA and 
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%CD8+DR-DP-DQ+ T-cell as observed in previous analysis that was not adjusted for ethnicity 
(Table 4.11). 
 
Furthermore we analyzed if plasma levels of EFV were associated with HIV-1 persistence. In 
86 patients with EFV we found that drug levels were not associated with any marker of viral 
persistence; however, univariable analysis showed that levels EFV levels were eligible for 
inclusion in the multi-variable analysis when modelling for residual HIV-1 RNA levels in 
patient (N=84) with HIV-1 RNA<11 copies/ml (Table 4.12). Based upon these data we 
explored factors associated with residual HIV-1 RNA copies/ml when levels of EFV when 
included into the multivariable model. Results confirmed the association between residual 
HIV-1 RNA and sCD27 even though with weaker effect as observed in previous analysis 
without adjustment for EFV drug levels (Table 4.13). 
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Table 4.4 Univariate and multivariable linear regression analysis of factors associated with the mean difference in residual plasma HIV-
1 RNA load 
*only variables with p≤0.2 were included in the multivariable analysis  
 
 
Characteristic 
 
Univariate Multivariable 
Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.01 -0.08, 0.05 0.67    
Nadir CD4 count per 100 cell/mm3 higher  0.02 -0.02, 0.07 0.29    
Pre-ART HIV-1 RNA per log10 copies/ml higher  0.01 -0.08, 0.09 0.86    
Duration of suppressive ART per 10 years longer -0.19 -0.38, -0.01 0.04* -0.16 -0.34, 0.03 0.10 
NNRTI concentration below the MEC “yes” vs “no” 0.08 0.04, 0.21 0.18* 0.04 -0.09, 0.17 0.56 
CD4 count per 100 cells/mm3 higher 0.001 -0.02, 0.03 0.95    
CD4/CD8 ratio per 1 unit higher 0.01 -0.16, 0.15 0.89    
2-LTRc DNA per log10 cps/10
6 PBMC cells higher 0.06 -0.12, 0.24 0.47    
Total HIV-1 DNA per log10 cps/10
6 PBMC higher 0.02 -0.08, 0.12 0.74    
CD4+CD38+ per 50% higher 0.09 -0.16, 0.37 0.47    
CD4+CD26+ per 50% higher 0.05 -0.16, 0.26 0.64    
CD4+CD69+ per 50% higher 0.24 -2.33, 2.8 0.85    
CD8 count per 100 cells/mm3 higher 0.004 -0.01, 0.02 0.45    
CD8+CD38+ per 50% higher 0.25 -0.21, 0.72 0.28    
CD8+HLA-DR/DP/DQ+ per 50% higher -0.02 -0.22, 0.19 0.87    
sCD14 per log10 μg/ml higher 0.22 -0.35, 0.79 0.22    
D-Dimer per log10 μg/ml higher -0.08 -0.25, 0.08 0.33    
hs-CRP per log10 ng/ml higher 0.06 -0.09, 0.21 0.43    
IL6 per log10 pg/ml higher 0.08 -0.12, 0.29 0.41    
sCD27 per log10 U/ml higher 0.45 0.08, 0.82 0.02 * 0.31 -0.11, 0.72 0.15 
sCD30 median per log10 ng/ml higher 0.20 -0.07, 0.46 0.15 * 0.09 -0.19, 0.37 0.50 
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Table 4.5 Univariate and multivariable linear regression analysis of factors associated with the mean difference in residual plasma HIV-
1 RNA load in patients with residual plasma load ≤11 copies/ml (N=102) 
*only variables with p≤0.2 were included in the multivariable analysis   
 Univariate Multivariable 
Characteristic Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.01 -0.07, 0.05 0.78    
Nadir CD4 count per 100 cell/mm3 higher 0.01 -0.06, 0.05 0.58    
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.00 -0.08, 0.08 0.99    
Duration of suppressive ART per 10 years longer -0.13 -0.29, 0.03 0.12* -0.07 -0.24, 0.09 0.39 
NNRTI concentration below the MEC “yes” vs “no” 0.12 0.01, 0.23 0.04* 0.06 -0.05, 0.18 0.25 
CD4 count per 100 cells/mm3 higher -0.001 -0.02, 0.02 0.92    
CD4/CD8 ratio per 1 unit higher 0.04 -0.11, 0.17 0.62    
2-LTRc DNA per log10 cps/10
6 PBMC cells higher 0.05 -0.11, 0.20 0.57    
Total HIV-1 DNA per log10 cps/10
6 PBMC higher -0.01 -0.09, 0.08 0.87    
CD4+CD38+ per 50% higher 0.08 -0.14, 0.30 0.47    
CD4+CD26+ per 50% higher 0.08 -0.10, 0.27 0.37    
CD4+CD69+ per 50% higher -0.61 -2.97, 1.75 0.60    
CD8 count per 100 cells/mm3 higher 0.002 -0.01, 0.01 0.70    
CD8+CD38+ per 50% higher 0.32 -0.11, 0.75 0.16* 0.25 -0.19, 0.67 0.26 
CD8+HLA-DR/DP/DQ+ per 50% higher -0.03 -0.21, 0.15 0.76    
sCD14  per log10 μg/ml higher 0.26 -0.24, 0.75 0.31    
D-Dimer  per log10 μg/ml higher -0.08 -0.22, 0.07 0.28    
hs-CRP  per log10 ng/ml higher 0.07 -0.05, 0.20 0.24    
IL6  per log10 pg/ml higher 0.13 -0.05, 0.30 0.15* 0.12 -0.05, 0.29 0.18 
sCD27  per log10 U/ml higher 0.49 0.17, 0.81 0.003* 0.37 0.01, 0.73 0.05 
sCD30 median  per log10 ng/ml higher 0.21 -0.02, 0.45 0.07* 0.02 -0.25, 0.28 0.90 
98 
 
 
Table 4.6 Univariate and multivariable linear regression analysis of factors associated with the mean difference in 2-LTR circular HIV-
1 DNA load in PBMC. 
 Univariate Multivariable 
Characteristic Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.08 -0.15, -0.02 0.01a    
Nadir CD4 count per 100 cell/mm3 higher 0.002 -0.04, 0.05 0.92    
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.06 -0.03, 0.16 0.17* 0.09 -0.01, 0.18 0.06 
Duration of suppressive ART per 10 years longer -0.19 -0.39, 0.02 0.08* -0.25 -0.47, -0.04 0.02 
NNRTI concentration below the MEC “yes” vs “no” -0.01 -0.15, 0.13 0.91    
CD4 count per 100 cells/mm3 higher -0.13 -0.04, 0.01 0.33    
CD4_CD8 ratio per 1 unit higher -0.04 -0.21, 0.14 0.69    
Residual HIV-1 RNA per log10 cps/ml higher 0.08 -0.14, 0.29 0.47    
Total HIV-1 DNA per  log10 cps/10
6 PBMC higher 0.14 0.03, 0.25 0.01b    
CD4+CD38+ per 50% higher 0.07 -0.21, 0.35 0.62    
CD4+CD26+ per 50% higher 0.19 -0.04, 0.42  0.10* 0.15 -0.07, 0-38 0.44 
CD4+CD69+ per 50% higher -0.16 -3.01, 2.70 0.91    
CD8 count per 100 cells/mm3 higher -0.01 -0.02, 0.01 0.45    
CD8+CD38+ per 50% higher 0.19 -0.33, 0.71 0.45    
CD8+HLA-DR/DP/DQ+ per 50% higher 0.02 -0.22, 0.23 0.98    
CD14  per log10 μg/ml higher 0.25 -0.39, 0.88 0.44    
D-Dimer  per log10 ng/ml higher -0.06 -0.24, 0.12 0.51    
hs-CRP  per log10 μg/ml higher -0.01 -0.26, 0.05 0.19* -0.06 -0.22, 0.09 0.44 
IL6  per log10 pg/ml higher -0.05 -0.27, 0.17 0.65    
CD27  per log10 U/ml higher -0.30 -0.72, 0.11 0.15* -0.29 -0.73, 0.14 0.18 
CD30 per log10 ng/ml higher -0.19 -0.49, 0.11 0.21    
*only variables with p≤0.2 were included in the multivariable analysis; a age was excluded from the multivariable analysis due to colinearity with duration of 
suppressive ART; b excluded from the multivariable analysis due to colinearity with 2-LTR circular HIV-1 DNA.cps=copies 
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Table 4.7 Univariate and multivariable linear regression analysis of factors associated with the mean difference in total HIV-1 DNA load 
in PBMC 
 Univariate Multivariable 
Characteristic Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.08 -0.20, 0.04 0.18* -0.14 -0.25, -0.2 0.03 
Nadir CD4 count per 100 cell/mm3 higher 0.06 -0.02, 0.14 0.14* 0.40 -0.43, 0.12 0.34 
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.22 0.06, 0.37 0.01* 0.29 0.14, 0.40 <0.001 
Duration of suppressive ART per 10 years longer 0.02 -0.35, 0.39 0.91    
NNRTI concentration below the MEC “yes” vs “no” 0.01 -0.24, 0.25 0.97    
CD4 count per 100 cells/mm3 higher 0.001 -0.05, 0.05 0.96    
CD4/CD8 ratio per 1 unit higher 0.15 -0.17, 0.46 0.35    
Residual HIV-1 RNA per log10 copies/ml higher 0.06 -0.32, 0.44 0.74    
2-LTRc HIV-1 DNA  per log10 copies/10
6 PBMC 0.43 0.10, 0.76 0.01a    
CD4+CD38+ per 50% higher 0.08 -0.42, 0.57 0.74    
CD4+CD26+ per 50% higher -0.09 -0.51, 0.31 0.63    
CD4+CD69+ per 50% higher -0.80 -5.7, 4.20 0.75    
CD8 count per 100 cells/mm3 higher -0.01 -0.03, 0.02 0.65    
CD8+CD38+ per 50% higher 0.59 -0.31, 1.50 0.20* 0.77 -0.14, 1.66 0.09 
CD8+HLA-DR/DP/DQ+ per 50% higher 0.32 -0.07, 0.71 0.10* 0.53 0.13, 0.92 0.01 
CD14  per log10 μg/ml higher 0.71 -0.40, 1.81 0.20* 0.49 -0.54, 1.5 0.35 
D-Dimer  per log10 ng/ml higher -0.08 -0.41, 0.23 0.59    
hs-CRP  per log10 μg/ml higher -0.14 -0.42, 0.14 0.32    
IL6  per log10 pg/ml higher -0.29 -0.67, 0.10 0.14* -0.24 -0.61, 0.14 0.21 
CD27  per log10 U/ml higher 0.21 -0.53, 0.95 0.57    
CD30 median  per log10 ng/ml higher -0.34 -0.87, 0.18 0.19* -0.45 -0.97, 0.08 0.09 
*only variables with p≤0.2 were included in the multivariable analysis; a excluded from the multivariable analysis due to the high co-linearity 
with total HIV-1 DNA 
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Table 4.8 Univariate and multivariable linear regression analysis of factors associated with the mean difference in total HIV-1 DNA load 
in CD4 T-cells 
*only variables with p≤0.2 were included in the multivariable analysis; aexcluded from the multivariable analysis due to the high co-linearity with 
total HIV-1 DNA 
  
 
 
 Univariate Multivariable 
Characteristic Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.06 -0.18, 0.07 0.38    
Nadir CD4 count per 100 cell/mm3 higher 0.04 -0.05, 0.12 0.40    
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.22 0.06, 0.39 0.01* 0.25 0.09, 0.40 0.002 
Duration of suppressive ART per 10 years longer -0.09 -0.47, 0.28 0.62    
NNRTI concentration  below the MEC “yes” vs “no” 0.05 -0.20, 0.31 0.67    
Residual HIV-1 RNA per log10 copies/ml higher 0.11 -0.28, 0.50 0.57    
2-LTRc HIV-1 DNA  per log10 copies/10
6 PBMC 0.42 0.07, 0.76 0.02a    
CD4+CD38+ per 50% higher 0.10 -0.41, 0.61 0.69    
CD4+CD26+ per 50% higher -0.22 -0.63, 0.19 0.30    
CD4+CD69+ per 50% higher 2.59 -2.5, 7.69 0.32    
CD8 count per 100 cells/mm3 higher -0.007 -0.02, 0.03 0.57    
CD8+CD38+ per 50% higher 0.47 -0.47, 1.40 0.32    
CD8+HLA-DR/DP/DQ+ per 50% higher 0.43 0.04, 0.83 0.03* 0.53 0.15, 0.92 0.002 
CD14  per log10 μg/ml higher 0.54 -0.61, 1.67 0.36    
D-Dimer  per log10 ng/ml higher -0.04 -0.37, 0.28 0.79    
hs-CRP  per log10 μg/ml higher -0.14 -0.43, 0.15 0.33    
IL6  per log10 pg/ml higher -0.27 -0.67, 0.13 0.18* -0.28 -0.66, 0.10 0.15 
CD27  per log10 U/ml higher 0.19 -0.59, 0.95 0.62    
CD30 median  per log10 ng/ml higher -0.41 -0.97, 0.12 0.13* -0.39 -0.91, 0.12 0.14 
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Table 4.9 Influence of Black and White ethnicity on markers of HIV-1 persistence (N=100) 
 Univariate (Black ethnicity “yes” or “no”) 
Characteristic N tot Mean difference  95% CI P 
    
Residual HIV-1 RNA per log10 cps/ml higher  100 0.25 0.30, 0.15 0.67 
Residual HIV-1 RNA <11 cps/ml per log10 copies/ml higher 98
b 0.20 -0.09, 0.13 0.72 
2-LTRc HIV-1 DNA  per log10 cps/10
6 PBMC 100 -0.12 -0.25, 0.17 0.09 
Total HIV-1 DNA  per log10 cps/10
6 PBMC 100 0.10 -0.09, 0.25 0.35 
Total HIV-1 DNA  per log10 cps/10
6 CD4 T-cells 100 0.14 -0.25, 0.31 0.09 
btwo patients had HIV-1 RNA>12 cps/ml and one had white and the other black ethnicity. 
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Table 4.10 Univariate and multivariable linear regression analysis of factors associated with the mean difference in 2-LTR circular HIV-
1 DNA load in PBMC in 100 patients with white or black ethnicity 
 Univariate Multivariable 
Characteristic 
Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.09 -0.16, -0.02 0.01a    
Ethnicity black “yes” vs “no” -0.12 -0.25, 0.17 0.09* -0.08 -0.23, 0.05 0.22 
Nadir CD4 count per 100 cell/mm3 higher 0.003 -0.05, 0.05 0.89    
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.07 -0.03, 0.17 0.16* 0.08 -0.01, 0.17 0.08 
Duration of suppressive ART per 10 years longer -0.19 -0.40, 0.02 0.08* -0.25 -0.47, -0.03 0.03 
NNRTI concentration below the MEC “yes” vs “no” -0.02 -0.16, 0.13 0.81    
CD4 count per 100 cells/mm3 higher -0.01 -0.04, 0.01 0.29    
CD4_CD8 ratio per 1 unit higher 0.04 -0.22, 0.15 0.69    
Residual HIV-1 RNA per log10 cps/ml higher 0.08 0.15, 0.30 0.49    
Total HIV-1 DNA per  log10 cps/10
6 PBMC higher 0.14 0.03, 0.26 0.02b    
CD4+CD38+ per 50% higher 0.09 -0.21, 0.38 0.55    
CD4+CD26+ per 50% higher 0.20 -0.04, 0.49 0.09* 0.13 -0.11, 0.37 0.29 
CD4+CD69+ per 50% higher -0.17 -3.08, 2.73 0.90    
CD8 count per 100 cells/mm3 higher -0.01 -0.02, 0.01 0.40    
CD8+CD38+ per 50% higher 0.18 -0.35, 0.71 0.49    
CD8+HLA-DR/DP/DQ+ per 50% higher 0.001 -0.23, 0.23 0.99    
CD14  per log10 μg/ml higher 0.26 -0.40, 0.91 0.44    
D-Dimer  per log10 ng/ml higher -0.07 -0.26, 0.13 0.49    
hs-CRP  per log10 μg/ml higher -0.12 -0.28, 0.05 0.16* -0.04 -0.21, 0.13 0.62 
IL6  per log10 pg/ml higher -0.06 -0.28, 0.17 0.60    
CD27  per log10 U/ml higher -0.32 -0.75, 0.12 0.15* -0.26 -0.72, 0.20 0.27 
CD30 per log10 ng/ml higher -0.24 -0.56, 0.08 0.14* -0.16 -0.49, 0.18 0.36 
*only variables with p≤0.2 were included in the multivariable analysis; a age was excluded from the multivariable analysis due to colinearity with duration of 
suppressive ART; b excluded from the multivariable analysis due to colinearity with 2-LTR circular HIV-1 DNA. cps=copies 
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Table 4.11 Univariate and multivariable linear regression analysis of factors associated with the mean difference in total HIV-1 DNA load 
in CD4 T-cells in 100 patients with white or black ethnicity 
 Univariate Multivariable 
Characteristic Mean difference  95% CI P Mean difference  95% CI P 
Age, per 10 years higher -0.06 -0.18, 0.07 0.35    
Ethnicity black “yes” vs “no” 0.14 -0.25,0.31 0.09* 0.15 -0.08,3.69 0.19 
Nadir CD4 count per 100 cell/mm3 higher 0.04 -0.04, 0.13 0.31    
Pre-ART HIV-1 RNA per log10 copies/ml higher 0.22 0.05, 0.39 0.01* 0.24 0.09,0.40 0.003 
Duration of suppressive ART per 10 years longer -0.12 -0.49, 0.25 0.52    
NNRTI concentration  below the MEC “yes” vs 
“no” 
0.04 -0.21, 0.29 0.73    
Residual HIV-1 RNA per log10 copies/ml higher 0.13 -0.26, 0.52 0.51    
2-LTRc HIV-1 DNA  per log10 copies/10
6 PBMC 0.39 0.05, 0.73 0.02    
CD4+CD38+ per 50% higher 0.16 -0.35, 0.67 0.54    
CD4+CD26+ per 50% higher -0.17 -0.58, 0.24 0.42    
CD4+CD69+ per 50% higher 2.5 -2.50, 7.40 0.33    
CD8 count per 100 cells/mm3 higher -0.01 -0.02, 0.03 0.60    
CD8+CD38+ per 50% higher 0.47 -0.45, 1.40 0.31    
CD8+HLA-DR/DP/DQ+ per 50% higher 0.49 0.09, 0.88 0.02* 0.65 0.27, 1.02 0.001 
CD14  per log10 μg/ml higher 0.46 -0.67, 1.59 0.42    
D-Dimer  per log10 ng/ml higher -0.03 -0.30, 0.36 0.87    
hs-CRP  per log10 μg/ml higher -0.19 -0.47, 0.09 0.18* -0.19 -0.47,0.07 0.15 
IL6  per log10 pg/ml higher -0.29 -0.60, 0.10 0.15* -0.32 -0.69, 0.05 0.09 
CD27  per log10 U/ml higher 0.07 -0.68, 0.82 0.86    
CD30 median  per log10 ng/ml higher -0.54 -1.08, 0.002 0.05* -0.41 -0.95, 0.13 0.13 
*only variables with p≤0.2 were included in the multivariable analysis. 
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Table 4.12 Influence of EFV levels on markers of HIV-1 persistence (N=86) 
 Univariate EFV levels for log10 ng/ml higher 
Characteristic N tot Mean difference  95% CI P 
    
Residual HIV-1 RNA per log10 cps/ml higher  86 -0.11 -0.31,0.09 0.30 
Residual HIV-1 RNA ≤11cps/ml per log10 copies/ml higher 84b -0.13 -0.29, 0.05 0.17 
2-LTRc HIV-1 DNA  per log10 cps/10
6 PBMC 86 -0.10 -0.33, 0.13 0.39 
Total HIV-1 DNA  per log10 cps/10
6 PBMC 86 -0.08 -0.46, 0.31 0.69 
Total HIV-1 DNA  per log10 cps/10
6 CD4 T-cells 86 -0.15 -0.54, 0.24 0.46 
btwo patients had HIV-1 RNA>11 cps/ml and they were excluded from the analysis 
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Table 4.13 Univariate and multivariable linear regression analysis of factors associated with the mean difference in residual plasma HIV-
1 RNA load in 84 patients on EFV 
 Univariate Multivariable 
Characteristic Mean 
difference  
95% CI P Mean 
difference  
95% CI P 
Age, per 10 years higher -0.30 -0.09,0.03 0.31    
Nadir CD4 count per 100 cell/mm3 higher 0.13 -0.03,0.06 0.57    
Pre-ART HIV-1 RNA per log10 copies/ml higher -0.03 -0.09,0.08 0.94    
Duration of suppressive ART per 10 years longer -0.11 -0.33, 0.10 0.30    
EFV concentration per log10 ng/ml higher -0.13 -0.29, 0.05 0.17* -0.06 -0.24,0.12 0.52 
CD4 count per 100 cells/mm3 higher 0.08 -0.02, 0.03 0.55    
CD4_CD8 ratio per 1 unit higher 0.43 0.13,0.21 0.62    
2-LTRc HIV-1 DNA per  log10 cps/10
6 PBMC higher 0.04 -0.13,0.20 0.66    
Total HIV-1 DNA per  log10 cps/10
6 PBMC higher -0.02 -0.12,0.08 0.73    
CD4+CD38+ per 50% higher 0.06 -0.18,0.3 0.63    
CD4+CD26+ per 50% higher 0.08 -0.13,0.29 0.44    
CD4+CD69+ per 50% higher -1.08 -3.52,1.37 0.38    
CD8 count per 100 cells/mm3 higher 0.01 -0.01,0.2 0.40    
CD8+CD38+ per 50% higher 0.01 -0.59,0.62 0.97    
CD8+HLA-DR/DP/DQ+ per 50% higher 0.05 -0.26, 0.16 0.64    
CD14  per log10 μg/ml higher 0.23 -0.34,0.79 0.42    
D-Dimer  per log10 ng/ml higher -0.04 -0.20, 0.11 0.58    
hs-CRP  per log10 μg/ml higher 0.09 -0.07,0.25 0.29    
IL6  per log10 pg/ml higher 0.18 -0.07,0.31 0.22    
CD27  per log10 U/ml higher 0.52 0.15, 0.88 0.01* 0.44 -0.03,0.84 0.04 
CD30 per log10 ng/ml higher 0.20 -0.07,0.47 0.15* 0.08 -0.19,0.37 0.54 
*only variables with p≤0.2 were included in the multivariable analysis. 
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4.4 DISCUSSION 
 
This study provides an in-depth characterization of the relationship between virological 
markers of HIV-1 persistence and immunological characteristic in a well-defined 
population which included 104 patients on stably suppressive ART for up to 14 years 
with the same NNRTI plus two NRTI. Patients with longer duration of treatment 
showed improved immune reconstitution and lower HIV-1 RNA loads and to a lesser 
extent lower 2-LTR circular HIV-1 DNA in PBMC; meanwhile total DNA loads did 
not vary between patients with short vs long duration of suppressive ART.  Pre-ART 
HIV-1 RNA load was associated with total HIV-1 DNA but not with plasma residual 
viremia or 2-LTR circular HIV-1 DNA. Plasma levels of soluble CD27 showed 
association with residual plasma viremia, whereas cellular markers of immune 
activation including CD8+HLA-DR/DP/DQ+ T showed association with total HIV-1 
DNA.  
 
Previous studies consistently demonstrated HIV-1 detection in populations with 
heterogeneous treatment history and duration (Palmer et al., 2008, Siliciano et al., 2003, 
Maldarelli et al., 2007, Lorenzo-Redondo et al., 2016). In our population where patient 
treatment history was overall homogenous and the viral load suppression was 
continuous at HIV-1 RNA<50 copies/ml from the first six months of starting therapy, 
we also detected plasma RNA and intracellular HIV-1 DNA. In plasma, half of patients 
had detectable HIV-1 RNA levels in line with previous reports (Maldarelli et al., 2007, 
Kiselinova et al., 2015) and the majority of patients had HIV-1 RNA levels <11 
copies/ml as found by others (Kiselinova et al., 2015). In cells, 2-LTR circular HIV-1 
DNA was detected in 23% of patients at low levels as also reported by another study 
(Besson et al., 2014) that measured 2-LTR circular HIV-1 DNA levels in long-term 
virological suppressed individuals (with HIV-1 RNA<50 copies/ml within first 32 
weeks of starting therapy) with a low detection limit of 5 copies/106 PBMC similar to 
our case. Moreover overall levels of 2-LTR circular DNA that we found were 
comparable to what were found in the previous study (Besson et al., 2014) and in others 
(Kiselinova et al., 2015). Total HIV-1 DNA was detected in all patients at around 2-2.5 
log10 copies/106 PBMC as also found by others (Besson et al., 2014, Malatinkova et 
al., 2015).  
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The significance of HIV-1 detection in plasma and the cellular source is still debated. 
Residual HIV-1 RNA has been proposed to be the product of ongoing viral replication 
in sanctuary sites unrelated to peripheral blood (Eriksson et al., 2013). If this is true, 
residual plasma viral HIV-1 could lack of association with the cellular HIV-1 reservoir. 
In line with this, our data did not show association between residual viral load and the 
total HIV-1 or 2-LTR circular HIV-1 DNA. This data was both in accordance and 
discordance with one previous study (Kiselinova et al., 2015) that showed that residual 
HIV-1 RNA was associated with total HIV-1 DNA but not with 2-LTR circular HIV-1 
DNA. However in that study, patients also on PI were observed and it still need to be 
determined if treatment composition can influence total HIV-1 DNA. Moreover 
methods for total HIV-1 DNA and 2-LTR circular HIV-1 DNA quantification were 
different and this could also explain such discrepancies. 
 
When looking at levels of markers of HIV-1 persistence during ART, we found that 
patients with longer treatment showed a trend for lower levels of plasma HIV-1 RNA 
and of 2-LTR circular HIV-1 DNA loads that are the biological products of viral 
replication and infection. Of note, when two patients with levels of residual HIV-1 
RNA>11 with less than 3 years of ART were excluded from the analysis, similar levels 
of residual plasma HIV-1 at very low levels (≤11 copies/ml) were found in patients with 
different duration of suppressive ART. Taken together these findings could be a simple 
reflection of the success of the therapy over time in our virological suppressed 
population. Conversely, total HIV-1 DNA levels were similar in patients with different 
duration of suppressive ART and they were highly predicted by the pre-ART HIV-1 
RNA. This finding is in line with previous reports demonstrating that the HIV-1 
reservoir is established early after viral infection and it is insufficiently responsive to 
treatment (Williams et al., 2014, Josefsson et al., 2013, Siliciano et al., 2003, 
Hocqueloux et al., 2013, Buzon et al., 2014a). Overall levels of HIV-1 DNA or RNA 
did not significantly vary between patients with white vs black ethnicity. Previous 
literature debated regarding the influence of ethnicity on virological outcome in ART-
treated patients. Some studies that looked at patients with a wide range of different ART 
regimen found a higher rate of virological failure in Black compared with White 
(Hodder et al., 2012, Fourie et al., 2011, Svedhem-Johansson et al., 2013). However 
one study reported no significant effect of race when comparing efficacy of EFV and 
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NVP at early stage of treatment (Keiser et al., 2002). Our data adds onto this by showing 
that in patients on stable suppressive ART with continuous follow up (at least one visit 
every six months) ethnicity is not a factor associated with greater HIV-1 persistence. 
 
The mechanisms that support viral persistence are still unclear, although growing 
evidence is currently focussing the attention on host environment as central player in 
the viral persistence (Cockerham et al., 2016, Crowell and Hatano, 2015, Hatano, 2013) 
during suppressive therapy. 
 
One recent work (Riddler et al., 2016) studied factors associated with residual plasma 
viremia in patients with 4 years of ART and demonstrated a strong association between 
residual HIV-1 RNA and pre-ART HIV-1 RNA alongside a lack of association with 
patient’s characteristics such as age and ethnicity. Our results add onto this by saying 
that the lack of association between residual HIV-1 RNA and patients characteristics 
persists even after longer suppressive therapy. Conversely, we did not find an 
association with pre-ART HIV-1 RNA in accordance with others that studied patients 
on ART for median 6-7 years (Kiselinova et al., 2015). Moreover, we expanded the 
previous literature, by looking at a wide range of cellular and soluble markers of 
immune activation. As described by others (Hatano et al., 2013), we found that residual 
HIV-1 RNA was not associated with cellular markers of immune activation. On the 
other hand, our data showed a trend for a positive association between residual HIV-1 
RNA and levels of soluble CD27 (sCD27), a marker of T cell activation. This has been 
identified as a marker of immune dysfunction in different disease (De Milito et al., 
2002) such as rheumatoid arthritis, systemic lupus erythematosus, and AIDS-associated 
lymphoma (Widney et al., 1999). In HIV-1 patients on ART, sCD27 has been identified 
as a marker of chronic immune activation  and it was defined a predictor of virologic 
rebound in case of treatment interruption (De Milito et al., 2002). The association we 
found seems unlikely to be an indication of viral replication in blood as discussed 
above. Conversely, it could reflect CD4 T-cell activation at peripheral as well as 
lymphoid tissue where infected CD4 T-cell could drive levels of replication (Chun et 
al., 2008). Our data did not show any association between residual HIV-1 DNA and 
markers of CD4 T-cell activation in plasma, whereas we could not conclude about 
lymphoid cell activation. Of note, this association appeared to be unrelated to levels of 
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EFV drugs in plasma; however previous reports (Fletcher et al., 2014, Lorenzo-
Redondo et al., 2016) showed that suboptimal drug concentration in lymphoid tissue 
was unrelated to levels of drug concentration in plasma. The association between 
residual HIV-1 RNA in plasma, sCD27 and drug levels warrants further investigation 
and possibly expansion to lymphoid tissue analysis.  
 
Overall our population did not show abnormal levels of soluble makers of inflammation 
(Tenorio et al., 2014, Gao et al., 2015, De Milito et al., 2002, Sandler et al., 2011, 
McBride and Cooper, 2008) compared to healthy individuals with the only exception 
being the D-Dimer (Lichtfuss et al., 2011). Whilst 2-LTR circular HIV-1 DNA and total 
HIV-1 DNA did not show any association with soluble markers of immune activation, 
we found a positive association between markers of cellular immune activation, in 
particular CD8+HLA-DR/DP/DQ+ T-cells and total HIV-1 DNA both in PBMC and in 
CD4 T-cell as also observed by others (Cockerham et al., 2016, Hatano et al., 2013). 
We could speculate that this association could reflect clonal expansion of activated cells 
carrying HIV-1 DNA as a response to stimuli that could induce simultaneous activation 
of the CD8 T-cells and HIV-1 CD4 T-cells that would result in an association between 
higher levels of activated CD8 T-cells and HIV-1 DNA load. Alternatively HIV-1 virus 
particles themselves could trigger the immune system leading to CD8 T-cell activation 
against HIV-1: in this case, plasma HIV-1 RNA could be associated with higher levels 
of activation. Nonetheless, our data did not show evidence of association between CD8 
T-cell activation and plasma HIV-1 RNA, as observed also by others (Hatano et al., 
2013). We could propose that this data indicate that virus particles may not be triggering 
a CD8 T-cell response. Further studies aimed at the characterization of the CD8 T-cell 
antigen-specificity could provide useful information to solve such a conundrum.  
 
This study has its limitations. First the cross-sectional design did not allow us to 
conclude for causality. Furthermore, we did not have a gender-age matched uninfected 
control population as reference for the immunological results as we only compared our 
results with existing literature, with possible bias derived from population heterogeneity 
as well as quantification methods. Moreover, due to the limited amount of blood 
obtained from the study subjects, we could not determine the specificity of the 
immunological response; for the same reason, we used PCR-based assay instead of 
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functional in vitro assay to determine HIV-1 load, even though quantification by PCR 
could not discriminate between replication competent and non-competent viruses.  
 
Nonetheless we confirmed that HIV-1 is still detected in plasma and cells a population 
of patients on first-line ART that achieved virological suppression after the first 6 
months of starting therapy and maintained the suppression while being on ART with 2 
NRTI and with 1 NNRTI. We also showed association of some markers of HIV-1 
persistence and immune activation. Our findings may confirm the importance of the 
host environment in HIV-1 persistence and question the relevance and significance of 
markers of immune activation as prognostic factors for HIV-1 persistence during 
suppressive therapy. 
 
In this chapter we studied the total HIV-1 DNA as a surrogate for the cellular HIV-1 
reservoir. Although in stably suppressed patients, most of the intracellular viral DNA 
was found to be integrated (Chomont et al., 2009), we thought there was scope to 
explore factors associated with the integrated HIV-1 DNA in a study group of 50 people 
with similar characteristics to the one described in this chapter. In the next chapters we 
will describe the optimization of the method used to quantify the integrated HIV-1 
DNA. Furthermore we will present the results we obtained from univariate and 
multivariable linear regression analysis on factors associated with integrated HIV-1 
DNA. Such study was published in 2015 in EBiomedicine journal. 
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5 Chapter 5: Establishing an assay for measuring integrated 
HIV-1 DNA load in peripheral blood mononuclear cells 
and purified CD4 T-cell subsets 
5.1 INTRODUCTION 
HIV-1 eradication has not yet been achieved mainly because the integrated virus 
reservoir that is established in CD4 T-cells early after infection (Pierson et al., 2000) is 
unresponsive to antiretroviral drugs. Viral persistence during seemingly effective 
antiretroviral therapy (ART) can be sustained by at least two mechanisms, which are 
not mutually exclusive. Resting T-cell biology includes homeostatic proliferation, 
which amplifies integrated provirus without requiring resumption of virus replication. 
Further, latently infected resting CD4 T-cells can become activated upon antigenic 
stimulation, which leads to resumed expression of integrated provirus and virus (Chun 
et al., 1995, Chun et al., 1997a) production. The latter mechanism requires the 
integrated provirus to be replication-competent, e.g. to carry no major genome defects. 
This proposed model of HIV-1 persistence implies that integrated provirus can be found 
in both activated and resting CD4 T-cells (Chun et al., 2005) and that its quantification 
can provide a measure of the viral pool that can give rise to infectious virus (Chun et 
al., 1997a, Finzi et al., 1999, Siliciano et al., 2003, Laird et al., 2013).  
 
One methodology to quantify replication-competent virus within resting CD4 T-cells is 
the viral outgrowth assay (VOA). In this assay, resting CD4 T-cells purified from 
peripheral blood of HIV-positive patients are stimulated in vitro in order to induce 
activation and virus production. The frequency of cells producing virus is obtained and 
results are expressed as infectious unit per million (IUMP) (Mexas et al., 2012, Siliciano 
and Siliciano, 2005). The assay (Laird et al., 2013) is labour-intensive and expensive, 
and has been suggested to be lacking in sensitivity as it appears to underestimate the 
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replication-competent fraction (Hatano et al., 2013). Several PCR-based methods have 
been developed to measure integrated HIV-1 DNA, including gel separation, linker 
ligation PCR, inverse PCR, and Alu-gag PCR (Liszewski et al., 2009). Among these, 
the Alu-gag method shows a good correlation with the VOA (Eriksson et al., 2013). In 
this assay, 40 replicates of cellular DNA isolated from HIV-infected individuals 
undergo a first PCR amplification which targets both human Alu and HIV-1 gag 
sequences. At this stage, both integrated and unintegrated HIV-1 DNA forms are 
amplified in exponential and linear fashion respectively. In the next step, a HIV-1 
specific real-time PCR (qPCR) is used for quantification of HIV-1 DNA. To 
discriminate between integrated and unintegrated amplicons, 30 additional replicates 
are run in parallel with only the gag primer to produce linear amplification of 
unintegrated HIV-1 DNA alone. The read out from this “gag control” provides the 
background signal that is use to set the threshold above which one sample can be 
defined as positive for integration. This technique presents a potential drawback: the 
requirement for a reliable standard for quantification (Liszewski et al., 2009). 
Preparation of the standard is costly and time consuming, and requires periodic 
infection of CEM-ss cells with green fluorescent protein (GFP)-labelled HIV-1 viruses 
capable of only one-round infection. Infected cells are then sorted based upon the GFP 
expression and DNA is extracted, quantified and checked for integration site variety. A 
desirable standard should mimic the natural variation of integration sites observed in 
patients (Brady et al., 2013). However, Ward De Spiegelaere and colleagues at 
University of Ghent in Belgium described a modified Alu-gag method that obviates the 
need a standard (De Spiegelaere et al., 2014), whereby the integrated HIV-1 DNA copy 
number is obtained by Poisson’s principles that allow absolute quantification (Chapter 
2).  
 
In this chapter we sought to adopt the novel assay developed in Ghent, optimise its use 
on different assay platforms, and apply it to the quantification of integrated HIV-1 DNA 
in peripheral blood of HIV-positive patients receiving suppressive ART. In order to 
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optimise the assay, we also investigated the yield of integrated HIV-1 DNA in separated 
CD4 T-cell subsets comprising resting and activated CD4 T-cells.  
5.2 METHODS 
5.2.1 Study population 
Peripheral blood anticoagulated with EDTA was obtained from patients recruited 
within the ERAS cohort studies described in Chapter 2. All patients started first-line 
ART with two NRTIs plus efavirenz or nevirapine, achieved a plasma HIV-1 RNA 
level <50 copies/ml within six months, and showed all subsequent viral load 
measurements <50 copies/ml without transient elevations above 50 copies/ml while 
maintaining the initial NNRTI. The duration of uninterrupted suppressive therapy 
ranged between 1 and 15 years. ERAS 1 subjects were tested in Ghent and ERAS 2 
subjects were tested in Liverpool.   
5.2.2 Isolation of CD4 T subsets 
CD4 T-cells and resting and non-resting CD4 T-cells were isolated from fresh 
peripheral blood mononuclear cells (PBMC) using magnetic beads in a two-steps 
protocol as described by Laird et.al 2013 and as described in details in Chapter 2. 
Briefly, CD4 T-cells were enriched by depleting PBMC of CD8 and γ/δ T cells, B cells, 
NK cells, monocytes, neutrophils and other granulocytes, eosinophils, and erythrocytes 
using relevant antibodies described in Chapter 2. Resting CD4 T-cells were then 
obtained by depletion of CD4 T-cells expressing markers of immune activation that 
included CD25, CD69 and HLA-DR. Obtained resting and non-resting CD4 T-cell 
subsets were counted by haemocytometer as described in Chapter 2 and the purity was 
assessed by flow cytometry. Resting CD4 T-cells purity was first tested by CD25, 
CD69, and HLA-DR expression to set up purification conditions; following setting up, 
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cell separation purity was only tested for HLA-DR expression (Laird et al., 2013) and 
only fractions where HLA-DR positive cells represented <0.5% were considered 
suitable for further analysis of integrated HIV-1 DNA load. Non-resting CD4 T-cells 
were defined as the fraction complementary to the resting CD4 T-cells, therefore 
positive for the expression of CD25, CD69, and HLA-DR. Due to reduced sample 
availability, only HLA-DR expression was tested regularly.  
5.2.3 Integrated HIV-1 DNA assay 
The two-steps Alu-gag PCR assay was first practiced in Ghent and then established in 
Liverpool. To ensure reproducibility of the assay, validation tests were performed. 
Based upon sample availability, 4 patients were tested at 10 copies/replicate of total 
HIV-1 DNA both in Gent and in Liverpool and results were compared. Furthermore, 
for 1 out of the 4 patient, 20 copies of total HIV-1 DNA copy input was further tested 
in Liverpool. All the quantitative PCR were tested on different platforms and results 
were compared. PCR1 in Ghent and Liverpool were performed with the Gene Amp 
PCR system 2700 (Applied Bio Systems, USA) and Verity® Thermal Cycler (Applied 
Bio Systems) platforms, respectively. For the real time qPCR, the LightCycler 480 
platform (Roche, Belgium) was used in Ghent, whereas the ABI 7500 or ABI 7900HT 
platforms (Applied Bio Systems, UK) were used in Liverpool. Integrated HIV-1 DNA 
load was calculated by inputting the Ct values obtained by qPCR assay into a pre-
defined computational sheet (available on: http://www.integratedhivpcr.uGhent.be) as 
described in Chapter 2. Briefly, mean Ct values obtained from unintegrated HIV-1 
DNA replicates were used to calculate the threshold above which each single reaction 
was identified as positive for the presence of integrated HIV-1 DNA replicates. A 
minimum number of 4 positive reactions was required to allow the calculation of 
integrated HIV-1 copies/replicate by Poisson statistics. In the computational sheet, 
input number of cells was included to obtain integrated HIV-1 DNA load per 106 cells. 
115 
 
 
Integrated HIV-1 DNA in PBMC and CD4 T-cell subsets was measured. Load in 
PBMC was measured by Mrs Lydia Ritter (MRes student). 
5.2.4 Quantification of total HIV-1 DNA 
Total DNA was measured in PBMC with the in house assay described in Chapter 2 by 
research technicians and by Dr. Maria Tsakiroglou. Briefly, DNA was extracted from 
frozen cells by using the QIAamp DNA mini kit (Qiagen, UK), measured by NanoDrop, 
and amplified by quantitative real-time PCR. One µg of cellular DNA (equivalent to 
150,000 cells) was tested in duplicate, for a total of 300,000 cells tested for each patient. 
In order to detect inhibition, a 1:10 dilution of the extracted DNA was tested in parallel. 
Assay 50% and 95% detection rates were 20 and 40 HIV-1 DNA copies/106 PBMC, 
respectively. A standard curve with 6, 60, 600, 6000 HIV-1 DNA copies/106 cells was 
produced by using a cloned HIV-1 LTR DNA plasmid. In some assays, the Generic 
HIV DNA Cell kit (Biocentric,France) was employed according to manufacturer 
instructions. The in house-assay had been previously calibrated against the commercial 
kit ensuring comparable performance as shown in the Chapter 2.  
5.3 RESULTS 
5.3.1 Study population 
Table 5.1 summarises the characteristics of the cross-sectional cohort. Overall, the 41 
patients (73% male) were receiving combined ART with two NRTIs plus either 
efavirenz (85%) or nevirapine and had a median duration of viral load suppression 
(plasma HIV RNA <50 copies/ml) of seven years. Median nadir and current CD4 cell 
count were 204 cells/mm3 (IQR 127-240) and 592 cells/mm3 (IQR 497-725) 
respectively. All subjects had detectable HIV-1 DNA at median 2.5 log10 copies/10
6 
PBMC (IQR 2.2-2.9).   
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Table 5.1 Characteristic of the ERAS study population 
Characteristic  
Individuals, N total 41 
Male n (%) 30 (73%) 
Age median years (IQR) 45 (35-51) 
Nadir CD4 count median cells/mm3 (IQR) 204 (127-240) 
Duration of ART median years (IQR) 7 (3-10) 
Duration of suppressive ART median years (IQR)a 7 (3-10) 
CD4 count median cells/mm3 (IQR) 592 (497-725) 
Efavirenz as initial NNRTI n (%) 35 (85%) 
Changed NRTI backbone n (%) 15 (37%) 
Median NRTI backbone change (IQR) 1 (1-2) 
Pre-ART HIV-1 RNA median log10 cps/ml (IQR) 4.9 (4.6-5.1) 
Detectable residual plasma HIV-1 RNA n (%)  16 (40%) 
Residual HIV-1 RNA median cps/ml (IQR)b  2 (2-3) 
Total HIV-1 DNA median log10 cps/10
6 PBMC (IQR) 2.5 (2.2-2.9) 
 aDefined as the length of time following the first viral load <50 copies/ml. b Samples with 
undetectable HIV-1 RNA were assigned an arbitrary value of 1.5 copies/ml. IQR= interquartile 
range; ART= antiretroviral therapy; NRTI= nucleoside/nucleotide reverse transcriptase 
inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; PBMC= peripheral blood 
mononuclear cells; cps=copies. ERAS population included ERAS1 and ERAS2. 
 
 
 
 
5.3.2 Isolation of CD4 T subsets 
Purity of the resting CD4 T-cell fraction was first assessed by testing expression of 
activation markers CD25, CD69, and HLA-DR and a representative example is given 
in Figure 5.1.  
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Figure 5.1 Representative example of resting CD4 T-cell purity 
 a) Representative dot plot indicating CD4 and CD25 expression. b) Representative dot plot 
indicating CD69 and HLA-DR expression.  
 
 
 
 
Our experimental procedure was able to produce resting CD4 T-cells that had 
contamination of 0.2% cells expressing CD25, 0.1% cells expressing for CD69, and 
0.4% cells expressing HLA-DR. The data showed that overall the protocol was able to 
produce a highly pure resting CD4 T-cell fraction. Cell fractions from the whole 
population were further tested only for HLA-DR expression that was mean 0.2% (range 
0.1%-0.6%) in the resting CD4 T-cells and mean 5% (range 1%-12%) in the non-resting 
CD4 T-cells ( 
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Table 5.2). With this method we were able to isolate resting CD4 T-cell fraction with 
purity levels ranging between 99.4 % and 99.9% across all experiments.  
 
 
 
 
 
 
 
 
 
 
Table 5.2 Recovery and purity of resting and non-resting CD4 T-cells 
Parameters  
Total TEST 30 
PBMC 106 cells/ml of blood mean (range) 2 (3-1) 
CD4 T-cell 106 cells/ml of blood mean (range) 0.4 (0.2-0.6) 
Resting CD4 T-cells 106 cells/ml of blood mean (range) 0.2 (0.1-0.4) 
Non-resting CD4 T-cells 106 cells/ml of blood mean (range) 0.1 (0.1-0.3) 
% Resting CD4 T-cells expressing HLA-DR mean (range) 0.2 (0.1-0.6) 
% Activated CD4 T-cells expressing HLA-DR mean (range) 5 (1-12) 
 
 
 
 
Overall, mean 2x106 (range 3-1) PBMC and mean 0.4x106 (range 0.2-0.6) CD4 T-cells 
were recovered per each ml of whole blood; within the CD4 T-cell population, mean 
0.2x106 (range 0.1-0.4) and 0.1x106 (range 0.1-0.3) were resting or non-resting CD4+ 
T-cell, respectively. 
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5.3.3 Establishment of the integrated HIV-1 DNA assay  
The assay was established by running three sets of experiments (Table 5.3). First, four 
plates (from one patient each) with PCR1 products that had been amplified in Ghent 
were quantified in Liverpool with the AB 7500 qPCR equipment (test 1-2-3-4, Table 
5.3). With samples from three of four patients, the number of positive wells and 
background Ct values were reproduced. With one patient, there were a lower number 
of detected wells than measured in Ghent (23 instead of 17, test 2, Table 5.3). Further, 
we tested the same four samples by performing both PCR1 and qPCR2 in Liverpool. 
Results showed good reproducibility in number of positive wells and background Ct 
values. In addition, qPCR2 was run using two AB qPCR platforms, with similar results. 
Finally, one sample was tested using an input of 20 HIV-1 copies instead of 10, which 
doubled the detection of integrated HIV-1 DNA as expected (test 4II, Table 5.3). These 
data provided reassurance about assay performance. 
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Table 5.3 Setting up of the integrated HIV-1 DNA method in Liverpool 
  Test (platform)a HIV-1 N positive wellsb Average Ct valuec Cut-off Ct value 
  Ghent LivI LivII  Ghent LivI LivII Ghent LivI LivII 
1 (AB7500)  10 cps 7 7 7 34 35 35 31 32 32 
2 (AB7500) 10 cps 23 17 23 34 34 35 32 31 32 
3 (AB7500) 10 cps 5 5 4 35 36 35 33 34 32 
3 (AB7900) 10 cps --- --- 5 --- --- 36 --- --- 34 
4 (AB7500) 10 cps 9 8 8 36 35 37 33 33 35 
4 (AB7900) 10 cps --- --- 7 --- 36 36 --- --- 32 
4II (AB7500) 20 cps --- --- 16 --- --- 34 --- --- 33 
aplatform= qPCR platform; bwells that were scored positive for integrated HIV-1 DNA; cAvarage Ct values produced by the background.  Ghent=PCR1 
and PCR2 performed in Ghent; Liverpool I= PCR1 performed in Ghent, PCR2 in Liverpool; Liverpool II= PCR1 and PCR2 performed in Liverpool; 
Ct= cycle threshold; AB7500= Applied Biosystem model 7500 qPCR; AB 7900= Applied Biosystem model 7900HT qPCR; cps=copies. 
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Having successfully set up the assay, integrated HIV-1 DNA load was measured in 
PBMC from 41 ERAS patients and results are shown in Table 5.4.  
 
 
 
Table 5.4 HIV-1 DNA loads in PBMC from ERAS1 and ERAS2 populations 
 Total ERAS1 ERAS2 P  
Total test 41 24 17 --- 
Total HIV-1 DNA median 
log10 cps/10
6 PBMC (IQR) 
2.5 (2.2-2.9) 2.6 (2.2-2.9) 2.4 (2.2-2.9) 0.64 
Integrated HIV-1 DNA 
median log10 cps/10
6 PBMC 
(IQR) 
2.1 (1.8-2.4) 2.0 (1.8-2.5) 2.1 (1.7-2.3) 0.57 
Integrated HIV-1 DNA measurements from ERAS1 and ERAS2 populations are compared. 
Data for ERAS1 and ERAS2 data were obtained in Ghent and Liverpool respectively. Mann 
Whitney p test are shown. cps= copies 
 
 
 
 
Overall, total HIV-1 DNA was median 2.5 log10 cps/10
6 PBMC (IQR 2.2-2.9); HIV-1 
DNA loads in ERAS1 and ERAS2 subjects were 2.6 log10 cps/10
6 PBMC (2.2-2.9) and 
2.4 log10 cps/10
6 PBMC (2.2-2.9), respectively (p=0.64, Mann Whitney). Integrated 
HIV-1 DNA was overall median 2.1 log10 cps/10
6 PBMC (IQR 1.8-2.4), whereas it was 
median 2.0 log10 cps/10
6 PBMC (1.8-2.5) and 2.1 (1.7-2.3) log10 cps/10
6 PBMC (2.2-
2.9) in ERAS1 and ERAS2 subjects, respectively (p=0.57, Mann Whitney).  
 
122 
 
 
5.3.4 Integrated HIV-1 DNA load in resting and non-resting CD4 T-
cells 
In eight subjects, integrated HIV-1 DNA was measured in resting and non-resisting 
CD4 T-cells. In these subsets, less than 0.5% of resting CD4 T-cells and up to 12% of 
non-resting CD4 T-cells expressed HLA-DR. Results are shown in Table 5.5. Median 
integrated HIV-1 DNA levels were 2.3 log10/ 10
6 cells (IQR 1.9-2.6) and 2.5 log10/ 10
6 
cells (IQR 2.2-2.6) for resting and non-resting CD4 T-cells, respectively and there was 
not significant loads difference (p=0.56, Mann Withney). This demonstrated that 
integrated HIV-1 DNA load in a population of resting CD4 T-cells containing <0.5% 
of HLA-DR+ cells was not significantly different compared with non-resting CD4 T-
cells containing up to 12% of HLA-DR+ cells. 
 
 
 
Table 5.5 Integrated HIV-1 DNA loads in resting and non-resting CD4 T-cells 
 CD4+ T-cells  
 Resting  Non-resting P  
Total test 8 8 --- 
Integrated HIV-1 DNA median 
log10 cps/10
6 PBMC (IQR) 
2.3 (1.9-2.6) 2.5 (2.2-2.6) 0.56 
Mann Withney p values are shown. cps= copies.  
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5.4 DISCUSSION 
In the present chapter, the Alu-gag method described by De Spiegelaere et al. for 
measuring integrated HIV-1 DNA was established on a different platform in our 
laboratory and the yield in resting and non-resting CD4 T-cell fractions was evaluated. 
The assay was implemented with good reproducibility and then applied to the 
measurement of integrated HIV-1 DNA load in subjects receiving stably suppressive 
ART. All patients had detectable integrated HIV-1 DNA and levels were not 
significantly different in resting and non-resting CD4 T-cells. 
 
The Alu-gag PCR is becoming established in research settings as a reliable 
methodology for measuring integrated HIV-1 DNA (De Spiegelaere et al., 2014, 
Eriksson et al., 2013, Graf and O'Doherty, 2013, Liszewski et al., 2009, Agosto et al., 
2011). In this two-step method, an initial PCR is run to allow amplification of integrated 
HIV-1 DNA and a second quantitative PCR is employed for quantification of PCR1 
products. A drawback of the technique in its original application is that it requires 
preparation of a quantification standard is time consuming and costly. De Spiegelaere 
and colleagues proposed an alternative method for quantification that uses the number 
of wells scored as positive for the presence of the integrated HIV-1 DNA to calculate 
the integrated HIV-1 DNA load with the use of the Poisson statistics. An extensive set 
of experiments were performed in order to ensure the assay would transfer reliably 
between laboratories. We were in the favourable position of having patient samples that 
could be tested both in the host laboratory and in Liverpool. In the first set of 
experiments, good reproducibility was demonstrated with samples that underwent 
testing at both laboratories. Two key elements were reproduced: number of positive 
wells detected, which represent integrated HIV-1 DNA load, and background Ct values, 
which reflect linear amplification of the non-integrated HIV-1 DNA. As a further 
indication of assay reliability, when the HIV-1 copies input was doubled the amount of 
integrated HIV-1 DNA measured was also doubled. We also found consistency when 
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integrated HIV-1 DNA was measured in subjects with similar treatment histories. We 
tested samples from patients that had been recruited within the ERAS1 and ERAS2 
studies that were all on first-line ART with 2 NRTIs and one NNRTI and showed 
continuous viral load suppression <50 copies/ml starting from the first 6 months of 
ART until recruitment without blips while being on the same NNRTI. ERAS1 subjects 
were tested in Ghent and ERAS2 subjects were tested in Liverpool. Consistent with the 
highly stable treatment status, integrated HIV-1 DNA load was similar in the two 
groups. It should be noted that two groups also showed similar levels of total HIV-1 
DNA. In stably suppressed patients, integrated HIV-1 DNA is believed to represent the 
major molecular form of intracellular HIV-1 DNA (Chomont et al., 2008).  
 
Resting CD4 T-cells are believed to be the major site of HIV-1 persistence during 
suppressive ART and the major reservoir of replication competent HIV-1 provirus 
(Chun et al., 1995, Chun et al., 1997a, Murray et al., 2014). Therefore, we sought to 
define whether testing integrated HIV-1 DNA load in purified resting CD4 T-cells 
would improve the assay by eliminating variation due to PBMC composition.  The 
important prerequisite was to obtain a cell fraction of high purity, and this was 
successfully demonstrated, with results consistent with those reported by Laird et al., 
who recommend that resting CD4 T-cell purity should be >99.5%, and the proportion 
of cells expressing HLA-DR activation markers in the resting fraction should not 
exceed 0.5%. We tested only resting CD4 T-cells that had less than 0.5% of cells 
expressing HLA-DR.  Subsequently, we detected integrated HIV-1 DNA in both resting 
and non-resting CD4 T-cells, and the levels were similar. Whilst the definition of purity 
of the resting cells was straightforward and based upon levels of activation markers 
expression, the definition of non-resting CD4 T-cells needs further discussion. The 
methodology that we used is designed to positively isolate cells that express markers of 
immune activation and therefore should selectively binds only the activated non-resting 
cell fractions. However, contamination of the resting CD4 T-cells in the non-resting 
CD4 T-cell could not be checked given the absence of specific markers that define the 
resting CD4 T-cell, and therefore could not be excluded. Nonetheless, whilst our 
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finding may be at odds with the known biology of HIV infection, the infection of non-
resting/activated CD4 T-cells as they are transitioning to a resting memory state may 
be the primary mechanism by which latency is established (Chun et al., 2005, Chavez 
et al., 2015). Furthermore, there is a close association between T-cell activation and 
HIV persistence, which is not entirely understood (Hatano, 2013).  
 
Previous studies have investigated the presence of integrated HIV-1 DNA in activated 
T-cells with conflicting findings.  In two studies from Murray and Chun, the integrated 
HIV-1 DNA was measured in both activated and resting cells (Chun et al., 2011, 
Murray et al., 2014), where activated CD4 T-cells were defined as HLA-DR+CD38+ or  
CD25+CD69+HLA-DR+, and resting CD4 T-cells were defined by the absence of the 
same activation markers. However, only Tae-Wook Chun et al. reported differences in 
the integrated HIV-1 DNA levels when looking at CD4 T-cells fractions, in particular 
they found that highly purified (>99%) FACS-enriched activated (CD25+CD69+HLA-
DR+) CD4 T-cells presented higher integrated HIV-1 DNA loads compared with resting 
(CD25-CD69-HLA-DR-) CD4 T-cells (Chun et al., 2005). The two studies were 
different between each other and different from our own in terms of study population 
that included 11 subjects in Chun et al., 12 in the Murray et al., and 8 in our study. 
Further treatment history was different and in particular the other two studies included 
PI, NNRTI, and integrase inhibitor (RAL) in addition to 2NRTIs; whereas our study 
population only included patients that were taking one NNRT plus 2 NRTIs. 
Furthermore, methods for cell fractions isolation were different in the three studies.   
 
This study has limitations. In order to ensure comparability, resting and non-resting 
CD4 T-cells were defined here as previously reported by Laird et al. Other studies have 
used a variety of other definitions and therefore the data cannot be generalised. 
Nonetheless, we were able to demonstrate that limiting the measurement of integrated 
HIV-1 DNA to the resting CD4 T-cell fraction would exclude an additional source of 
integrated HIV-1 DNA, while adding considerable labour intensity and cost. Based 
upon these observations, further work on integrated HIV-1 DNA was planned using 
 126 
PBMC. In a second stage, we undertook further work on assay development that may 
in the future improve sensitivity, as described in Chapter 7.  
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6 Chapter 6: Integrated HIV-1 DNA load in peripheral 
blood is associated with the frequency of CD8 cells 
expressing HLA-DR/DP/DQ in patients receiving long-
term suppressive antiretroviral therapy 
In this chapter, the integrated HIV-1 reservoir was studied in relation to virological and 
immunological factors in 50 patients on stably suppressive ART for 1-15 years. Data 
were published in EBiomedicine journal (Ruggiero et al., 2015) and the full paper is 
attached to this thesis as Appendix (Appendix 1). The present chapter was adapted from 
the paper to fit the University of Liverpool thesis submission requirements. 
6.1 INTRODUCTION 
HIV establishes a reservoir of replication-competent integrated provirus early after 
transmission (Hocqueloux et al., 2013).  The provirus is found predominantly in 
memory CD4 T-cells; it is poorly responsive to antiretroviral therapy (ART), and 
supports virus replication upon treatment discontinuation (Ruelas and Greene, 2013, 
Soriano-Sarabia et al., 2014, Siliciano et al., 2003). Different mechanisms have been 
proposed to support HIV persistence during successful ART, which could be grouped 
into two based on presence or absence of virus production, respectively. In the presence 
of virus production, continuous replenishment of the reservoir may occur through 
ongoing virus production (Hatano et al., 2013, Buzon et al., 2010), perhaps in sites 
where ART penetration or activity is suboptimal (Fletcher et al., 2014). In the absence 
of virus production, maintenance of the reservoir can also occur through proliferation 
of latently infected CD4 T-cells, as a possibly key determinant of HIV persistence 
during ART (Maldarelli et al., 2014, Josefsson et al., 2013, Chomont et al., 2009, 
Wagner et al., 2014). These proposed models are not mutually exclusive. 
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HIV replication causes chronic immune activation and inflammation, typically 
accompanied by an expansion of CD8 T-cells, which improve but rarely resolve with 
ART (Klatt et al., 2013). Moreover, in treated patients, persistent HIV production or 
partial antigenic expression may drive ongoing immune activation. In turn, immune 
activation can promote T-cell proliferation, leading to HIV transcription and production 
(Klatt et al., 2013). Furthermore, early in the course of the infection, HIV induces gut 
damage, which allows translocation of gastrointestinal microbial products into the 
systemic circulation. As a results, immune activation is raised and causes further gut 
damage, establishing a self-perpetuating cycle that can become independent of virus 
production (Shan and Siliciano, 2014). In addition, other persistent infections, such as 
with cytomegalovirus (CMV), play a linked role in ongoing immune activation despite 
suppressive ART (Gianella et al., 2014).  
 
How markers of immune activation correlate with parameters of HIV persistence during 
long-term suppressive therapy is still unclear. Available data are inconsistent, possibly 
a consequence of heterogeneous study populations and measures of HIV persistence, 
but also a reflection of complex bilateral interactions (Hatano et al., 2013, Chun et al., 
2011, Cockerham et al., 2014). Further characterization of this relationship is needed 
in order to improve our understanding of HIV pathogenesis and design improved 
curative strategies.  
 
The aim of this study was to investigate factors associated with the levels of integrated 
HIV-1 DNA measured in peripheral blood during stably suppressive ART, including 
the relationship with markers of immune activation. Heterogeneity of the study 
population was minimized, by exclusively selecting patients who started first-line ART 
with two NRTIs plus one NNRTI, achieved a plasma HIV-1 RNA (“viral”) load <50 
copies/ml within the first six months of therapy, and subsequently showed consistent 
viral load suppression <50 copies/ml over up to 14 years of continuous treatment on the 
same NNRTI.  
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6.2 METHODS 
6.2.1 Study population  
Study subjects were recruited within the ERAS1 cohort study described in Chapter 2 
and 4. Briefly, eligible patients were on first-line ART with two NRTIs plus efavirenz 
or nevirapine, and showed continuous viral load suppression (<50 copies/ml) with no 
blips from the first six months of therapy up to sampling date. Only changes of the 
initial NRTI (e.g., for toxicity) were allowed provided they were not associated with a 
treatment interruption or viral load rebound >50 copies/ml. Recruitment was stratified 
by duration of ART to range from 1 to 14 years.  
6.2.2 Quantification of residual HIV-1 RNA in plasma 
Plasma HIV-1 RNA below 50 copies/ml was quantified using a modified version of the 
Abbott RealTime HIV-1 assay (Maidenhead, UK) as described in Chapter 2 and 4. The 
assay 50% and 95% detection rates for 8 ml input were 1 and 3 HIV-1 RNA copies/ml, 
respectively. 
6.2.3 HIV-1 subtyping 
The HIV-1 subtype was available prior to this study. Polymerase sequences were obtain 
from HIV-1 DNA recovered from PBMC, and the subtype was determined s previously 
described (16).  
6.2.4 Quantification of total, integrated and 2-LTR circular HIV-1 
DNA in peripheral blood mononuclear cells 
Total and integrated HIV-1 DNA loads were measured as described in Chapter 2,4, and 
5. Total HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) was 
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determined by a qPCR as previously described (Geretti et al., 2013) and the assay 50% 
and 95% detection rates were 20 and 40 HIV-1 DNA copies/106 PBMC, respectively. 
Integrated HIV-1 DNA was quantified by repetitive-sampling Alu-gag as previously 
described (De Spiegelaere et al., 2014). The assay was set up in Ghent and validated in 
Liverpool prior to sample testing as described in Chapter 5. The 2-LTR circular HIV-1 
DNA levels were measured in collaboration with Prof Douglas Richman group as 
previously described (Strain et al., 2013). Assay details are given in Chapter 2. The 
lower limit of detection was median 5 copies/106 PBMC (interquartile range, IQR 4-6).  
6.2.5 Markers of immune activation 
Cellular markers of immune activation were measured with flow cytometry at the Royal 
Free Hospital, London as described in Chapter 2 and 4. In brief, fresh blood was stained 
with relevant antibodies (Table 2.5). PE or FITC labelled antibodies against CD4 plus 
either CD26, CD38, or CD69, and against CD8 plus either CD38 or HLA-DR/DP/DQ. 
Cell suspensions were fixed with 1% paraformaldehyde (PFA) prior to acquisition 
using FACScan and analysis by CellQuest software version 3.3. Soluble CD14 (sCD14) 
as a marker of bacterial lipopolysaccharide (LPS)-induced monocyte/macrophage 
activation was measured in plasma by enzyme-linked immune-enzymatic assay 
(ELISA). Details were given in Chapter 2. Raw data were available prior to the study 
and analysed by using a pre-calculated excel file provided from the manufacturer.  
6.2.6 Detection of cytomegalovirus and Epstein-Barr virus DNA  
Plasma was tested for CMV and Epstein-Barr Virus (EBV) DNA with a real-time PCR 
assay targeting the viral UL123/UL55 and p143 regions, respectively. DNA was 
extracted from 800 µl of plasma using the Qiasymphony DSP Virus/Pathogen Midi kit 
on the Qiagen QiaSymphony automated platform according to the manufacturers’ 
instruction (Qiagen). Eluted DNA was tested at the Royal Liverpool University 
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Hospital, Liverpool collaboration with Dr. Mark Hopkins. The lower limits of detection 
were 50 IU/ml for CMV DNA and 100 copies/ml for EBV DNA. 
6.2.7 Statistical analysis 
The characteristics of the study population were stratified into two groups based upon 
duration of suppressive ART, which was defined as the length of time following the 
first viral load measurement <50 copies/ml recorded after starting ART. To compare 
continuous and categorical variables from the database, the non-parametric Wilcoxon-
Mann-Whitney and the Fisher’s exact test were used respectively. Where the analyses 
required variables to be expressed in median levels, undetectable HIV-1 RNA results 
were given an arbitrary midpoint value between zero and the assay 95% detection rate 
(=1.5 copies/ml), whereas undetectable 2-LTR circular HIV-1 DNA results were 
assigned a midpoint value between zero and the assay median lower limit of detection 
(=2.5 copies/106 PBMC). For measured residual plasma HIV-1 RNA, 2-LTR circular 
HIV-1 DNA, total and integrated HIV-1 DNA, sCD14, and frequency of activated CD4 
and CD8 cells, the mean differences (with 95% confidence interval, CI) over 10 years 
of suppressive ART were analysed by univariate linear regression analysis after log 
transformation of the variables. The correlation between integrated HIV-1 DNA load 
or frequency of CD8+HLA-DR/DP/DQ+ cells and other measured parameters was 
explored by the Spearman’s test. The association between integrated HIV-1 DNA load 
and other variables was characterised further by univariate and multivariable linear 
regression modelling. A ‘best subset’ approach and the Mallow Cp test were used for 
the selection of variables to be included in the multivariable model as described in 
Chapter 2. All available variables were initially considered for inclusion, with the 
exception of gender and NNRTI use (due to predominance of males and efavirenz use: 
40/50, 80% for both variables) and total HIV-1 DNA load (due to strong co-linearity 
with integrated HIV-1 DNA load). Pre-ART viral load (Cp value 3.5), duration of 
suppressive ART (3.6), residual plasma HIV-1 RNA load (3.6), frequency of 
CD8+HLA-DR/DP/DQ+ cells (0.4), and sCD14 levels (1.7) were identified for 
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inclusion in the multivariate model. The CD4 cell count was added to the multivariable 
model as a possible confounding factor. In a second multivariable model, nadir CD4 
count was included instead of pre-ART viral load. A sensitivity analysis was also 
performed replacing integrated with total HIV-1 DNA as the outcome variable in the 
same two models. The analyses were performed with SAS 9.4 with the support of Dr. 
Alessandro Cozzi-Lepri at University College London. 
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6.3 RESULTS 
6.3.1 Study population  
Fifty patients, who were receiving two NRTIs plus either efavirenz (80%) or nevirapine 
for median duration of viral load suppression <50 copies/ml of 6.4 years (Table 6.1), 
were recruited. Patients with duration of suppressive ART above the median of 6.4 
years were older and had a lower nadir CD4 cell count, a marginally higher current 
CD4 cell count, and lower frequencies of CD4 and CD8 cells expressing CD38 relative 
to subjects with shorter duration. They were also more likely to have experienced 
changes in the composition of the NRTI backbone after first starting ART. Overall 
25/50 patients (50%) changed one or more component of the NRTI backbone, with 
median 1 drug change per subject (IQR 0-1). At the time of sampling, NRTI backbones 
were tenofovir/emtricitabine (37/50, 74%), abacavir/lamivudine (10/50, 20%), or 
zidovudine/lamivudine (3/50, 6%). Residual plasma HIV-1 RNA was detected in 29/50 
patients (58%) at levels ranging between 1 and 35 copies/ml, whereas 2-LTR circular 
HIV-1 DNA was detected in 16/50 patients (32%) at levels ranging between 5 and 35 
copies/106 PBMC. All subjects had detectable HIV-1 DNA, with total and integrated 
HIV-1 DNA levels of median 2.6 and 1.9 log10 copies/10
6 PBMC, respectively. None 
of the patients had detectable CMV DNA in plasma, whereas 3/50 patients (6%) had 
detectable EBV DNA.  
 
Differences in measured parameters per 10 years of suppressive ART were determined 
by linear regression analysis of data obtained from the cross-sectional sampling (Table 
6.2). Longer duration of suppressive ART was associated with higher CD4 cell counts 
and lower levels of CD38 expression on CD4 and CD8 cells. There were also lower 2-
LTR circular HIV-1 DNA levels and a trend for lower residual HIV-1 RNA levels. A 
sub-analysis compared subjects with integrated HIV-1 DNA load either in the lowest 
quartile (<1.7 log10 copies/10
6 PBMC) or the highest quartile (>2.2 log10 copies/10
6 
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PBMC) (Table 6.3). Subsets in the lowest quartile showed significant lower levels of 
total HIV-1 DNA and sCD14, and lower frequency of CD8+HLA-DR/DP/DQ+ cells. 
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Table 6.1 Characteristics of the study population overall, and stratified by duration of suppressive therapy as below (Group 
I) or above (Group II) the median of 6.4 years 
Characteristic Total (n=50) Group I (n=25) Group II (n=25) P  
Male n (%) 40 (80) 22 (88) 18 (72) 0.29 
Age median years (IQR) 46 (40-53) 44 (36-49) 48 (43-55) 0.04 
HIV-1 subtype B n (%) 32 (64) 18 (72) 14 (56) 0.38 
Nadir CD4 count median cells/mm3 (IQR) 206 (110-265) 246 (160-292) 176 (97-213) 0.007 
Duration of ART median years (IQR) 6.7 (3.4-9.1) 3.4 (2.5-5.0) 9.2 (8.0-10.3) <0.001 
Duration of suppressive ART median years (IQR)a 6.4 (3.1-8.8) 3.1 (2.1-4.8) 9.0 (7.7-10.0) <0.001 
Efavirenz as initial NNRTI n (%) 40 (80) 22 (44) 18 (36) 0.29 
Changed NRTI backbone n (%) 25 (50) 4 (16) 21 (84) <0.001 
Pre-ART HIV-1 RNA median log10 copies/ml (IQR) 
 
5.0 (4.7-5.5) 4.8 (4.5-5.3) 5.1 (4.9-5.6) 0.09 
Table 6.1 continue on next page 
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Table 6.1 (continued) 
Characteristic Total (n=50) Group I (n=25) Group II (n=25) P  
Detectable residual plasma HIV-1 RNA n (%)  29 (58) 15 (60)  14 (56)  1.00 
Residual HIV-1 RNA median copies/ml (IQR)b  2 (2-4) 2 (2-7) 2 (2-4) 0.33 
Detectable 2-LTR circular HIV-1 DNA n (%)  16 (32) 10 (40) 6 (25) 0.36 
2-LTR circular HIV-1 DNA median copies/106 PBMC (IQR)c 3 (3-7) 3 (3-7) 3 (3-5) 0.28 
Total HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 2.6 (2.3-2.9) 2.6 (2.4-2.9) 2.5 (2.2-2.7) 0.36 
Integrated HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 1.9 (1.7-2.2) 1.9 (1.7-2.1) 1.8 (1.7-2.4) 0.91 
CD4 count median cells/mm3 (IQR) 572 (478-734) 552 (442-606) 640 (502-794) 0.05 
CD4+CD26+ median percentage (IQR) 54 (43-63) 54 (42-63) 54 (44-63) 0.55 
CD4+ CD38+ median percentage (IQR) 22 (17-34) 25 (21-35) 20 (14-24) 0.02 
CD4+CD69+ median percentage (IQR) 2 (1 -2) 1 (1-3) 2 (1-2) 0.48 
CD8+CD38+ median percentage (IQR) 5 (3-7) 6 (3-8) 4 (3-6)  0.04 
CD8+HLA-DR/DP/DQ+ median percentage (IQR) 32 (20-48) 37 (22-53) 30 (16-42) 0.19 
sCD14 median μg/ml (IQR) 2.2 (1.8-2.6) 2.0 (1.6-2.6) 2.2 (2.0-2.7) 0.16 
aDefined as the length of time following the first viral load <50 copies/ml; it ranged between 0.7 and 6.4 years in Group 1, and between 6.4 and 
14.4 years in Group II. bSamples with undetectable HIV-1 RNA were assigned an arbitrary value of 1.5 copies/ml. cSamples with undetectable 2-
LTR circular HIV-1 DNA were assigned an arbitrary value of 2.5 copies/106 PBMC. IQR= interquartile range; ART= antiretroviral therapy; 
NRTI= nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; PBMC= peripheral blood 
mononuclear cells; sCD14= soluble CD14. 
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Table 6.2 Univariate linear regression analysis of mean difference in log-transformed virological and immunological 
variables per 10 years of suppressive antiretroviral therapy 
Variablea Mean difference 95% CI P 
Residual HIV-1 RNA copies/ml -0.27 -0.57, 0.03 0.08 
2-LTR circular HIV-1 DNA copies/106 PBMC  -0.34 -0.59,-0.08 0.01 
Total HIV-1 DNA copies/106 PBMC -0.12 -0.56, 0.32 0.60 
Integrated HIV-1 DNA copies/106 PBMC   0.22 -0.19, 0.62 0.28 
CD4 count cells/mm3  0.14  0.00, 0.27 0.05 
CD4+CD26+ percentage -0.03 -0.02, 0.10 0.69 
CD4+CD38+ percentage -0.23 -0.39,-0.07 0.01 
CD4+CD69+ percentage -0.11 -0.28, 0.07 0.22 
CD8+CD38+ percentage -0.30 -0.54, -0.07 0.01 
CD8+HLA-DR/DP/DQ+ percentage -0.15 -0.37,  0.07 0.17 
sCD14 μg/ml   0.07 -0.03, 0.16 0.19 
aVariables in log10. CI= Confidence interval; PBMC= peripheral blood mononuclear cells; sCD14= soluble CD14. 
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Table 6.3 Comparative analysis of subjects whose integrated HIV-1 DNA load fell within the lowest or the highest quartile 
Characteristic Lowest quartilea  
(n = 13) 
Highest quartile  
(n = 13) 
P  
Male n (%) 9 (70) 11 (84) 0.64 
Age median years (IQR) 40 (31-49) 47 (43-53) 0.07 
HIV-1 subtype B n (%) 8 (61) 5 (38) 0.43 
Nadir CD4 count median cells/mm3 (IQR) 180 (80-240) 208 (118-260) 0.41 
Duration of ART median years (IQR) 6.7 (5.7-8.2) 9.1 (3.0-10.7) 0.29 
Duration of suppressive ART median years (IQR) 6.6 (5.7-7.7) 8.9 (2.7-10.6) 0.24 
Efavirenz as initial NNRTI n (%) 13 (100) 10 (77) 0.22 
Changed NRTI backbone n (%) 8 (61) 5 (38) 0.43 
Pre-ART HIV-1 RNA median log10 copies/ml (IQR) 4.9 (4.6-5.5) 5.1 (5.0-5.5) 0.26 
Table 6.3 continues on the next page 
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Table 6.3 (continued) 
Characteristic Lowest quartilea  
(n = 13) 
Highest quartile  
(n = 13) 
P  
Detectable residual plasma HIV-1 RNA n (%)  9 (69) 6 (46) 0.43 
Residual HIV-1 RNA median copies/ml (IQR)  2 (2-3) 2 (2-5) 0.89 
Detectable 2-LTR circular HIV-1 DNA n (%)  4 (31) 6 (46) 0.68 
2-LTR circular HIV-1 DNA median copies/106 PBMC (IQR) 3 (3-7) 3 (3-7) 0.65 
Total HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 2.4 (2.1-2.6) 2.8 (2.7-3.0) 0.003 
CD4 count median cells/mm3 (IQR) 721 (552-758) 513 (482-640) 0.25 
CD4+CD26+ median percentage (IQR) 53 (34-60) 54 (44-59) 0.85 
CD4+ CD38+ median percentage (IQR) 23 (17-34) 20 (16-24) 0.28 
CD4+CD69+ median percentage (IQR) 2 (1-2) 2 (1-2) 0.64 
CD8+CD38+ median percentage (IQR) 4 (3-7) 3 (2-7) 0.43 
CD8+HLA-DR/DP/DQ+ median percentage (IQR) 24 (16-37) 35 (32-49) 0.01 
sCD14 median μg/ml (IQR) 1.8 (1.6-2.3) 2.4 (2.1-2.7) 0.04 
aQuartile cut-offs= 1.7 and 2.2 log10 copies/106 PBMC. PBMC= peripheral blood mononuclear cells; IQR= interquartile range; 
ART= antiretroviral therapy; NNRTI= non-nucleoside reverse transcriptase inhibitor; sCD14= soluble CD14. 
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6.3.2 Factors associated with integrated HIV-1 DNA load 
Integrated HIV-1 DNA load was positively associated with total HIV-1 DNA load 
(p<0.0001), frequency of CD8+HLA-DR/DP/DQ+ cells (p=0.01), and sCD14 levels 
(p=0.04), but not with the levels of residual plasma HIV-1 RNA (p=0.80) and 2-LTR 
circular HIV-1 DNA (p=0.50), or the frequency of CD8+CD38+ cells (p=0.33) (Figure 
6.1). The associations were also tested by univariate and multivariable linear regression 
analysis (Table 6.4). An initial model was built including pre-ART viral load, duration 
of suppressive ART, CD4 cell counts, residual plasma HIV-1 RNA levels, frequency 
of CD8+HLA-DR/DP/DQ+ cells, and sCD14 levels. In this adjusted model, integrated 
HIV-1 DNA load was a mean of 0.5 log10 copies higher for each 50% increment in the 
frequency of CD8+HLA-DR/DP/DQ+ cells (95% CI 0.2, 0.9; p=0.01) (Table 6.4). We 
also found that CD8+HLA-DR/DP/DQ+ cells were not associated with plasma HIV-1 
RNA or intracellular 2-LTR circular HIV-1 DNA (Figure 6.2).   
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Figure 6.1 Association between integrated HIV-1 DNA and virological and immunological factors 
Y axis: integrated HIV-1 DNA log10/10
6 PBMC; x axis: a) total HIV-1 DNA load, b) residual plasma HIV-1 RNA levels, c) 2-LTR circular HIV-1 DNA 
levels, d) frequency of CD8+HLA-DR/DP/DQ+ cells, e) frequency of CD8+CD38+ cells, and f) levels of sCD14. Scatter plots with integrated HIV-1 
DNA by the fitted fractional polynomial curves (with 95% confidence interval) and Spearman’s rho (with p values) are shown. 
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Table 6.4 Univariate and multivariable linear regression analysis of factors associated with the mean difference in integrated 
HIV-1 DNA load 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Univariate Multivariable 
Factor 
Mean 
difference  
95% CI 
P 
Mean 
difference 
95% CI P 
Age, per 10 years higher   0.11  -0.03, 0.25 0.11    
HIV-1 subtype B vs. non B    0.11  -0.18, 0.39 0.46    
Nadir CD4 count per 100 cell/mm3 higher   0.06  -0.04, 0.17 0.25    
Duration of suppressive ART per 10 years longer   0.22  -0.19, 0.62 0.28 0.23 -0.20, 0.66 0.30 
Changed NRTI backbone yes vs. no  -0.14  -0.41, 0.13 0.30    
Pre-ART HIV-1 RNA per log10 copies/ml higher   0.10  -0.08, 0.28 0.27 0.13 -0.05, 0.30 0.15 
Residual HIV-1 RNA per log10 copies/ml higher    0.20  -0.17, 0.57 0.28 0.27 -0.08, 0.62 0.13 
2-LTR circular HIV-1 DNA per log10 copies/10
6 PBMC higher   0.04 -0.39, 0.46 0.85    
CD4 count per 100 cells/mm3 higher   0.03  -0.02, 0.08 0.25 0.02 -0.03, 0.07 0.38 
CD4+CD26+ per 50% higher   0.01  -0.44, 0.47 0.96     
CD4+CD38+ per 50% higher  -0.78  -2.11, 0.54 0.24    
CD4+CD69+ per 50% higher   1.02  -5.29, 7.33 0.75    
CD8+CD38+ per 50% higher  -0.27  -1.22, 0.67 0.57    
CD8+HLA-DR/DP/DQ+ per 50% higher   0.38   0.02, 0.74 0.04 0.51  0.15, 0.86 0.01 
sCD14 per log10 μg/ml higher   0.97  -0.14, 2.08 0.09 0.90 -0.16, 1.97 0.10 
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Figure 6.2 Association between residual plasma HIV-1 RNA levels and 2-LTR circular HIV-1 DNA levels and %CD8+HLA-
DR/DP/DQ+ 
a) Residual plasma HIV-1 RNA levels, and b) 2-LTR circular HIV-1 DNA levels. Scatter plots with predicted CD8+HLA-DR/DP/DQ+ cells 
by the fitted fractional polynomial curves (with 95% confidence interval) and Spearman’s rho (with p values) are shown. 
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The association between integrated HIV-1 DNA load and frequency of CD8+HLA-
DR/DP/DQ+ cells was confirmed in a separate model including the nadir CD4 cell count 
in place of pre-ART viral load. In this second model integrated HIV-1 DNA load was 
mean 0.5 log10 copies higher for each 50% increase in the frequency of CD8
+HLA-
DR/DP/DQ+ cells (95% CI 0.1, 0.8; p=0.02) (Table 6.5). In a sensitivity analysis, 
integrated HIV-1 DNA was replaced with total HIV-1 DNA in the two multivariable 
models (Table 6.6). In the model including pre-ART viral load as one of variables, total 
HIV-1 DNA load was 0.4 log10 copies higher for each 50% increase in the frequency 
of CD8+HLA-DR/DP/DQ+ cells (95% CI -0.02, 0.8; p=0.06); in the model including 
the nadir CD4 cell count in place of pre-ART viral load, total HIV-1 DNA load was 
similarly 0.5 log10 copies higher for each 50% increase in the frequency of CD8
+HLA-
DR/DP/DQ+ cells (95% CI -0.1, 0.8; p=0.12).  
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Table 6.5 Multivariable linear regression analysis of factors associated with the mean difference in integrated HIV -1 DNA load 
over 10 years of suppressive antiretroviral therapy in a model including nadir CD4 cell count. 
Factor Mean differencea 95% CI P 
Nadir CD4 count per 100 cell/mm3 higher 0.04 -0.09, 0.16 0.55 
CD4 count per 100 cells/mm3 higher 0.01 -0.04,0.06 0.60 
Duration of suppressive ART per 10 years longer 0.37 -0.12, 0.86 0.13 
Residual HIV-1 RNA per log10 copies/ml higher 0.26 -0.10, 0.62 0.15 
CD8+HLA-DR/DP/DQ+ per 50% higher 0.45   0.08, 0.82 0.02 
sCD14 per log10 μg/ml higher 0.76 -0.40, 1.92 0.19 
aMean difference in integrated HIV-1 DNA in log10 copies/10
6 PBMC. PBMC= peripheral blood mononuclear cells; ART= antiretroviral 
therapy. 
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Table 6.6 Sensitivity analysis replacing integrated with total HIV-1 DNA in the two multivariable modelsa. 
Factors Model I Model II 
Mean difference 95% CI P Mean difference 95% CI P 
Nadir CD4 count per 100 cell/mm3 higher - - - -0.02 -0.16, 0.13 0.83 
CD4 count per 100 cells/mm3 higher -0.02 -0.08, 0.04 0.53 -0.02 -0.09, 0.04 0.43 
Duration of suppressive ART per 10 years longer -0.12 -0.62, 0.39 0.65 -0.01 -0.60, 0.58 0.98 
Pre-ART HIV-1 RNA per log10copies/ml higher 0.23 0.03, 0.43 0.03 - - - 
Residual HIV-1 RNA per log10 copies/ml 0.14 -0.26, 0.55 0.48 0.14 -0.30, 0.57 0.53 
CD8+HLA-DR/DP/DQ+ per 50% higher 0.39 -0.02, 0.80 0.06 0.35 -0.09, 0.80 0.12 
sCD14 per log10 μg/ml higher 0.56 -0.68, 1.78 0.37 0.57 -0.83, 1.97 0.41 
aMean difference in log10 copies/10
6 PBMC. Model 1 included pre-ART viral load; model 2 replaced pre-ART viral load with nadir CD4 
cell count. PBMC: peripheral blood mononuclear cells; ART: antiretroviral therapy.  
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6.4 DISCUSSION 
This analysis of subjects receiving first-line NNRTI-based ART demonstrated that 
integrated HIV-1 DNA load did not differ by duration of suppressive therapy and was 
positively associated with the frequency of CD8 cells expressing HLA-DR/DP/DQ. 
Subjects with higher integrated HIV-1 DNA load also had higher levels of sCD14, 
although the association did not persist in adjusted analyses. While there was a 
predictable positive correlation with total HIV-1 DNA levels, integrated HIV-1 DNA 
load did not show a correlation with putative measures of recent HIV-1 replication 
(residual plasma HIV-1 RNA, 2-LTR circular HIV-1 DNA), or with the frequency of 
CD4 and CD8 cells expressing CD38. 
 
Previous studies reported that during suppressive ART integrated HIV-1 DNA shows a 
constant load and little evidence of genetic evolution (Siliciano et al., 2003, von 
Stockenstrom et al., 2015, Josefsson et al., 2013, Besson et al., 2014). Our study adds 
to these previous analyses by demonstrating that the HIV-1 DNA load did not differ by 
duration of suppressive therapy in a population with a relatively homogenous treatment 
history and exact requirements in terms of evidence of plasma viral load suppression 
<50 copies/ml. There were indications that subjects treated for longer had lower levels 
of 2-LTR circular HIV-1 DNA and residual plasma HIV-1 RNA, accompanied by a 
reduction in the frequency of CD4+CD38+ and CD8+CD38+ cells, together suggesting 
that control of virus replication and resolution of immune dysfunction improve with 
longer duration of therapy. In contrast, the frequency of CD8+HLA-DR/DP/DQ+ cells 
was also not related to the duration of suppressive ART and we were able to quantify 
the association between two key parameters of virus persistence and immune activation, 
whereby integrated HIV-1 DNA load increased by 0.5 log10 copies/10
6 PBMC for each 
50% increase in the frequency of CD8+HLA-DR/DP/DQ+ cells. 
 
The function of CD8+ cells expressing HLA-DR/DP/DQ+ remains to be fully elucidated 
and may include both regulatory and effector functions (Arruvito et al., 2014, Saez-
Cirion et al., 2007, Zubkova et al., 2014). In the context of suppressive ART, 
CD8+CD38-/HLA-DR+ cells may be maintained by low-level expression of HIV or 
other persistent pathogens, including microbial translocation from the gut. It has been 
proposed that CD8+ cells expressing HLA-DR without CD38 are preferentially 
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generated in response to low antigenic stimulation and that by retaining good effector 
function may play a role in suppressing HIV replication in elite controllers, as well as 
clearing hepatitis C infection (Zubkova et al., 2014, Saez-Cirion et al., 2007). It may 
seem therefore counterintuitive that CD8+HLA-DR/DP/DQ+ cells should have a 
positive (rather than inverse) correlation with integrated HIV-1 DNA load. Yet, in line 
with previous data (Hatano et al., 2013), our adjusted analyses showed a positive 
association between frequency of CD8+HLA-DR/DP/DQ+ cells and integrated HIV-1 
DNA load. Several hypotheses may be proposed to explain the observed positive 
association. Firstly, low-level HIV production may both stimulate CD8+HLA-
DR/DP/DQ+ cells and continuously replenish the integrated reservoir. Further to this, 
CD8+HLA-DR/DP/DQ+ cells may directly stimulate HIV-infected CD4 cells, causing 
their proliferation and expansion of the reservoir, which can be measured as increased 
integrated HIV-1 DNA load (Klatt et al., 2013). Thirdly, a stimulant or multiple 
stimulants may act simultaneously on CD8+HLA-DR/DP/DQ+ cells and HIV-infected 
CD4 cells, resulting in an indirect association between the two parameters.  
 
The population we studied did not overall show evidence of ongoing HIV replication. 
Patients experienced no viral load rebound >50 copies/ml during follow-up (Doyle et 
al., 2012). In line with previous studies, just over half had traces of detectable plasma 
HIV-1 RNA (Palmer et al., 2008), whereas a third had detectable intracellular 2-LTR 
circular HIV-1 DNA. There was no association however between these two putative 
markers of recent HIV-1 replication and either integrated HIV-1 DNA load, or the 
frequency of CD8+HLA-DR/DP/DQ+ cells. While this indicates that HIV production 
was unlikely, the finding may also reflect insufficient sensitivity of the analytic systems 
and the limitation of assaying peripheral blood (Cockerham et al., 2014). It will be 
important to determine the antigenic specificity of CD8+HLA-DR/DP/DQ+ cells, for 
example against persistent viruses such as CMV and EBV (Gianella et al., 2014). As 
described in Chapter 1 of this thesis, CD8 T cells specific for those two herpes viruses 
have been found in ART-experienced HIV-1 infected individuals and activated CD8 T 
cells have been correlated with HIV-1 viral load (Doisne et al., 2004, Paiardini and 
Muller-Trutwin, 2013). Of note, the two  viruses were not commonly detected in our 
population, which is consistent with containment by effective immune responses. One 
other aspect that warrants investigation is the relationship with levels of sCD14, which 
are an important predictor of disease progression and mortality in both treated and 
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untreated patients (Sandler et al., 2011, Marchetti et al., 2011, Hunt et al., 2014). 
Soluble CD14 is produced by monocytes in presence of microbial products and it can 
be defined as an indirect measurements of microbial translocation and GUT damage 
following HIV-1 infection. GUT damage sustains chronic immune activation that could 
drive T cells activation with consequent expansion of the viral reservoir. In this study, 
median sCD14 levels were within the range reported in healthy HIV-negative controls 
(Sandler et al., 2011). However, patients whose integrated HIV-1 DNA load fell within 
the highest quartile showed significantly higher sCD14 levels than those with integrated 
HIV-1 DNA load in the lowest quartile, a finding that warrants further investigation in 
larger cohorts.  
 
A strong positive association was measured between total and integrated HIV-1 DNA, 
supporting the notion that integrated HIV-1 DNA is the most prevalent form of HIV-1 
DNA during suppressive ART (Graf and O'Doherty, 2013), and total HIV-1 DNA was 
associated with the frequency of CD8+HLA-DR/DP/DQ+ cells. Two previous studies 
have reported an association between the frequency of CD8 cells expressing HLA-DR 
and total HIV-1 DNA load in peripheral blood (Cockerham et al., 2014, Hatano et al., 
2013). One study was unable to detect a consistent association between the expression 
of activation markers on CD8 cells and integrated HIV-1 DNA load among 19 subjects 
(Cockerham et al., 2014). The reasons for the discrepant findings are unclear, and may 
include a smaller and more heterogeneous study population relative to this cohort, as 
well as possible differences in the methods to quantify integrated HIV-1 DNA load. 
 
This study also has limitations, including that parameters were measured cross-
sectionally, albeit after stratifying recruitment according to duration of ART and 
causality of the observed associations cannot be concluded. Study size limited the 
number of variables included in the multivariable analysis of factors associated with 
integrated HIV-1 DNA load, and unmeasured variables may have contributed to the 
findings. Importantly, the cohort had received NNRTI-based ART exclusively, and 
findings may not necessarily be extrapolated to other treatment regimens.  Further, we 
measured CD38 and HLA-DR/DP/DQ expression on CD8 cells separately. Unlike the 
frequency of CD8+HLA-DR/DP/DQ+ cells however, the frequency of CD8+CD38+ 
cells declined with duration of suppressive ART and showed no statistical association 
with integrated HIV-1 DNA load. Further analyses are needed to confirm the 
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association between integrated HIV-1 DNA load and CD8+CD38-HLA-DR/DP/DQ+ 
cells, characterise the antigenic specificity of CD8+HLA-DR/DP/DQ+ cells, and 
determine the direction of causality. Moreover, the data describe CD8 cells expressing 
HLA-DR/DP/DQ and it will be of interest to study the association between integrated 
HIV-1 DNA load and individual HLA isotypes. Meanwhile, our data add to the growing 
evidence indicating that a complex interplay between HIV-1 persistence and immune 
activation continues over many years of stably suppressive ART. 
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7 Chapter 7: Methodological development of experimental 
approaches to study HIV-1 persistence 
7.1 Section A: Development of a new integrated HIV-1 DNA load 
assay 
7.1.1 INTRODUCTION 
The Alu-gag PCR assay for measuring integrated HIV-1 DNA has a good correlation 
with the IUMP (Eriksson et al., 2013) and provides a useful tool for investigating HIV 
persistence. The method comprises an initial first PCR reaction (PCR1) that amplifies 
integrated HIV-1 DNA and a second PCR reaction (qPCR2) that allows quantification 
of the first PCR products (De Spiegelaere et al., 2014, Liszewski et al., 2009). In PCR1, 
42 replicates are run using one primer that binds the HIV-1 gag region and another that 
binds one of the Alu sequences randomly distributed within the human genome: this 
allows amplification of the integrated HIV-1 DNA (herein referred to as “integrated 
HIV-1 DNA replicates”). During this step, unintegrated HIV-1 DNA can also be 
linearly amplified by the binding of the gag primer only; to avoid bias in the 
quantification step, 30 replicates are run by using the gag primer only (herein referred 
to as “HIV-1 control”) and the mean quantification cycle (Ct) obtained from these 
replicates is set as threshold above which an integrated HIV-1 DNA replicate is scored 
as positive. This test can detect 10% of the total integration events with a 7500-15000 
cells input for each replicate (Liszewski et al., 2009, Swiggard et al., 2005). This limit 
of detection is a reflection of the efficiency of PCR1: integrated HIV-1 DNA that is 
situated at around 3.5 kb away from the human Alu sequence is amplified. This limit is 
partially compensated by running a large number of replicates for each sample, 
increasing the possibility of detecting the integrated HIV-1 DNA. This approach, 
however, makes the assay expensive and labour intensive, emphasizing the need for 
more sensitive and affordable assays.  
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In the Alu-gag PCR assay, the PCR1 step amplifies integrated HIV-1 DNA using one 
forward primer that is anchored to one of the Alu sequences that are randomly 
distributed within the human genome at approximately 5 kb distance from each other, 
and one reverse primer that binds the HIV-1 gag region located 1505 bp away from the 
5’LTR end ( 
Figure 7.1). This reaction is performed using the GoTaq polymerase enzyme (Promega, 
Southampton UK) that allows amplification of fragments that are maximum 5 kb long. 
Under these conditions, the 5kb long fragment would include 1505 bp on the viral 
genome plus 3495 bp on the human genome and this setting would therefore enable the 
amplification of all integrated HIV-1 DNA up to 3495 bp away from an Alu sequence. 
Published data indicated that this level of amplification represents 10% of the whole 
integration events. 
 
 
 
 
 
 
Figure 7.1 Primer combinations for Alu-gag and Alu-5LTR assays 
Figure depicting the different primers used in the Alu-gag and in the Alu-5LTR assay 
for the PCR1 step. agag reverse primer that binds HIV-1 genome at 1505-1486 bp; 
b5LTR reverse primer that binds HIV-1 genome at 647-628 bp. The black and the blue 
dashed lines represent 5kb long fragments. With the Alu-gag assay integration events 
that are up to 3495bp away from the human alu sequence can be amplified, whereas 
with the alu-5’LTR assay integration events that are up to 4236 bp from an alu sequence 
can be amplified. LTR= long terminal repeats. 
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In the study presented here we propose the use a different reverse primer for PCR1 that 
binds the HIV-1 genome 647 bp away from the 5’LTR end. By using the same GoTaq 
polymerase described above with these primer settings, the 5 kb long fragment would 
include 647 bp on the viral genome plus 4236 bp on the human genome. This would 
allow the amplification of all integration events that occur up to 4236 bp away from an 
Alu sequence. The new conditions will improve the previous method by amplifying 
integrated HIV-1 DNA genomes that are present between 3495 and 4236 bp away from 
the Alu sequence. 
7.1.2 METHODS AND RESULTS  
We set up experiments to test the use of a different PCR1 primer that binds to the 5’LTR 
region rather than the gag region of the HIV-1 genome. We also changed the primer 
and probe combination for the qPCR2, even if both settings targeted HIV-1 LTR region 
as described in Chapter 2. PCR cycles and mastermix conditions were kept constant. 
The quantification cycles (Ct) numbers obtained from the qPCR for each replicate (42 
for the integrated HIV-1 DNA and 30 for the HIV-1 control) were used as input into a 
pre-designed worksheet for quantification (De Spiegelaere et al., 2014) as per the 
established methodology. We compared results between the two assays by testing 
samples from four patients of the ERAS1 cohort and the results are shown in Figure 
7.2. The number of positive reactions within the integrated HIV-1 DNA replicates was 
three times greater when using the Alu-5LTR compared with Alu-gag assay (Figure 
7.2a). Furthermore, we analysed Ct values for each replicate. Results showed that the 
overall mean Ct values obtained with Alu-5LTR assay were lower than the ones 
obtained by Alu-gag (Figure 7.2b), which indicates an increased load of the target DNA, 
in our case the integrated HIV-1 DNA. Moreover, the single fluorescent curves for each 
sample produced with the Alu-5LTR assay lay in a larger range of Ct values compared 
to the curves produced by the Alu-gag assay (Figure 7.2c). The Ct values reflect the 
quantity of the target DNA, and in this assay the initial target DNA input is greater if 
the pre-amplification in the PCR1 step is more efficient. Greater variety of Ct values 
means that the assay is detecting a larger number of integrated HIV-1 DNA generated 
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by PCR1. This data confirms that the new method can detect more integration events, 
which have a different PCR efficiency as expected.    
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Figure 7.2 Results from the qPCR2 on the Alu-gag and Alu-5LTR PCR assays 
Y axis represent number of positive wells (a) or mean Ct values obtained from the integrated HIV-1 DNA wells (b); X axis= patients. a) number of 
positive wells and b) mean Ct values over 40 replicates. Black diamond represents results from Alu-gag whereas blue stars indicate Alu-3LTR. c) 
Representative graph with fluorescence curve for patient 3. Axis: Y=ΔRn; X=Ct(cycle numbers). 
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We wanted to further determine whether the greater detection with the Alu-5LTR assay 
was only a reflection of the new setting for the PCR1 or also for the PCR2. Therefore, 
we ran the same sample with the two qPCR2 settings. Data showed that positive wells 
detection with the two methods was identical, and the average Ct and the CUT-OFF 
values were comparable (Table 7.1). This result indicates that the increased integrated 
HIV-1 DNA detection obtained with the Alu-5LTR assay is probably not produced by 
the different conditions used in the qPCR2 step, but is a reflection of the new primer 
set used in the PCR1. 
 
 
Table 7.1 qPCR2 efficiency with Alu-gag and Alu-3LTR PCR assay settings 
 PCR2 settings 
 Alu-gag  Alu-5LTR  
Number of positive wells 8 8 
Average Ct values 34.80 36.89 
CUT-OFF 32.94 34.53 
   
 
Collectively our preliminary data on a new method for measuring integrated HIV-1 
DNA showed that we were able to achieve improved sensitivity of detection compared 
to the widely used Alu-gag assay. In our Alu-5LTR assay, we changed the settings for 
both PCR1 and qPCR2, whereas all the other conditions were kept as per the Alu-gag 
assay. Nonetheless, our data seems to indicate that the greater sensitivity was mostly 
driven by the changes in the PCR1 rather than the ones in the PCR2. 
7.1.3 DISCUSSION  
In this section we explored a new methodology to measure integrated HIV-1 DNA. In 
particular, we used an alternative primer set for the amplification PCR1 that binds HIV-
1 genome towards the HIV-1 integration site. This modification allowed us to detect 
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integration events that occurred around 4kb from an Alu sequence compared to the 
previous Alu-gag method that could only detect integrated HIV-1 DNA situated up to 
3kb distant from the Alu sequence. Our results were analysed with the Poisson 
distribution (De Spiegelaere et al., 2014) that calculates the copies of integrated HIV-1 
DNA based on the number of wells scored as positive for the presence of the target 
DNA, which in our case was the integrated HIV-1 DNA. Data showed that with the 
new method, the number of positive wells was three times higher than with the previous 
method demonstrating improved sensitivity of detection. 
 
De Spiegelaere and colleagues recently described a new method of quantification for 
the Alu-gag assay that enables absolute sample quantification without the use of serial 
dilution of a standard curve (De Spiegelaere et al., 2014). In this method, the Ct values 
obtained from a quantitative PCR (qPCR2) are inputted into a pre-designed calculation 
sheet that estimates the threshold Ct value above which one replicate is scored as 
positive (contains integrated HIV-1 DNA). The test is valid when at least 4 reactions 
are scored as positive. However this assay requires 70 replicates for each sample (with 
an estimated cost at around £80 per test) and considerable amounts of sample as 
reaction input. These two conditions are needed to compensate for the poor efficiency 
of the PCR1 that is ran prior to the quantitative PCR2 and its function is to amplify the 
region between the HIV-1 gag sequence and human Alu. In order to improve the PCR1 
step we proposed a new primer combination that targets the 5’ HIV-1 long terminal 
repeats (5’LTR) instead of the gag region. Consequently, we also had to change the 
primers for the quantitative qPCR2. Data produced by testing four patients on stable 
suppressive ART showed that we were able to detect greater number of wells that were 
scored as positive for the presence of the integrated HIV-1 DNA. This result indicated 
that the new primer set was able to amplify a greater number of integrated HIV-1 
genomes and this was further confirmed by the analysis on the Ct values produced by 
qPCR2. These values indicate the PCR cycle number at which the fluorescent signal 
produced by the amplification of one sample is higher than the fluorescent signal 
emitted by the passive reference, therefore, smaller Ct values are indicative of greater 
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sample concentration. We found lower Ct values in the samples ran with the Alu-5LTR 
assay compared with the ones produced with the Alu-gag assay, which means that 
integrated HIV-1 DNA load was higher. Furthermore, we wanted to determine whether 
the greater amplification was engendered by the modifications we introduced in the 
PCR1 or in the qPCR2. We therefore ran the qPCR2 on the sample using the settings 
of the Alu-5LTR assay as opposed to the settings used for the Alu-gag assay. We found 
identical results and this data allowed us to assume that the greater amplification was a 
reflection of improved sensitivity in the PCR1. 
 
The PCR1 serves to amplify specifically the integrated HIV-1 DNA. Integration sites 
are situated at heterogeneous distance from the Alu sequences that are randomly 
dispersed in the human genome at ~5kb distances from each other. Therefore, integrated 
HIV-1 may integrate up to 5kb from an Alu sequence. The polymerase used in this step 
can amplify up to 5kb long fragments and with the Alu-gag assay only integrations that 
are situated up to 3kb away from an Alu sequence can be amplified. We then thought 
to move this primer toward the end of the genome: in this way the 5kb long fragment 
produced by the polymerase could cover more human genome. As a result of this, we 
were able to detect integration events that occur up to 4kb away from an Alu sequence. 
A previous study described a two-step method for the quantification of integrated HIV-
1 DNA where the PCR1 was ran with a primer binding one region of the HIV-1 LTR 
very close to the one we targeted (Brussel et al., 2005). However, in that study the 
achieved detection limit that was lower compared to the Alu-gag assay. The 
discrepancy could derive from the fact that they used two outward-facing primers 
targeting the Alu sequence. This choice could have increased the linear amplification 
of the Alu sequences that are more abundant with respect to the HIV-1 sequence with 
direct consequences on PCR1 efficiency. Our study is adding to this by demonstrating 
improved sensitivity when using an amplification PCR setting that includes one single 
primer biding the HIV-1 LTR sequence and one primer biding the Alu sequence. 
Furthermore, we used an innovative quantitative method that was originally developed 
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to analyse results generated by the Alu-gag assay and that avoids the use of a standard, 
rendering the assay more applicable to a larger scale. 
 
Interestingly, we observed that samples ran with the Alu-5LTR assay had a greater 
heterogeneity in terms of Ct values obtained from each replicate. This data could be 
explained if we take into account that each single integration event carries its own 
efficiency of amplification (De Spiegelaere et al., 2014). Given that we are detecting 
more integration events it is likely that we were able to observe greater variety of PCR 
efficiency that is reflected by different Ct values between the replicates. We could also 
speculate that the different efficiency of amplification could be associated with different 
cell sub-populations within the PBMC that carry different amount of integrated HIV-1 
DNA copies; however, this hypothesis needs further investigation and cannot be 
concluded from our results.  
 
The results produced are preliminary and require further validation including running 
of a reference standard to determine assay sensitivity. Further assay modifications 
include evaluation of a reduced DNA input and consideration of reducing the number 
of replicates without affecting the Poisson statistics.  
7.2 Section B: In vitro system to study cell-to-cell transmission 
7.2.1 INTRODUCTION 
 
The integrated HIV-1 DNA reservoir persists despite effective antiretroviral therapy 
(ART) and the underlying mechanisms are still debated. It has been proposed cell-to-
cell virus transmission (Sigal et al., 2011) may contribute to the maintenance of the 
reservoir and potentially escape full suppression by ART. Retroviruses can initiate 
infection without requiring budding and extracellular release of free viral particles (Sato 
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et al., 1992), by transfer from the “donor” cell to the “target” cell via formation of a 
virological synapse (VS). This process has been described mainly in sites where cell 
density is high (Sigal et al., 2011), such as lymphoid tissue. Sigal and colleagues also 
proposed that cell-to-cell transmission is markedly less sensitive to the antiretroviral 
drugs tenofovir and efavirenz in vitro (Sigal et al., 2011) when compared to inhibition 
of cell-free virus. In the context of my research on HIV-1 persistence, there was scope 
to explore in vitro systems to study cell-to-cell HIV transmission in vitro.  
 
The aim of this set of experiments was therefore to develop an in vitro system to study 
cell-free and cell-to-cell virus transmission. Such a system should include a population 
of virus-donor cells and one of target cells, where the two cell types could be 
discriminated with confidence. The read out for the target cells could be the 
quantification of a viral protein intracellularly, or alternatively a reporter gene which is 
expressed only upon HIV-1 infection. Sigal and colleagues  described a method where 
donor cells were HLA-A2 negative peripheral mononuclear cells (PBMC) or 
fluorescent cells lines mCherry-MT4 cells, whereas target cells were HLA-A2 positive 
PBMC or Rev-CEM cells, which express green fluorescent protein (GFP) upon HIV-1 
transcription (Iyer et al., 2009, Wu et al., 2007). We decided to use this system as a 
starting point for our assay to try and replicate the system proposed by Sigal. This 
project included genetically modified organisms and it was approved by local safety 
committee and notified to HSE prior to start the work (HSE approval number: 
GM99/09.1a). 
7.2.2 METHODS AND RESULTS 
7.2.2.1 Lentiviral vectors production  
NL4-3 HIV (National Institute of Health (NIH) AIDS Research & Reference Reagent 
Program (cat# 114) and mCherry lentiviral vectors (provided by dr. Alex Sigal, PhD; 
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Division of Biology, California Institute of Technology) were produced by transfection 
of the relevant plasmids in HEK-293 that are listed in Table 7.2.  
 
 
 
Table 7.2 Plasmids characteristics 
Lentiviral 
vector 
Plasmid used Antibiotic 
selection 
(conc) 
Restriction 
enzymes used 
for validationa 
HIV-1 NL4-3 pNL4-3 Amp 
(0.1mg/ml) 
PstI; EcoRI 
mCherry 
lentivirus 
vector 
pHAGE6-wtCMV-mCherry-
W 
Amp 
(0.1mg/ml) 
HindIII; EcoRI 
HDM-Hpgm2 Amp 
(0.1mg/ml) 
HindIII; BamHI 
HDM-VSVG Amp 
(0.1mg/ml) 
HindIII; EcoRI 
The table summarizes the characteristics of the plasmid used to produce the lentiviral 
vectors. aall purchased by New England Biolabs, Hitchin, UK. conc=concentration.  
 
 
 
 
First, virus plasmids were amplified by transformation in Dh5α bacterial cells (Thermo 
Fisher scientific, Loughborough UK): plasmid DNA (10ng) was added to  
Dh5α cells (100µl) and incubated as described below: 
1. 30’ on ice; 
2. 90’’ at 37oC; 
3. 2’ on ice; 
30’ at 37oC after the addition of 800 µl of pre-warmed SOC (Thermo Fisher scientific 
Loughborough, UK). After centrifugation at 2,000xg for 1’, cell pellet was re-
suspended in ~100 µl prior to plate on LB agar plates (Sigma-Adrich, Poole Dorset UK) 
containing the relevant selective antibiotic as indicated in Table 7.2. After the overnight 
growth, the positive bacterial colonies were selected upon antibiotics resistance and 
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expanded by growing in LB broth (Sigma-Adrich, Poole Dorset UK) containing the 
relevant antibiotic selection. Plasmid DNA was then extracted with QIAprep spin 
minikit (Qiagen, Manchester UK) and each plasmid was treated with the relevant 
restriction enzyme (listed in Table 7.2) according to manufacturer instruction for 
validation Briefly, digestions reactions were performed by mixing 1 µg of DNA, 20 U 
of enzyme, 2 µl of enzyme buffer, and water to a final volume of 20 µl. Following 
digestion reaction for 1 hr at 37°C, the DNA fragments were separated by agarose gel 
electrophoresis and fragments sizes were compared to the ones obtained in silico by the 
analysis with NEBcutter v.02 free tool (a representative example is given in Figure 7.3).  
 
 
 
 
 
Figure 7.3 Example of validation of plasmid via restriction enzyme mapping 
The figure shows the restriction map (a) and the agarose gel electrophoresis (b) of 
pHAGE-EF1a-mCherry-W (1213). Total length of the plasmid was 5757 base pair (bp). 
The full length linear form of the plasmid was obtained by cut with EcoRI, whereas 
HindIII produced two segments at 3071 bp and 2686 bp.  
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Verified plasmids were then transfected into HEK-293 cells by using Fugene HD 
transfection reagent (Promega, Southampton UK), as described in Sigal et al. Briefly, 
0.2x106 HEK-293 (provided by prof Andrew Owen, University of Liverpool) adherent 
cells were seeded in DMEM growing media made up as described in Chapter 2. The 
day after, the relevant plasmid mixes (Table 7.3) were added to FuGENE® HD in Opti-
MEM® I Reduced Serum Medium (Thermo Fisher scientific, UK) and incubated 
for 15’ at room temperature prior to being added to the cell for 5 hrs incubation at 37oC 
and 5% CO2. After incubation, transfection media was replaced with fresh DMEM 
growing media. 
 
 
 
Table 7.3 Transfection mixes 
  Transfection mixa 
Lentiviral vector Plasmid used DNA  Fugeneb 
HIV-1 NL4-3 pNL4-3 5 µg 15 µl 
mCherry lentivirus vector 
pHAGE6-wtCMV-mCherry-W 2.5 µg 
12 µl HDM-Hpgm2 0.9 µg 
HDM-VSVG 0.6 µg 
a for 0.2x106 cells in 6 well plate. bDNA(µg):Fugene (µl)=1:3 
 
 
 
 
Virus was collected at 48 hours and virus titre was estimated by Lenti-X p24 Rapid titer 
kit as recommended from manufacturer (Takara Clonotech, Saint-Germain-en-Laye 
France) as described in Chapter 2. The results are shown in Table 7.4. 
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Table 7.4 Virus titre estimation by p24 Elisa assay 
Recombinant virus 
p24  
(ng/ml) 
Viral titre  
(lentiviral particles/ml) 
Lentivirus mCherry  25 3.6 x108 
HIV-1 NL4-3a 200 2.5 x10
9 
HIV-1 NL4-3b 1000 1010 
a after transfection; b at week4 after virus growing. 
 
 
 
 
We obtained p24 concentration of 25 ng/ml and 200 ng/ml for the mCherry lentivirus 
and NL4-3 HIV-1 virus, respectively; the results were in the range obtained from Sigal 
lab for the HIV-1 virus, but the mCherry lentivirus concentration was lower. The NL4-
3 HIV-1 virus titre was further increased by passaging in Rev-CEM cells: 200 ng p24 
and polybrene (8 µg/ml) (Pace et al., 2012) were added to the 2 ml of 107 cells and 
centrifuged at 1,000xg at room temperature (RT) for 2 hrs. After centrifugation, cell 
pellet was resuspended at a concentration of 2x106 cells/ml. Five million of fresh cells 
at 106 cells/ml concentration were added every 3 days. At week 4, p24 concentration 
was 1000 ng/ml ( Figure 7.4, plot) and such concentration was sufficient to run the 
desired assay (Sigal et al., 2011). 
7.2.2.2 Co-culture system I: MT4-mCherry cell line as donor cells and 
Rev-CEM as target cells.  
MT4 and Rev-CEM are T-cell lines; details on cell maintenance were given in Chapter 
2. Briefly cells were grown in suspension in RPMI-1640 prepared as described in 
Chapter 2. They were split twice a week depending on growth rate. 
 
MT4-mCherry cells were produced by infection of MT4 cells with mCherry lentivirus 
in order to produce mCherry+ MT4 cells: 106 MT4 suspension cells were infected with 
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supernatant containing virus that has been previously diluted 1:4. At 48 hrs after the 
infection, cells were fixed with 3.7% PFA solution and proportion of mCherry positive 
MT4 cells was estimated by flow cytometry. Results showed that 3.6% of MT4 cells 
expressed mCherry protein ( Figure 7.4a). 
 
Rev-CEM cells are engineered to produce green fluorescent protein (GFP) upon HIV-
1 infection. Prior to use in the assay, we first tested GFP production upon HIV-1 
infection: this step was critical to allow discrimination between infected and non-
infected target cells. Rev-CEM cells were infected with NL4-3 HIV (1.7x105 cells and 
113 ng p24) (Sigal et al., 2011), or mock-infected with the same volume of growth 
medium. At 24, 48 and 52 hours post infection (Sigal et al., 2011), we checked cell 
viability and GFP expression by flow cytometry and microscopy. Cells were washed 
twice in 1 ml of PBS and centrifugation at 300xg for 5’ at room temperature. After the 
last wash, cells were resuspended in 500 µl of 3.7% formaldehyde in PBS. Half of the 
volume was used for flow cytometry analysis, whereas the other half was processed for 
microscopy analysis. Briefly, cell suspension was centrifuged by CytospinTM 4 
Cytocentrifuge (Thermo Fisher scientific, UK) to allow thin layer cell preparation on 
the slide. Vectashield mounting media (Vector Laboratories, Peterborough UK) was 
applied between cover slip and slide in order to minimize quenching and the slides were 
sealed with nail polish. Images were collected using a Zeiss LSM 510 META detector 
and analysed using the Zeiss AIM software (Zeiss, Germany) in collaboration with Dr. 
Marco Marcello at the centre for cell imaging at the University of Liverpool. 
 
Results showed that cell viability was overall >90% and around 80% in mock-infected 
and HIV-1 infected cells, respectively ( Figure 7.4b). We observed that the proportion 
of cells expressing GFP was 8.1% at 24 hours; 8.8% at 48 hrs; and 14.5% at 52 hours 
(Figure 7.4c), which indicated that GFP production increased with virus growing as 
expected. Furthermore we analysed cells by immunofluorescence and we observed that 
mock-infected cells had green and red fluorescence which was unexpected (Figure 7.5).
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Figure 7.4 Validation of MT4-mCherry and Rev-CEM cell lines 
Bar chart representing a) mCherry expression in MT4 cells at 48 hrs after infection with the mCherry lentivirus; b) Rev-CEM viability and c) GFP production 
at 24, 48, 52 hrs after infection with NL4-3 HIV-1 virus. Red pattern bars= MT4 cells that express mCherry; white pattern bars= mock infected cell; black 
bars= NL4-3 HIV-1 infected cells. One single experiment. 
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Figure 7.5 Characterization of Rev-CEM by immunofluorescence 
DIC= Differential interference contrast; RED+= red channel; GREEN+= green 
channel. Bar= 50µm. 
 
 
 
This data on the development of a co-culture system showed that we obtained 3.7% 
mCherry+ MT4 cells and we observed that Rev-CEM cells expressed GFP production 
upon virus infection by flow cytometry. However, microscopy analysis showed 
fluorescence signal in absence of infection in Rev-CEM, which meant that those cells 
could not be used for fluorescent assays because the read-out was biased by the auto-
fluorescence produced by the cells per se. 
 
7.2.2.3 Co-culture system II: HLA-A2 negative PBMC as donor cells 
and HLA-A2 positive PBMC as target cells.  
We further used co-cultures of infected PBMC to induce cell-to-cell spread as described 
in Sigal et al. 2011. Donors with HLA-A2 positive and negative phenotypes were 
enrolled within the Institute of Infection and Global Health and signed written consent 
form prior to participate to the study. Blood was collected in Heparin tubes and 
processed fresh to isolate peripheral blood mononuclear cells (PBMC) as described in 
Methods. Isolate cells were then cultured for 3 days in RPMI growing media in the 
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presence of 5 µg/ml of Pha-p (Sigma, UK) to ensure cell activation and maintained in 
RPMI growing media supplemented with 100 U/ml of human interleukin-2 (IL-2, 
Miltenyi Biotec Ltd., Bisley UK). The co-culture assay was performed as described by 
Sigal et al. Briefly, 1.5 x 106 HLA-A2-negative PBMC were first infected with HIV-1 
NL4-3 (700 ng of p24); at 2 days after the infection the HLA-A2-negative PBMC 
(donor cells) were washed, counted, diluted to 106 cells/ml and added to HLA-A2-
positive PBMC (target cells) at an approximately 1:10 donor:target ratio. Target cells 
were also directly infected with NL4-3 (250 ng of p24). Two days after target-cell 
infection, the number of infected target cells was determined by flow cytometry by 
staining the intracellular p24 viral protein. Briefly, cells were first incubated with HLA-
A2 PE-conjugated antibody, washed in PBS as described above and fixed in 3.7% PFA; 
following incubation cells underwent intracellular staining with anti p24 FITC-
conjugate antibody. Donor and target cells were discriminated based upon HLA-A2 
expression and cells that were PE positive were defined as target cells. HIV-1 infection 
was estimated upon intracellular p24 expression and FITC positive cells were 
considered as infected. Results are shown in Figure 7.6. At 2 days post infection, donor 
cells were 70% alive and we judged this viability to be good enough to proceed with 
the co-culture assay (Figure 7.6 a). Analysis of the target cells showed that target cell 
viability was 70% and 60% in direct infection and co-culture conditions, respectively 
(Figure 7.6b). Infection rate was 17% in cell-free infection condition compared to 7% 
in the co-culture assay (Figure 7.6c) which was in the range published by Sigal et al.   
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Figure 7.6 Co-culture assay in PBMC 
a) viability of donor cell after 48 hr of infection with NL4-3 HIV prior to co-culture with target cells; b) Target cells viability after 48 hrs of 
co-culture; c) infection rate after co-culture or cell-free infection. White bars=infection with 0 ng p24 input; black bars=infection with 700 ng p24 
input. One single experiment. 
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7.2.3 DISCUSSION 
We present preliminary methodological developments for an in vitro assay to study 
cell-to-cell HIV-1 infection, based upon a publication from 2013 that proposed that 
commonly used antiretrovirals were less effective against cell-to-cell transmission 
when compared to inhibition of replication of cell free virus. In this previous study two 
systems were proposed for the cell-to-cell viral infection. One system used engineered 
cells lines to act as virus donor and target cells, whereas another used HLA-A2 pseudo-
typed PBMC.  
 
In the first system, MT4-mCherry cells were used as virus donor cells whereas Rev-
CEM cells were used as target cells. We first produced the MT4-mCherry cells by the 
infection of the MT4 cells with a lentivirus that carries the fluorescent protein. Our data 
showed that only 3.7% of cells expressed mCherry protein and this result was not 
consistent with the Sigal paper where the proportion of mCherry+ cells was higher at 
levels >90%. The discrepancy might have derived from different efficiencies of the 
infection with the lentivirus; we concluded that further optimization of the infection 
conditions was needed. We then tested the ability of the Rev-CEM to produce GFP 
upon viral infection. Data produced by flow cytometry showed that 7% of cells 
expressed GFP at 48 hrs after the infection and that the expression increased over time, 
in line with one previous study (Wu et al., 2007). Of note, we tested the Rev-CEM cells 
by microscopy and found that cells showed auto-fluorescence in the red and green 
channel in absence of any infection. This was not checked or reported by Sigal and 
colleagues. This finding needs further investigation including testing different fixing 
and mounting conditions that might affect the photo-bleaching of the slides. From this 
first set of data we concluded that Rev-CEM efficiently produced GFP upon virus 
infection at 48 hours after infection and that further optimization was needed for the 
production of the MT4-mCherry stable cell line.  
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We further developed the co-culture system by using HLA-A2 negative (donor cells) 
and positive (target cells) PBMC. We infected donor cells with the recommended viral 
dose and following assessment of viability we used them to infect the target cells. 
Results showed that target cells had 17% and 7% infection rate when cells were infected 
by cell-free virus or co-culture with donor cells, respectively. For the cell-free infection, 
we obtained higher levels of infection compared to Sigal et al., which had 7.6% of 
infected cells, whereas cell-to-cell infection showed lower infection rate compared to 
Sigal et al. which obtained 8% of infected cells. Given the limited set of data we could 
draw limited conclusions; nonetheless we obtained cell-free and cell-to-cell virus 
transmission in a primary cell system. Further optimization is needed for this assay to 
be used for further testing. 
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8 Chapter 8: General discussion and future directions 
Current ART is unable to eradicate HIV that persists in sanctuary sites such as lymphoid 
organs, and the nervous system as well as in peripheral blood (Sturdevant et al., 2015, 
Palmer et al., 2008, Chun et al., 2008). This virus reservoir contains a pool of competent 
viruses that can fuel viral rebound when ART is stopped (Finzi et al., 1997, Finzi et al., 
1999, Wong et al., 1997, Alexaki et al., 2008, Chun et al., 1997b). The mechanisms that 
contribute to maintenance of the viral reservoir are still debated. Some previous studies 
showed the influence of immunological activation and inflammation (Hatano et al., 
2013, Cockerham et al., 2014, Malatinkova et al., 2015), drugs levels (Fletcher et al., 
2014), and patient’s characteristics such as ethnicity (Keiser et al., 2002, Hodder et al., 
2012) on virological outcome and HIV-1 persistence in patients with a wide range of 
different ART regimens. In this context, I studied the characteristics associated with 
HIV-1 persistence in blood measured as residual HIV-1 RNA, 2-LTR circular DNA 
and total HIV-1 DNA in a large population of patients with continuous viral load 
suppression (HIV-1 RNA<50 copies/ml) without evidence of transient elevations of 
viremia above 50 HIV-1 RNA copies/ml while on ART with 1NNRTI plus 2NRTIs. 
 
We first studied levels of HIV-1 in plasma and PBMC and we found detection of both 
HIV-1 DNA and RNA in line with previous studies (Besson et al., 2014, Chomont et 
al., 2009, Palmer et al., 2008, Kiselinova et al., 2015, Malatinkova et al., 2015). The 
significance of residual HIV-1 RNA levels in stably suppressed patients is not clearly 
defined. It is still controversial as to whether detection of low HIV-1 RNA copies 
reflects ongoing virus replication (Palmer et al., 2008, Maldarelli et al., 2007) in 
sanctuary sites or if it arises from intermittent viral production which is quickly 
suppressed by ART (Kiselinova et al., 2015, Fourati et al., 2014). The two mechanisms 
are not mutually exclusive. Two previous studies showed a positive association 
between residual HIV-1 DNA and total HIV-1 DNA that could indicate the presence of 
virus replication in the blood. Conversely, Bailey et al. showed that residual HIV-1 
RNA is dominated by viral clones that are profoundly unrepresented in peripheral blood 
cells indicating that an additional source of residual viremia might be present (Bailey 
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et al., 2006, Eriksson et al., 2013, Lorenzo-Redondo et al., 2016, Fletcher et al., 2014). 
Our study adds onto this by showing lack of association between residual HIV-1 RNA 
and levels of total or integrated HIV-1 DNA in PBMC. Our data may support the view 
that the source of residual HIV-1 RNA could not directly be represented by the viral 
reservoir contained in the blood. 
 
In the context of the study of factors that may support the virus persistence, the immune 
system has been identified as a possible player. Previous studies have shown a positive 
association between cellular total HIV-1 DNA and markers of cellular immune 
activation in blood of patients with virologic suppression on heterogeneous ART 
treatments (Cockerham et al., 2014, Hatano et al., 2013). Our results showed a strong 
positive association between activated CD8 T-cells and both total and integrated HIV-
1 DNA in a population of patients on ART with the same NNRTI plus 2 NRTIs. Further 
to this, residual HIV-1 RNA was not associated with any markers of cellular immune 
activation in line with previous studies (Hatano et al., 2013), but we found a positive 
association with plasma levels of sCD27, which is a marker of T cell activation (Lens 
et al., 1998, Huang et al., 2013). We could propose that similar mechanisms are driving 
CD8 and CD4 T-cells activation in peripheral blood and possibly reflects activation in 
lymphoid tissue. HIV-1 infected activated cells may expand in blood resulting in 
integrated HIV-1 DNA load increase; at the same time, activated cells may drive HIV-
1 replication in sanctuary sites (Fletcher et al., 2014, Lorenzo-Redondo et al., 2016) 
resulting in an indirect association between markers of immune activation and HIV-1 
DNA and RNA. In this context, it would be of extreme interest to study levels of soluble 
and cellular markers of immune activation in lymphoid tissues in relation to HIV-1 
replication.  
 
Furthermore it remains to be determined whether circulating CD4 T-cells carry 
replication competent or incompetent virus (Ananworanich and Mellors, 2015). Events 
of abortive virus integration following infection can be tracked by studying the 
unintegrated HIV-1 DNA forms including 2-LTR circular HIV-1 DNA. In our 
population, only a small proportion of patients showed low levels of 2-LTR circular 
HIV-1 DNA and this was in line with previous works (Besson et al., 2014, Malatinkova 
et al., 2015). Additionally, we found no association between 2-LTR circular HIV-1 
DNA and any markers of immune activation or virus replication. Of note, 2-LTR 
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circular HIV-1 DNA was historically defined as a short-live marker of recent 
replication, but some studies (Agosto et al., 2011, Pace et al., 2013) questioned its 
stability. Whilst our data may indicate that HIV-1 replication is reduced in peripheral 
blood confirming viral control by ART, the role and significance of 2-LTR circular 
HIV-1 DNA during suppressive therapy needs further investigation. 
 
In this thesis, the integrated HIV-1 reservoir load was significantly predicted by the 
pre-ART viral load which confirms previous studies demonstrating that the viral 
reservoir is established early after infection and it is stable during ART. In line with 
this, recent results from the START trial demonstrated that early treatment initiation 
limits the extent of the viral reservoir and generally improves therapy outcome (Group 
et al., 2015). Based on these results, it is likely that early treatment initiation will 
become the standard clinical practice in future to start ART irrespectively of CD4 T-
count (Ryom et al., 2016). In this context, the identification of methodological tools 
capable of ultrasensitive detection of markers of HIV-1 persistence is needed.  
 
The study on patients switching from Atripla to Eviplera that we performed, showed 
that monitoring residual HIV-1 RNA levels in plasma increases the possibility of 
detecting virologic rebound during treatment switch; therefore similar approaches 
could be taken into consideration in intervention strategies. Moreover, we proposed an 
innovative method to measure integrated HIV-1 DNA reservoir that showed higher 
sensitivity compared to all previous published assays. Of note, previous assays were 
not only less sensitive but also relatively expensive given the high number of replicates 
that was needed for each test to allow quantification. Greater sensitivity could be 
translated into a cheaper price with the possibility of reducing the number of replicates 
needed for testing. Furthermore, the assay could be tested with lower DNA input per 
reaction to reduce the amount of clinical specimen required for the test. The results 
presented in this thesis are promising and encourage further testing to ensure clinical 
applicability.  
 
As discussed previously in this dissertation, lymphoid tissues play a central role in 
maintaining the HIV-1 reservoir supporting viral replication and cell-to-cell virus 
transmission in the context of sub-optimal drug penetration. Innovative drugs 
formulation, such as nanomedicines (McDonald et al., 2014, Tatham et al., 2015), 
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showed improved oral bioavailability. There could be scope to test whether the 
bioavailability is translated also into improved drug penetration in different tissues. In 
this scenario, the development of in vitro assays will be needed. Our preliminary results 
validated a set of useful tools that represent the potential starting point for the setting 
up of such systems. 
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ABSTRACT 
Background: Characterising the correlates of HIV persistence improves understanding 
of disease pathogenesis and guides the design of curative strategies. This study 
investigated factors associated with integrated HIV-1 DNA load during consistently 
suppressive first-line antiretroviral therapy (ART).  
Method: Total, integrated, and 2-long terminal repeats (LTR) circular HIV-1 DNA, 
residual plasma HIV-1 RNA, T-cell activation markers, and soluble CD14 (sCD14) 
were measured in peripheral blood of 50 patients that had received 1-14 years of 
efavirenz-based or nevirapine-based therapy. 
Results: Integrated HIV-1 DNA load (per 106 peripheral blood mononuclear cells) was 
median 1.9 log10 copies (interquartile range 1.7-2.2) and showed a mean difference of 
0.2 log10 copies per 10 years of suppressive ART (95% confidence interval -0.2, 0.6; 
p=0.28). It was positively correlated with total HIV-1 DNA load and frequency of 
CD8+HLA-DR/DP/DQ+ cells, and was also higher in subjects with higher sCD14 
levels, but showed no correlation with levels of 2-LTR circular HIV-1 DNA and 
residual plasma HIV-1 RNA, or the frequency of CD4+CD38+ and CD8+CD38+ cells. 
Adjusting for pre-ART viral load, duration of suppressive ART, CD4 cell counts, 
residual plasma HIV-1 RNA levels, and sCD14 levels, integrated HIV-1 DNA load was 
mean 0.5 log10 copies higher for each 50% higher frequency of CD8
+HLA-DR/DP/DQ+ 
cells (95% confidence interval 0.2, 0.9; p=0.01).  
Conclusions: The observed positive association between integrated HIV-1 DNA load 
and frequency of CD8+HLA-DR/DP/DQ+ cells indicates that a close correlation 
between HIV persistence and immune activation continues during consistently 
suppressive therapy. The inducers of the distinct activation profile warrant further 
investigation. 
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Research into context 
Evidence before this study. We searched PubMed for studies describing the 
relationship between integrated HIV-1 DNA load and markers of immune activation 
during antiretroviral therapy (ART). The last search was completed in April 2015. The 
search terms comprised combinations of [HIV, DNA, integrated] plus [CD8, activation, 
DR, HLA, CD38, CD14]. References cited in the selected papers were searched 
manually. The published data indicated that integrated HIV-1 DNA load remains 
constant in peripheral blood of subjects receiving long-term ART. Two studies 
described a positive association between total HIV-1 DNA load in peripheral blood 
mononuclear cells (PBMC) and frequency of CD8 cells expressing HLA-DR; one of 
the two studies also investigated integrated HIV-1 DNA load in relation to CD8+HLA-
DR+ cells in 19 subjects, with inconsistent results. 
Implications of all the available evidence. The mechanisms that prevent the decay of 
the integrated HIV-1 DNA reservoir during long-term suppressive ART remain 
unclear. Two main hypotheses are proposed. The first suggests that incomplete 
therapeutic efficacy allows ongoing virus replication and replenishment of the 
reservoir. The second hypothesis suggests that proliferation of infected CD4 T-cells 
causes expansion of integrated HIV-1 DNA, without requiring or leading to virus 
production. In the second model, factors that promote proliferation of infected CD4 T-
cells favour HIV persistence.  
Added value of this study. We studied a relatively homogenously treated population 
that was sampled cross-sectionally in recruitment strata defined by the duration of 
suppressive ART. Key eligibility criteria were continuation of the initial non-
nucleoside reverse transcriptase inhibitor (NNRTI) and consistent plasma HIV-1 RNA 
suppression <50 copies/ml during follow-up ranging between one and 14 years. 
Confirming previous observations, integrated HIV-1 DNA load did not differ 
significantly according to the duration of suppressive ART.  Integrated HIV-1 DNA 
load was also not associated with direct or indirect markers of virus replication, 
including levels of residual HIV-1 RNA in plasma and 2-long terminal repeats (LTR) 
circular HIV-1 DNA in PBMC, and frequency of CD4 and CD8 cells expressing the 
activation marker CD38 in peripheral blood. Rather, there was an independent, positive 
linear association between integrated HIV-1 DNA load and the frequency of CD8 cells 
expressing the activation marker HLA-DR/DP/DQ. These cells appear to have 
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important regulatory and effector function. Our findings add to growing evidence that 
immune activation sustains the HIV-1 reservoir during long-term suppressive ART.  
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INTRODUCTION 
Early after transmission, HIV establishes a reservoir of replication-competent 
integrated provirus that resides predominantly within memory CD4 T cells, is 
unresponsive to antiretroviral therapy (ART), and rapidly fuels resumption of virus 
replication upon treatment discontinuation (Ruelas and Greene, 2013, Soriano-Sarabia 
et al., 2014, Siliciano et al., 2003). The mechanisms underlying HIV persistence have 
not been fully elucidated and proposed models are not mutually exclusive. Continuous 
replenishment of the reservoir may occur through ongoing virus production (Hatano et 
al., 2013, Buzon et al., 2010), perhaps in sites where ART penetration or activity is 
suboptimal (Fletcher et al., 2014). In the absence of virus production, maintenance of 
the reservoir can also occur through proliferation of latently infected CD4 T-cells, as a 
possibly key determinant of HIV persistence during ART (Maldarelli et al., 2014, 
Josefsson et al., 2013, Chomont et al., 2009, Wagner et al., 2014). 
 
HIV replication causes chronic immune activation and inflammation, typically 
accompanied by an expansion of CD8 T-cells, which improve but rarely resolve with 
ART (Klatt et al., 2013). Persistent HIV production or partial antigenic expression may 
drive ongoing immune activation in treated patients. In turn, immune activation can 
promote T-cell proliferation, HIV transcription, and virus production (Klatt et al., 
2013). Furthermore, early in the course of the infection, HIV-induced gut damage 
allows translocation of gastrointestinal microbial products into the systemic circulation, 
and the resulting immune activation causes further gut damage, establishing a self-
perpetuating cycle that can become independent of virus production (Shan and 
Siliciano, 2014). Other persistent infections, for example with cytomegalovirus (CMV), 
have also been linked with ongoing immune activation despite suppressive ART 
(Gianella et al., 2014).  
 
There are inconsistent data on how markers of immune activation correlate with 
parameters of HIV persistence during long-term suppressive therapy, possibly a 
consequence of heterogeneous study populations and measures of HIV persistence, but 
also a reflection of complex bilateral interactions (Hatano et al., 2013, Chun et al., 2011, 
Cockerham et al., 2014). There remains a need to characterise this relationship further 
in order to improve our understanding of HIV pathogenesis and design improved 
curative strategies. The aim of this study was to investigate factors associated with the 
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levels of integrated HIV-1 DNA measured in peripheral blood during stably suppressive 
ART, including the relationship with markers of immune activation. Efforts were taken 
to minimise heterogeneity of the study population, by exclusively selecting patients 
who started first-line ART with two nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI), 
achieved a plasma HIV-1 RNA (“viral”) load <50 copies/ml within six months of 
starting ART, and subsequently showed consistent viral load suppression <50 copies/ml 
over up to 14 years of continuous treatment on the same NNRTI.  
 
METHODS 
Study population  
Study subjects were recruited at clinical centres across the United Kingdom (see study 
group). Eligible patients had started first-line ART with two NRTIs plus efavirenz or 
nevirapine, achieved viral load suppression <50 copies/ml within six months of starting 
therapy, and subsequently showed all viral load measurements <50 copies/ml while 
undergoing 2 viral load measurements per year, without transient elevations above 50 
copies/ml or treatment interruptions. Changes of the initial NNRTI were not allowed. 
Changes of the initial NRTI (e.g., for toxicity) were allowed provided they were not 
associated with a treatment interruption or viral load rebound >50 copies/ml. 
Recruitment was stratified by duration of ART to range from 1 to over 10 years. The 
study was approved by National Research Ethics Service (London-Dulwich) and was 
included in the National Institute for Health Research Clinical Research Network 
(NIHR CRN) Portfolio. All patients provided written informed consent. 
 
Quantification of residual HIV-1 RNA in plasma 
Plasma HIV-1 RNA below 50 copies/ml was quantified using a modified version of the 
Abbott RealTime HIV-1 assay (Maidenhead, UK), following ultracentrifugation of 8 
ml of plasma at 215,000g for 45’ at 4oC, and resuspension of the pellet in 1ml of 
basematrix (SeraCare, USA). Each run included negative, low positive, and high 
positive controls. Assay sensitivity was determined by spiking HIV-negative plasma 
with four dilutions of the World Health Organisation (WHO) 3rd International Standard 
for HIV-1 RNA in triplicate (NIBSC code:10/152, Hertfordshire, UK). The assay 50% 
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and 95% detection rates for 8 ml input were 1 and 3 HIV-1 RNA copies/ml, 
respectively. 
 
 
HIV-1 subtyping 
The HIV-1 subtype was determined using polymerase sequences obtain from HIV-1 
DNA recovered from PBMC, as previously described (16).   
 
Quantification of total, integrated and 2-LTR circular HIV-1 DNA in peripheral 
blood mononuclear cells 
Total HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) was determined 
by a quantitative real-time PCR targeting a conserved LTR region as previously 
described (Geretti et al., 2013). The assay 50% and 95% detection rates were 20 and 40 
HIV-1 DNA copies/106 PBMC, respectively. Integrated HIV-1 DNA was quantified by 
repetitive-sampling Alu-PCR as previously described (De Spiegelaere et al., 2014) 
using the primers shown in Supplementary Table 1. Briefly, 42 replicate Alu-HIV-1 
PCR amplifications were performed with gag reverse HIV-1 primer and Alu forward 
primer for integrated HIV-1 DNA, and 32 replicates with only HIV-1 gag primers for 
unintegrated HIV-1 DNA. After amplification, the first PCR product was subjected to 
a nested quantitative PCR targeting the HIV-1 LTR RU5 region. The integrated HIV-1 
DNA copy number was calculated according to Poisson’s principles with error 
estimation including the Wilson method (www.integratedhivpcr.ugent.be). Four Alu-
HIV positive wells were required as output to allow reliable quantification. 2-LTR 
circular HIV-1 DNA levels were measured by droplet digital PCR as previously 
described (Strain et al., 2013); the lower limit of detection was median 5 copies/106 
PBMC (interquartile range, IQR 4-6).  
 
Markers of immune activation 
Cellular markers were measured by staining freshly isolated PBMC with PE or FITC 
labelled antibodies against CD4 plus either CD26, CD38, or CD69, and against CD8 
plus either CD38 or HLA-DR/DP/DQ (Serotec, Oxford, UK; Becton Dickinson, NJ, 
USA). Cell suspensions were fixed with 1% paraformaldehyde (PFA) prior to 
acquisition using FACScan and analysis by CellQuest software version 3.3 (Becton 
Dickinson NJ, USA). Soluble CD14 (sCD14) as a marker of bacterial 
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lipopolysaccharide (LPS)-induced monocyte/macrophage activation was measured in 
plasma by enzyme-linked immune-enzymatic assay (ELISA) (R&D System sCD14 
ELISA, Abington, UK).  
 
Detection of cytomegalovirus and Epstein-Barr virus DNA  
Plasma was tested for CMV and Epstein-Barr Virus (EBV) DNA with a real-time PCR 
assay targeting the viral UL123/UL55 and p143 regions, respectively. The lower limits 
of detection were 50 IU/ml for CMV DNA and 100 copies/ml for EBV DNA. 
 
Statistical analysis 
Duration of suppressive ART was defined as the length of time following the first viral 
load measurement <50 copies/ml recorded after starting ART. The characteristics of 
the study population stratified into two groups based upon duration of suppressive ART, 
integrated HIV-1 DNA load, or frequency of CD8+HLA-DR/DP/DQ+ cells were 
compared using non-parametric Wilcoxon and Mann-Witney tests for continuous 
variables, and the Fisher’s exact test for categorical variables. Where the analyses 
required variables to be expressed in median levels, undetectable HIV-1 RNA results 
were given an arbitrary midpoint value between zero and the assay 95% detection rate 
(=1.5 copies/ml), whereas undetectable 2-LTR circular HIV-1 DNA results were 
assigned a midpoint value between zero and the assay median lower limit of detection 
(=2.5 copies/106 PBMC). Mean differences (with 95% confidence interval, CI) in 
measured residual plasma HIV-1 RNA, 2-LTR circular HIV-1 DNA, total and 
integrated HIV-1 DNA, sCD14, and frequency of activated CD4 and CD8 cells over 10 
years of suppressive ART were analysed by univariate linear regression analysis after 
log transformation of the variables. The correlation between integrated HIV-1 DNA 
load or frequency of CD8+HLA-DR/DP/DQ+ cells and other measured parameters was 
explored by the Spearman’s test. The association between integrated HIV-1 DNA load 
and other variables was characterised further by univariate and multivariable linear 
regression modelling. A ‘best subset’ approach and the Mallow Cp test were used for 
the selection of variables to be included in the multivariable model. All available 
variables were initially considered for inclusion, with the exception of gender and 
NNRTI use (due to predominance of males and efavirenz use: 40/50, 80% for both 
variables) and total HIV-1 DNA load (due to strong co-linearity with integrated HIV-1 
DNA load). Pre-ART viral load (Cp value 3.5), duration of suppressive ART (3.6), 
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residual plasma HIV-1 RNA load (3.6), frequency of CD8+HLA-DR/DP/DQ+ cells 
(0.4), and sCD14 levels (1.7) were identified for inclusion in the multivariate model. 
The CD4 cell count was added to the multivariable model as a possible confounding 
factor. In a second multivariable model, nadir CD4 count was included instead of pre-
ART viral load. A sensitivity analysis was also performed replacing integrated with 
total HIV-1 DNA as the outcome variable in the same two models. The analyses were 
performed with SAS 9.4. 
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RESULTS 
Study population  
The cohort comprised 50 patients who at the time of sampling were receiving two 
NRTIs plus either efavirenz (80%) or nevirapine and had a median duration of viral 
load suppression <50 copies/ml of 6.4 years (Table 1). Patients with duration of 
suppressive ART above the median of 6.4 years were older and had a lower nadir CD4 
cell count, a marginally higher current CD4 cell count, and lower frequencies of CD4 
and CD8 cells expressing CD38 relative to subjects with shorter duration. They were 
also more likely to have experienced changes in the composition of the NRTI backbone 
after first starting ART. Overall 25/50 patients (50%) changed one or more component 
of the NRTI backbone, with median 1 drug change per subject (IQR 0-1). At the time 
of sampling, NRTI backbones were tenofovir/emtricitabine (37/50, 74%), 
abacavir/lamivudine (10/50, 20%), or zidovudine/lamivudine (3/50, 6%). Residual 
plasma HIV-1 RNA was detected in 29/50 patients (58%) at levels ranging between 1 
and 35 copies/ml, whereas 2-LTR circular HIV-1 DNA was detected in 16/50 patients 
(32%) at levels ranging between 5 and 35 copies/106 PBMC. All subjects had detectable 
HIV-1 DNA, with total and integrated HIV-1 DNA levels of median 2.6 and 1.9 log10 
copies/106 PBMC, respectively. None of the patients had detectable CMV DNA in 
plasma, whereas 3/50 patients (6%) had detectable EBV DNA.  
 
Differences in measured parameters per 10 years of suppressive ART were determined 
by linear regression analysis of data obtained from the cross-sectional sampling (Table 
2). Longer duration of suppressive ART was associated with higher CD4 cell counts 
and lower levels of CD38 expression on CD4 and CD8 cells. There were also lower 2-
LTR circular HIV-1 DNA levels and a trend for lower residual HIV-1 RNA levels. A 
sub-analysis compared subjects with integrated HIV-1 DNA load either in the lowest 
quartile (<1.7 log10 copies/10
6 PBMC) or the highest quartile (>2.2 log10 copies/10
6 
PBMC) (Table 3). Subsets in the lowest quartile showed significant lower levels of total 
HIV-1 DNA and sCD14, and lower frequency of CD8+HLA-DR/DP/DQ+ cells. 
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Table 1. Characteristics of the study population overall, and stratified by duration of suppressive therapy as below 
(Group I) or above (Group II) the median of 6.4 years  
 
aDefined as the length of time following the first viral load <50 copies/ml; it ranged between 0.7 and 6.4 years in Group 1, and between 6.4 and 14.4 years in 
Group II. bSamples with undetectable HIV-1 RNA were assigned an arbitrary value of 1.5 copies/ml. cSamples with undetectable 2-LTR circular HIV-1 DNA 
Characteristic Total (n=50) Group I (n=25) Group II (n=25) P  
Male n (%) 40 (80) 22 (88) 18 (72) 0.29 
Age median years (IQR) 46 (40-53) 44 (36-49) 48 (43-55) 0.04 
HIV-1 subtype B n (%) 32 (64) 18 (72) 14 (56) 0.38 
Nadir CD4 count median cells/mm3 (IQR) 206 (110-265) 246 (160-292) 176 (97-213)   0.007 
Duration of ART median years (IQR) 6.7 (3.4-9.1) 3.4 (2.5-5.0) 9.2 (8.0-10.3) <0.001 
Duration of suppressive ART median years (IQR)a 6.4 (3.1-8.8) 3.1 (2.1-4.8) 9.0 (7.7-10.0) <0.001 
Efavirenz as initial NNRTI n (%) 40 (80) 22 (44) 18 (36) 0.29 
Changed NRTI backbone n (%) 25 (50) 4 (16) 21 (84) <0.001 
Pre-ART HIV-1 RNA median log10 copies/ml (IQR) 5.0 (4.7-5.5) 4.8 (4.5-5.3) 5.1 (4.9-5.6) 0.09 
Detectable residual plasma HIV-1 RNA n (%)  29 (58) 15 (60)  14 (56)  1.00 
Residual HIV-1 RNA median copies/ml (IQR)b  2 (2-4) 2 (2-7) 2 (2-4) 0.33 
Detectable 2-LTR circular HIV-1 DNA n (%)  16 (32) 10 (40) 6 (25) 0.36 
2-LTR circular HIV-1 DNA median copies/106 PBMC (IQR)c 3 (3-7) 3 (3-7) 3 (3-5) 0.28 
Total HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 2.6 (2.3-2.9) 2.6 (2.4-2.9) 2.5 (2.2-2.7) 0.36 
Integrated HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 1.9 (1.7-2.2) 1.9 (1.7-2.1) 1.8 (1.7-2.4) 0.91 
CD4 count median cells/mm3 (IQR) 572 (478-734) 552 (442-606) 640 (502-794) 0.05 
CD4+CD26+ median percentage (IQR) 54 (43-63) 54 (42-63) 54 (44-63) 0.55 
CD4+ CD38+ median percentage (IQR) 22 (17-34) 25 (21-35) 20 (14-24) 0.02 
CD4+CD69+ median percentage (IQR) 2 (1 -2) 1 (1-3) 2 (1-2) 0.48 
CD8+CD38+ median percentage (IQR) 5 (3-7) 6 (3-8) 4 (3-6)  0.04 
CD8+HLA-DR/DP/DQ+ median percentage (IQR) 32 (20-48) 37 (22-53) 30 (16-42) 0.19 
sCD14 median μg/ml (IQR) 2.2 (1.8-2.6) 2.0 (1.6-2.6) 2.2 (2.0-2.7) 0.16 
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were assigned an arbitrary value of 2.5 copies/106 PBMC. IQR= interquartile range; ART= antiretroviral therapy; NRTI= nucleoside/nucleotide reverse 
transcriptase inhibitor; NNRTI= non-nucleoside reverse transcriptase inhibitor; PBMC= peripheral blood mononuclear cells; sCD14= soluble CD14. 
Table 2. Univariate linear regression analysis of mean difference in log-transformed 
virological and immunological variables per 10 years of suppressive antiretroviral 
therapy 
 
Variablea Mean difference 95% CI P 
Residual HIV-1 RNA copies/ml -0.27 -0.57,  0.03 0.08 
2-LTR circular HIV-1 DNA copies/106 PBMC  -0.34 -0.59, -0.08 0.01 
Total HIV-1 DNA copies/106 PBMC -0.12 -0.56,  0.32 0.60 
Integrated HIV-1 DNA copies/106 PBMC   0.22 -0.19,  0.62 0.28 
CD4 count cells/mm3  0.14  0.00,  0.27 0.05 
CD4+CD26+ percentage -0.03 -0.02,  0.10 0.69 
CD4+CD38+ percentage -0.23 -0.39, -0.07 0.01 
CD4+CD69+ percentage -0.11 -0.28,  0.07 0.22 
CD8+CD38+ percentage -0.30 -0.54, -0.07 0.01 
CD8+HLA-DR/DP/DQ+ percentage -0.15 -0.37,  0.07 0.17 
sCD14 μg/ml   0.07 -0.03,  0.16 0.19 
aVariables in log10. CI= Confidence interval; PBMC= peripheral blood mononuclear 
cells; sCD14= soluble CD14. 
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Table 3. Comparative analysis of subjects whose integrated HIV-1 DNA load fell within the lowest or the highest 
quartilea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic Lowest quartile  
(n = 13) 
Highest quartile  
(n = 13) 
P  
Integrated HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 1.4 (1.4-1.6) 2.6 (2.5-2.9)   <0.0001 
Male n (%) 9 (70) 11 (84) 0.64 
Age median years (IQR) 40 (31-49) 47 (43-53) 0.07 
HIV-1 subtype B n (%) 8 (61) 5 (38) 0.43 
Nadir CD4 count median cells/mm3 (IQR) 180 (80-240) 208 (118-260) 0.41 
Duration of ART median years (IQR) 6.7 (5.7-8.2) 9.1 (3.0-10.7) 0.29 
Duration of suppressive ART median years (IQR) 6.6 (5.7-7.7) 8.9 (2.7-10.6) 0.24 
Efavirenz as initial NNRTI n (%) 13 (100) 10 (77) 0.22 
Changed NRTI backbone n (%) 8 (61) 5 (38) 0.43 
Pre-ART HIV-1 RNA median log10 copies/ml (IQR) 4.9 (4.6-5.5) 5.1 (5.0-5.5) 0.26 
Detectable residual plasma HIV-1 RNA n (%)  9 (69) 6 (46) 0.43 
Residual HIV-1 RNA median copies/ml (IQR)  2 (2-3) 2 (2-5) 0.89 
Detectable 2-LTR circular HIV-1 DNA n (%)  4 (31) 6 (46) 0.68 
2-LTR circular HIV-1 DNA median copies/106 PBMC (IQR) 3 (3-7) 3 (3-7) 0.65 
Total HIV-1 DNA median log10 copies/10
6 PBMC (IQR) 2.4 (2.1-2.6) 2.8 (2.7-3.0)   0.003 
CD4 count median cells/mm3 (IQR) 721 (552-758) 513 (482-640) 0.25 
CD4+CD26+ median percentage (IQR) 53 (34-60) 54 (44-59) 0.85 
CD4+ CD38+ median percentage (IQR) 23 (17-34) 20 (16-24) 0.28 
CD4+CD69+ median percentage (IQR) 2 (1-2) 2 (1-2) 0.64 
CD8+CD38+ median percentage (IQR) 4 (3-7) 3 (2-7) 0.43 
CD8+HLA-DR/DP/DQ+ median percentage (IQR) 24 (16-37) 35 (32-49) 0.01 
sCD14 median μg/ml (IQR) 1.8 (1.6-2.3) 2.4 (2.1-2.7) 0.04 
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aQuartile cut-offs= 1.7 and 2.2 log10 copies/106 PBMC. PBMC= peripheral blood mononuclear cells; IQR= interquartile range; ART= antiretroviral therapy; 
NNRTI= non-nucleoside reverse transcriptase inhibitor; sCD14= soluble CD14. 
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Factors associated with integrated HIV-1 DNA load 
Integrated HIV-1 DNA load was positively correlated with total HIV-1 DNA load 
(p<0.0001), frequency of CD8+HLA-DR/DP/DQ+ cells (p=0.01), and sCD14 levels 
(p=0.04), but not with the levels of residual plasma HIV-1 RNA (p=0.81) and 2-LTR 
circular HIV-1 DNA (p=0.50), or the frequency of CD8+CD38+ cells (p=0.33) (Fig. 1). 
The associations were also tested by univariate and multivariable linear regression 
analysis (Table 4). A first model was built including pre-ART viral load, duration of 
suppressive ART, CD4 cell counts, residual plasma HIV-1 RNA levels, frequency of 
CD8+HLA-DR/DP/DQ+ cells, and sCD14 levels. In this adjusted model, integrated 
HIV-1 DNA load was a mean of 0.5 log10 copies higher for each 50% increment in the 
frequency of CD8+HLA-DR/DP/DQ+ cells (95% CI 0.2, 0.9; p=0.01) (Table 4).  
 
The association between integrated HIV-1 DNA load and frequency of CD8+HLA-
DR/DP/DQ+ cells was confirmed in a separate model including the nadir CD4 cell count 
in place of pre-ART viral load. In this second model integrated HIV-1 DNA load was 
mean 0.5 log10 copies higher for each 50% increase in the frequency of CD8
+HLA-
DR/DP/DQ+ cells (95% CI 0.1, 0.8; p=0.02) (Supplementary Table 2). In a sensitivity 
analysis, integrated HIV-1 DNA was replaced with total HIV-1 DNA in the two 
multivariable models (Supplementary Table 3). In the model including pre-ART viral 
load as one of variables, total HIV-1 DNA load was 0.4 log10 copies higher for each 
50% increase in the frequency of CD8+HLA-DR/DP/DQ+ cells (95% CI -0.02, 0.8; 
p=0.06); in the model including the nadir CD4 cell count in place of pre-ART viral 
load, total HIV-1 DNA load was similarly 0.5 log10 copies higher for each 50% increase 
in the frequency of CD8+HLA-DR/DP/DQ+ cells (95% CI -0.1, 0.8; p=0.12). We found 
no evidence that the association between integrated HIV-1 DNA load and frequency of 
CD8+HLA-DR/DP/DQ+ cells varied by HIV-1 subtype (B vs. non-B) (not shown). 
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Table 4. Univariate and multivariable linear regression analysis of factors associated with the mean difference in integrated HIV-1 
DNA loada 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Univariate Multivariable 
Factor 
Mean 
difference  
95% CI 
P 
Mean 
difference 
95% CI P 
Age, per 10 years higher   0.11  -0.03, 0.25 0.11    
HIV-1 subtype B vs. non B    0.11  -0.18, 0.39 0.46    
Nadir CD4 count per 100 cell/mm3 higher   0.06  -0.04, 0.17 0.25    
Duration of suppressive ART per 10 years longer   0.22  -0.19, 0.62 0.28 0.23 -0.20, 0.66 0.30 
Changed NRTI backbone yes vs. no  -0.14  -0.41, 0.13 0.30    
Pre-ART HIV-1 RNA per log10 copies/ml higher   0.10  -0.08, 0.28 0.27 0.13 -0.05, 0.30 0.15 
Residual HIV-1 RNA per log10 copies/ml higher    0.20  -0.17, 0.57 0.28 0.27 -0.08, 0.62 0.13 
2-LTR circular HIV-1 DNA per log10 copies/10
6 PBMC higher   0.04 -0.39, 0.46 0.85    
CD4 count per 100 cells/mm3 higher   0.03  -0.02, 0.08 0.25 0.02 -0.03, 0.07 0.38 
CD4+CD26+ per 50% higher   0.01  -0.44, 0.47 0.96     
CD4+CD38+ per 50% higher  -0.78  -2.11, 0.54 0.24    
CD4+CD69+ per 50% higher   1.02  -5.29, 7.33 0.75    
CD8+CD38+ per 50% higher  -0.27  -1.22, 0.67 0.57    
CD8+HLA-DR/DP/DQ+ per 50% higher   0.38   0.02, 0.74 0.04 0.51  0.15, 0.86 0.01 
sCD14 per log10 μg/ml higher   0.97  -0.14, 2.08 0.09 0.90 -0.16, 1.97 0.10 
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DISCUSSION 
This analysis of subjects receiving first-line NNRTI-based ART demonstrated that 
integrated HIV-1 DNA load did not differ by duration of suppressive therapy and was 
positively associated with the frequency of CD8 cells expressing HLA-DR/DP/DQ. 
Subjects with higher integrated HIV-1 DNA load also had higher levels of sCD14, 
although the association did not persist in adjusted analyses. While there was a 
predictable positive correlation with total HIV-1 DNA levels, integrated HIV-1 DNA 
load did not show a correlation with putative measures of recent HIV-1 replication 
(residual plasma HIV-1 RNA, 2-LTR circular HIV-1 DNA), or with the frequency of 
CD4 and CD8 cells expressing CD38. 
 
Previous studies reported that during suppressive ART integrated HIV-1 DNA shows a 
constant load and little evidence of genetic evolution (Siliciano et al., 2003, von 
Stockenstrom et al., 2015, Josefsson et al., 2013, Besson et al., 2014). Our study adds 
to these previous analyses by demonstrating that HIV-1 DNA load did not differ by 
duration of suppressive therapy in a population with a relatively homogenous treatment 
history and exact requirements in terms of evidence of plasma viral load suppression 
<50 copies/ml. There were indications that subjects treated for longer had lower levels 
of 2-LTR circular HIV-1 DNA and residual plasma HIV-1 RNA, accompanied by a 
reduction in the frequency of CD4+CD38+ and CD8+CD38+ cells, together suggesting 
that control of virus replication and resolution of immune dysfunction improve with 
longer duration of therapy. In contrast, the frequency of CD8+HLA-DR/DP/DQ+ cells 
was also not related to the duration of suppressive ART and we were able to quantify 
the association between two key parameters of virus persistence and immune activation, 
whereby integrated HIV-1 DNA load increased by 0.5 log10 copies/10
6 PBMC for each 
50% increase in the frequency of CD8+HLA-DR/DP/DQ+ cells. 
 
The function of CD8+ cells expressing HLA-DR/DP/DQ+ remains to be fully elucidated 
and may include both regulatory and effector functions (Arruvito et al., 2014, Saez-
Cirion et al., 2007, Zubkova et al., 2014). In the context of suppressive ART, 
CD8+CD38-/HLA-DR+ cells may be maintained by low-level expression of HIV or, 
other persistent pathogens, including microbial translocation from the gut. It has been 
proposed that CD8+ cells expressing HLA-DR without CD38 are preferentially 
generated in response to low antigenic stimulation and that by retaining good effector 
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function, may play a role in suppressing HIV replication in elite controllers, as well as 
clearing hepatitis C infection (Zubkova et al., 2014, Saez-Cirion et al., 2007). It may 
seem therefore counterintuitive that CD8+HLA-DR/DP/DQ+ cells should have a 
positive (rather than inverse) correlation with integrated HIV-1 DNA load. Yet, in line 
with previous data (4), our adjusted analyses showed a positive association between 
frequency of CD8+38-HLA-DR/DP/DQ+ cells and integrated HIV-1 DNA load. Several 
hypotheses may be proposed to explain the observed positive association. Firstly, low-
level HIV production may both stimulate CD8+HLA-DR/DP/DQ+ cells and 
continuously replenish the integrated reservoir. Further, CD8+HLA-DR/DP/DQ+ cells 
may directly stimulate HIV-infected CD4 cells, causing their proliferation and 
expansion of the reservoir, which can be measured as increased integrated HIV-1 DNA 
load (Klatt et al., 2013). Thirdly, a stimulant or multiple stimulants may act 
simultaneously on CD8+HLA-DR/DP/DQ+ cells and HIV-infected CD4 cells, resulting 
in an indirect association between the two parameters.  
 
The population we studied did not overall show evidence of ongoing HIV replication. 
Patients experienced no viral load rebound >50 copies/ml during follow-up (Doyle et 
al., 2012). In line with previous studies, just over half had traces of detectable plasma 
HIV-1 RNA (Palmer et al., 2008), whereas a third had detectable intracellular 2-LTR 
circular HIV-1 DNA. There was no association however between these two putative 
markers of recent HIV-1 replication and either integrated HIV-1 DNA load, or the 
frequency of CD8+HLA-DR/DP/DQ+ cells (data not shown). While this indicates that 
HIV production was unlikely, the finding may also reflect insufficient sensitivity of the 
analytic systems and the limitation of assaying peripheral blood (Cockerham et al., 
2014). It will be important to determine the antigenic specificity of CD8+HLA-
DR/DP/DQ+ cells, for example against persistent viruses such as CMV and EBV 
(Gianella et al., 2014). The two herpes viruses were not commonly detected in our 
population, which is consistent with containment by effective immune responses. One 
other aspect that warrants investigation is the relationship with levels of sCD14, which 
are an important predictor of disease progression and mortality in both treated and 
untreated patients (Sandler et al., 2011, Marchetti et al., 2011, Hunt et al., 2014). In this 
study, median sCD14 levels were within the range reported in healthy HIV-negative 
controls (Sandler et al., 2011). However, patients whose integrated HIV-1 DNA load 
fell within the highest quartile showed significantly higher sCD14 levels than those 
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with integrated HIV-1 DNA load in the lowest quartile, a finding that warrants further 
investigation in larger cohorts.   
 
A strong positive association was measured between total and integrated HIV-1 DNA, 
supporting the notion that integrated HIV-1 DNA is the most prevalent form of HIV-1 
DNA during suppressive ART (Graf and O'Doherty, 2013), and total HIV-1 DNA was 
associated with the frequency of CD8+HLA-DR/DP/DQ+ cells. Two previous studies 
have reported an association between the frequency of CD8 cells expressing HLA-DR 
and total HIV-1 DNA load in peripheral blood (Cockerham et al., 2014, Hatano et al., 
2013). One study was unable to detect a consistent association between the expression 
of activation markers on CD8 cells and integrated HIV-1 DNA load among 19 subjects 
(Cockerham et al., 2014). The reasons for the discrepant findings are unclear, and may 
include a smaller and more heterogeneous study population relative to this cohort, as 
well as possible differences in the methods to quantify integrated HIV-1 DNA load. 
 
This study has limitations. Parameters were measured cross-sectionally, albeit after 
stratifying recruitment according to duration of ART, and causality of the observed 
associations cannot be concluded. Study size limited the number of variables included 
in the multivariable analysis of factors associated with integrated HIV-1 DNA load, and 
unmeasured variables may have contributed to the findings. Importantly, the cohort had 
received NNRTI-based ART exclusively, and findings may not necessarily be 
extrapolated to other treatment regimens.  Further, we measured CD38 and HLA-
DR/DP/DQ expression on CD8 cells separately. Unlike the frequency of CD8+HLA-
DR/DP/DQ+ cells however, the frequency of CD8+CD38+ cells declined with duration 
of suppressive ART and showed no statistical association with integrated HIV-1 DNA 
load. Further analyses are needed to confirm the association between integrated HIV-1 
DNA load and CD8+CD38-HLA-DR/DP/DQ+ cells, characterise the antigenic 
specificity of CD8+HLA-DR/DP/DQ+ cells, and determine the direction of causality. 
Moreover, the data describe CD8 cells expressing HLA-DR/DP/DQ and it will be of 
interest to study the association between integrated HIV-1 DNA load and individual 
HLA isotypes. Meanwhile, our data add to growing evidence indicating that a complex 
interplay between HIV-1 persistence and immune activation continues over many years 
of stably suppressive ART.  
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LEGEND TO FIGURE 1 
Figure 1. Correlation between integrated HIV-1 DNA load and a) total HIV-1 DNA 
load, b) residual plasma HIV-1 RNA levels, c) 2-LTR circular HIV-1 DNA levels, d) 
frequency of CD8+HLA-DR/DP/DQ+ cells, e) frequency of CD8+CD38+ cells, and f) 
levels of sCD14. Scatter plots with predicted HIV-1 DNA by the fitted fractional 
polynomial curves (with 95% confidence interval) and Spearman’s rho (with p values) 
are shown. 
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Supplementary Table 1. Primers used in the integrated HIV-1 DNA assay 
 
 
 
 
 
 
Supplementary Table 2. Multivariable linear regression analysis of factors associated with the mean 
difference in integrated HIV -1 DNA load over 10 years of suppressive antiretroviral therapy in a model 
including nadir CD4 cell count 
 
 
 
 
 
aMean difference in integrated HIV-1 DNA in log10 copies/106 PBMC. PBMC= peripheral blood mononuclear 
cells; ART= antiretroviral therapy. 
 
Supplementary Table 3. Sensitivity analysis replacing integrated with total HIV-1 DNA in the two multivariable modelsa. 
 
 
 
 
 
 Target  Primer sequence (5’ – 3’) 
PCR 1 
 
Human Alu (sense) GCCTCCCAAAGTGCTGGGATTACAG 
HIV-1 gag (anti-sense) GTTCCTGCTATGTCACTTCC 
PCR2 
  
HIV-1 RU5 (sense) TTAAGCCTCAATAAAGCTTGCC 
HIV-1 RU5 (anti-sense) GTTCGGGCGCCACTGCTAGA 
HIV-1 RU5 (probe) FAM/CCAGAGTCA/ZEN/CACAACAGACGGGCACA/3IABKFQ/ 
Factor Mean differencea 95% CI P 
Nadir CD4 count per 100 cell/mm3 higher 0.04 -0.09, 0.16 0.55 
CD4 count per 100 cells/mm3 higher 0.01 -0.04, 0.06 0.60 
Duration of suppressive ART per 10 years longer 0.37 -0.12, 0.86 0.13 
Residual HIV-1 RNA per log10 copies/ml higher 0.26 -0.10, 0.62 0.15 
CD8+HLA-DR/DP/DQ+ per 50% higher 0.45   0.08, 0.82 0.02 
sCD14 per log10 μg/ml higher 0.76 -0.40, 1.92 0.19 
Factor 
Model 1 Model 2 
Mean 
difference 
95% CI P 
Mean 
difference 
95% CI P 
Nadir CD4 count per 100 cell/mm3 higher - - - -0.02 -0.16, 0.13 0.83 
CD4 count per 100 cells/mm3 higher -0.02 -0.08, 0.04 0.53 -0.02 -0.09, 0.04 0.43 
Duration of suppressive ART per 10 years longer -0.12 -0.62, 0.39 0.65 -0.01 -0.60, 0.58 0.98 
Pre-ART HIV-1 RNA per log10copies/ml higher  0.23  0.03, 0.43 0.03 - - - 
Residual HIV-1 RNA per log10 copies/ml   0.14 -0.26, 0.55 0.48  0.14 -0.30, 0.57 0.53 
CD8+HLA-DR/DP/DQ+ per 50% higher  0.39 -0.02, 0.80 0.06   0.35 -0.09, 0.80 0.12 
sCD14 per log10 μg/ml higher  0.56 -0.68, 1.78 0.37   0.57 -0.83, 1.97 0.41 
 203 
 
aMean difference in log10 copies/106 PBMC. Model 1 included pre-ART viral load; model 2 replaced pre-ART viral load 
with nadir CD4 cell count. PBMC: peripheral blood mononuclear cells; ART: antiretroviral therapy.  
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